Posted on

Cannabis seed biology

The Seed of Industrial Hemp (Cannabis sativa L.): Nutritional Quality and Potential Functionality for Human Health and Nutrition

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (


Keywords: THC, Cannabis sativa L. legislation, hempseed oil, hempseed proteins, hempseed minerals, antinutritional compounds, phenylpropionammides, bioactive peptides, hempseed dietary supplementation, hempseed-based food

1. Introduction

Cannabis sativa L., commonly known as hemp, is an herbaceous, anemophilous plant belonging to the Cannabaceae family. It is considered one of the most ancient cultivated plants and due to its long history of cultivation, it is difficult to identify its exact centre of origin. According to phylogenetic studies based on molecular analysis and studies on sequence homology of ancient and modern DNA extracted from archaeobotanical and modern samples, respectively, most researchers agreed that this plant species originated in central Asia and was introduced in Europe as a cultivated and domesticated agricultural plant during the Bronze age (approximately, from the 22th until 16th century BC) [1,2]. Nevertheless, a recent work by McPartland and colleagues [2] provided evidence that C. sativa was indigenous also to Europe. Currently, there are no more traces of wild-type hemp and only domesticated (i.e., individuals of a species chosen and selected by humans for characteristics making them useful to people) and ruderal (i.e., forms growing outside of cultivation) hemp plants exist. Independently to its origin, the nowadays-domesticated form of C. sativa L. is widespread and cultivated not only in the Asian countries, but also in Canada, the United States (US), Europe, and Africa. It is a multipurpose, sustainable, and low environmental impact crop which can be useful for several application fields, from the agricultural and phytoremediation to food and feed, cosmetic, building, and pharmaceutical industries. Indeed, from this highly versatile plant, it is possible to obtain various products of industrial interest such as fibre and shives; bio-building and thermal insulated materials; seeds, flour and oil with important nutritional and functional features; and bioactive compounds of pharmacological interest [3] ( Figure 1 ).

The manifold applications of hemp plant: virtually, each part of this plant can be used in a specific industrial field. The seeds can be used in the food, feed, and cosmetical field as whole or dehulled, or it may be subjected to a cold press process to obtain an oil used in the food and cosmetic industries. From the stem, it is possible to obtain both shives and fibre, useful for animal, building, paper and textile applications. The hemp root system is highly developed in comparison to other herbaceous plants, and this feature is suitable for the phytoremediation of soil from heavy metals. Hemp flowers can be used for ornamental purposes or to obtain products of cosmetic and pharmaceutical interest, such as essential oils composed by delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) pure extracts.

Essentially, C. sativa L. can be grown for three main purposes: industrial, narcotic/recreational, and medicinal [4]. Traditionally, C. sativa L. plants were cultivated primarily as a fibre crop for the production of textiles and ropes, especially in the western world. Despite their high nutritional value, the seeds of this plant were initially considered as a by-product of the fibre production, and hence, they were mainly used as animal feed. From the first half of the 21st century, the cultivation of this crop declined because of the progressive diffusion of synthetic fibres and the use of some narcotic strains of the C. sativa L. plant for the production of intoxicant drugs. Only since the last two decades, there has been a reintroduction of the the C. sativa L. cultivation exclusively for industrial purposes, and in this context, Canada has been the first western country to restore this crop, followed by Europe and the US. Nowadays, a growing interest for the seeds of the C. sativa L. plant, commonly named hempseeds, has been developed due to the increased knowledge about their high nutritional value and potential functionality. However, there is still a lack of awareness and much confusion between “industrial hemp” and “drug hemp” especially among the public opinion, so the research of the potential health benefits provided by hempseed is still penalized by the negative reputation of drug hemp, which daunts interests and investments. Moreover, although in scientific literature there is a fairly good amount of information about the nutritional composition of hempseeds, there is still a lack of studies regarding the nutritional and health benefits related to hempseed-based food products for human consumption. Hence, in this review, we overview the literature about the nutritional and functional properties of hempseeds belonging to those varieties of C. sativa L. that have been allowed for cultivation. These varieties contain a delta-9-tetrahydrocannabinol (THC) level less than 0.3% or 0.2% of the reproductive part of the female plant at flowering and are named “industrial hemp”. Next, the literature studies about animal and human hempseed supplementation is reviewed. For more clarity and awareness, in the first part of the work, we provide information regarding the main biochemical, genetic, and legislative aspects of the C. sativa L. species, important to outline and understand the difference between industrial hemp and drug hemp.

2. Biochemistry, Genetic, Taxonomy and Legal Status of C. sativa L.

2.1. The Cannabinoids Synthesis in C. sativa L.

The major discriminant factor related to the different intended uses of C. sativa L. is the level of the two major and more known phytochemicals characteristic of this crop, namely the only one psychoactive and toxicant compound of the plant, THC, and the non-psychoactive cannabidiol (CBD). Both of them belong to the cannabinoids’ class which includes over of 100 secondary metabolites belonging to the family of terpenophenolic compounds, typical of all C. sativa L. plants. These compounds are synthesized, collected, and stored in stalked glandular trichomes, that are specialized tiny secretory epidermal glands [5,6], which are essentially present and abundant on the inflorescence of the female plant, whilst are present in lower numbers on leaves and stems, and are absent on roots and seeds, therefore, these latter organs do not contain cannabinoids [4,7,8]. A possible presence of cannabinoids in hempseeds could occur during the harvesting process, as a result of physical contact with the resin secreted by the glandular trichomes located on the bracts that surround the seed [9,10]. Hence, the presence of cannabinoids in hempseed actually represents a contamination, and the level of this contamination depends on both the cultivar (cv) and the cleaning process of the seed. Reasonably, THC contamination in seeds from C. sativa L. varieties which produce a low-THC level—as the industrial hemp varieties—should be extremely low [9]; anyway, the adoption of a method for the quantification of the possible cannabinoid’s contamination and the level in hempseed products and food may be appropriate [11,12,13].

C. sativa L. plants grown for an industrial purpose, are cultivated to obtain fibre, seeds, and their derivatives. These plants are popularly called “industrial hemp” or “fibre-type” hemp, and they contain low-THC level (i.e., C. sativa L. plants cultivated for narcotic/recreational purposes are characterized by high-THC level and those cultivated for medicinal purposes are characterized by high-THC and high-CBD levels.

Several works clarified well the cannabinoids’ biosynthetic pathway [14,15,16,17,18,19]. According to these studies, a common precursor of all the main cannabinoids exists, and it is the cannabigerolic acid (CBGA). In the cytosol, CBGA is converted into the acidic form of the three main cannabinoids, from which other related cannabinoid compounds will originate, namely tetrahydrocannabinol acid (THCA), that in the acidic form has no psychoactive activity; cannabidiolic acid (CBDA); and cannabichromenic acid (CBCA). This conversion is catalysed by an oxidocyclase specific for each cannabinoid (THCA-synthase, CBDA-synthase, and CBCA-synthase, respectively) ( Figure 2 ). Finally, the acidic form of each cannabinoid undergoes non-enzymatic decarboxylation to their neutral and active form, i.e., THC with psychoactive activity, CBD, and CBC that is found at high levels in juvenile plants [20,21], respectively.

The cannabinoid synthetic pathway: cannabigerolic acid (CBGA) is the common precursor of all main cannabinoids. It is synthesized through an alkylation of the phenolic moiety of olivetolic acid with the terpenoid component of geranyl pyrophosphate (GPP). The reaction is catalysed by a geranylpyrophosphate:olivetolate geranyltransferase (GOT). Olivetolic acid is originated in the cytosolic polyketide pathway through an aldol condensation of hexanoyl-Coenzyme A (CoA) with three molecules of malonyl-CoA, that is catalysed by the polyketide synthase (PKS) enzyme in the presence of olivetolic acid cyclase (OAC). The GPP is synthesized by the plastidial methylerythritol phosphate (MEP) pathway. In the cytosol, CBGA is converted into the acidic form of the three main cannabinoids, tetrahydrocannabinol acid (THCA) that in the acidic form has no psychoactive activity, cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA). GPS: geranyl pyrophosphate synthase; IPP: isopentenyl diphosphate; OAC: olivetolic acid cyclase.

2.2. Chemical Phenotype and Taxonomy of C. sativa L.

Elucidation of the cannabinoids’ biosynthetic pathway has been essential to demonstrate that the concentration of each cannabinoids in the plant is genetically determined, so that various genotypes related to different chemical phenotypes, diverging in types and concentration of cannabinoids (i.e., cannabinoids profile), exist. These phenotypes are known as “chemotypes” or “biotypes”, and three different principal chemotypes were commonly identified [8,20,22] on the basis of the two main cannabinoids (i.e., THC and CBD) content and ratio:

Chemotype I is characterized by a low CBD/THC ratio (0.00–0.05), due to high THC content (>0.3% of dry weight of the reproductive part of the female plant at flowering). This chemical phenotype is also known as “drug type”, “THC-predominant”, or C. sativa L. subsp. Indica and the varieties belonging to this chemotype are those commonly grown for narcotic/recreational purposes.

Chemotype II has both the two main cannabinoids, CBD and THC, in a content ratio (CBD/THC) close to the unity (0.5–3.0), usually with a slight prevalence of CBD. This chemical phenotype is also named “intermediate type” or “THC-intermediate”, and the varieties belonging to this chemotype are mainly grown for medicinal use.

Chemotype III is characterized by high CBD/THC ratio (15–25) due to high CBD amount and low THC content, not over than 0.3% of dry weight of the reproductive part of the female plant at flowering. This chemical phenotype is also known as “non-drug type”, “fibre-type”, “THC-predominant”, or C. sativa L. subsp. Sativa, and the varieties belonging to this chemotype are cultivated for industrial purposes, namely, for fibre, seeds, and their derivatives.

De Meijer and colleagues [23] for the first time gave a clear genetic meaning to the tripartite distribution of the chemotypes within the C. sativa L. population. Indeed, studying the inheritance of the chemotype traits of C. sativa L. plants, they identified the existence of a single locus named B locus, with two co-dominant alleles, named BT and BD, each of which codes for the THCA- and CBDA-synthases, respectively. Hence, according to this model, the THC-predominant phenotype (chemotype I) is related to the BT/BT genotype, the CBD-predominant phenotype (chemotype III) is determined by the BD/BD genotype, and the intermediate phenotype (chemotype II) is induced by the heterozygous state BT/BD. The same authors also showed that the value of the CBD/THC ratio in the heterozygous hybrids obtained from cross between parental homozygous pure-THC and pure-CBD, unexpectedly differed significantly and deviated from the expected 1.0 value. Therefore, they speculated that some heritable factor could affect the balance between THCA- and CBDA-synthase in their competition to convert the CBGA precursor. In particular, the authors hypothesized that the BT and BD alleles could be part of a wider allelic series coding for several isoenzymatic forms of THCA- and CBDA-synthase, respectively, with differential affinities for the CBGA substrate, resulting in significantly different CBD/THC ratios observed in the heterozygotes. Further studies pointed out the existence of several allelic variants of BD [7,20,24] and BT [7,8,24,25] genes coding for less or totally non-functional CBDA- and THCA-synthase, respectively, and which therefore, influence the cannabinoid profile of the plant and, from a practical point of view, also represent an useful genetic marker to differentiate the drug-type from the fibre-type C. sativa L. plants. Interestingly, a higher number of allelic variants of wild-type BD locus was found in comparison to the BT locus. Hence, considering the high number of the cannabinoid synthase genes’ allelic variants and the higher mutation rate of the CBDA-synthase allele, Onofri and colleagues [7] proposed a phylogenetic hypothesis according to which it is possible to consider all cannabinoids’ allelic variants as a gene family and to speculate that the wild-type CBDA-synthase allele may be the ancestral form of this gene family, from which events of duplication would have led to a higher CBDA-synthase variation, resulting in the formation of the CBDA-synthase pseudogenes (i.e., the CBDA-synthase allelic variants) and to the rise of a new sequence coding for a new enzyme able to convert the CBDA substrate in a new product, the THCA. According to this evolutionary theory, it has also been hypothesized that the low-functionally THCA-synthase allele found in some fibre type (CBD-predominant) plants [25], could be an evolutionarily intermediate between the CBDA-synthase ancestor and the fully functional THCA-synthase allele.

The high intrinsic genetic variability rate of C. sativa L. has been further accentuated by the long history of its domestication. Indeed, the different intended uses of the C. sativa L. cultivation’s products have led over the years, to an artificial phenotypic selection of specific features of the domesticated plants, useful for increasing the yield and/or the quality of the commercial interest’s cultivation products [26]. The direct consequence of this selection was the unaware artificial creation of the C. sativa L. varieties, each with specific genotypic and phenotypic features, which at first, induced the taxonomists and botanists to erroneously recognize two or three different species of C. sativa L., embracing a polytypic concept of the Cannabis genus [27]. To further complicate the taxonomic classification of the Cannabis genus, there has been also the fact that C. sativa L. is a crop which tends to exist in “crop-weed complexes”, that is complexes of domesticated forms in cultivation and related ruderal (weedy) forms growing outside of cultivation, developing morphological characteristics also very different from those of the domestic progenitor, as a consequence of adaptation to the wild environment [28]. However, it must be considered that, despite the high genetic variability of C. sativa L., the varieties that genotypically and phenotypically differ, are interfertile. Therefore, taking into account the Darwinian definition of biological species, “a group of organisms that can reproduce with one another in nature and produce fertile offspring”, C. sativa L. varieties cannot be consider as different species of the Cannabis genus. For this reason, to date, the polytypic concept has been definitely given up and replaced by the monotypic one. According to this, a single species of Cannabis genus exists, namely C. sativa L., which includes several varieties or cultivars (cvs) that genotypically and phenotypically differ, but they all are interfertile and therefore, they belong to the same species [29,30].

From a practical point of view, the main discrimination factor among the C. sativa L. cvs is the THC content, which, essentially for legal reasons, as described in the next paragraph, is an useful tool to discriminate between the drug-type plants with high THC content, used for medical or recreational purposes, and the fibre-type plants with low THC content, commonly named industrial hemp.

2.3. Legislation of C. sativa L.

Historically, industrial hemp or simply, hemp, that is, C. sativa L. plants grown for fibre and/or seeds, was frequently cultivated over the world, mainly for the production of technical textiles, until the first half of the 21st century. In the US, hemp was widely grown from the colonial period into the mid-1800s. In the early 1900s and prior to the late 1950s, hemp continued to be grown, being considered as an agricultural commodity: the US Department of Agriculture (USDA) supported its production, and USDA researchers continued to publish information related to hemp production and also reported on hemp’s potential for use in textiles and in paper manufacturing [31]. In Europe, at the end of the 1950s, Italy was the second country in the world after Russia for the areas under hemp cultivation (over 100,000 hectares) and was the world’s best for the quality of the obtained products [32]. However, following the discovery of the psychotropic activity of THC, and the increasing awareness of its deleterious effects on human health, many countries began to take measures in an effort to stem the use of C. sativa L. plants’ flowers and leaves for their psychotropic effects. The first provision was taken in the US and Canada. In the US, between 1914 and 1933, 33 states passed laws restricting legal production to medicinal and industrial purposes only. In 1937, the Marihuana Tax Act defined hemp as a narcotic drug, without any distinguishing between low THC plants (hemp) and high THC (drug hemp or simply, marijuana) ones: both were considered schedule I controlled substances, and it was required that farmers growing hemp hold a federal registration and special tax stamp. This effectively limited further production expansion; in fact, after 1943, production of hemp started to decline until the late 1950s when no production was recorded. Finally, in 1970, The Controlled Substances Act (CSA) was issued, and it placed the control of selected plants, drugs, and chemical substances under federal jurisdiction. Among the selected plants, there were also C. sativa L. ones to which were given the statutory definition of marijuana and were put in the Drug Enforcement Administration (DEA) schedule of controlled substances [31]. In Canada, the cultivation of hemp has been prohibited due to the presence of THC, in 1938 with the Canadian Opium and Narcotics Act [33,34]. In 1961, the United Nation (UN) endorsed and adopted the single convention on narcotic drugs, which established a universal system for limiting the cultivation, production, distribution, trade, possession, and use of narcotic substances to medical and scientific purposes, with a special focus on plant-derived substances, among which is cannabis. In the article 28, paragraph 2 of this convention, cannabis was defined as “the flowering or fruiting tops of the C. sativa L. plant (excluding the seeds and leaves when not accompanied by the tops) from which the resin has not been extracted, by whatever name they may be designated”. The same article described a system of control required if a country decides to permit the cultivation of C. sativa L. that is not for industrial or horticultural purposes [4,35]. Ten years later, in 1971, the UN endorsed the convention on psychotropic substances which established an international control system for psychotropic substances, among which is THC [36]. In line with these directives, in 1975 the Italian Republic issued the law n. 685/1975, introducing cannabis (intended as a drug product obtained from C. sativa L. plants) in the schedule of controlled substances.

The better knowledge of the biochemical and biomolecular features of the C. sativa L. species has made it possible to understand the genetics and biochemical mechanisms previously described, which are the basis of the cannabinoids’ synthesis and, in particular, of THC. Furthermore, thanks to the development of specific analysis techniques (e.g., gas chromatography or gas chromatography-mass spectrometry), it is now possible to resolutely and accurately quantify the THC content of C. sativa L. plants in order to distinguish between cvs with high and low THC contents. For these reasons, nowadays, the cultivation of industrial hemp has been reintroduced either in the US, Canada, and Europe. Canada was one of the first country to restore industrial hemp cultivation. Indeed, in 1994, it began to issue licenses for hemp as a research crop and then, in 1998, the cultivation of hemp varieties containing less than 0.3% THC of the dry weight of leaves and flowering parts was legalized, and it is currently permitted, provided that a license from the Office of Controlled Substances of Health Canada has been acquired. To date, Canada is the major hemp-producing and -exporting country, particularly of hemp-based foods, ingredients, and other related products [31]. In the EU, the hemp cultivation reintroduction took place in 2013 with the EU regulation n. 1307/2013 that allowed the growth of C. sativa L. plants for industrial purposes only for those plants with low levels of THC. According to this regulation, the granting of payments under the Common Agricultural Policy (CAP) is conditional upon the use of certified seeds of specific hemp varieties, that is, C. sativa L. cvs with a THC content not exceeding 0.2% of the dry weight of leaves and flowering parts [4]. Thus, the EU has adopted more stringent parameters compared to Canada, to ensure the safety of and to protect the health of citizens. Different genotypes of industrial hemp with a THC content < 0.2% have been selected and registered, and currently, there are about 70 allowed industrial hemp varieties listed in the European Plant Variety Database as agricultural species (Table 1 ) [37,38]. Some of these cvs are dioecious as the C. sativa L. plant naturally occurs; other cvs are monoecious and are obtained by ancestral breeding [39]. Often, but not always, the monoecious varieties are adopted for seed production since they give a higher yield of the product of interest, whereas the dioecious cvs are mainly adopted for fibre production. Moreover, the industrial hemp varieties listed in the EU plant variety database are constantly updated based on the results of the annual THC-content’s monitoring and on the possible request for the introduction of new cvs with a low THC amount.

Table 1

Industrial hemp cultivars registered and listed in the European Union Plant Variety Database and their origin. All these varieties are certified to contain less than 0.2% of THC of dry weight of leaves and flowering parts of the plant, according to the EU regulation 1307/2013.

No Registered Varieties Origin No Registered Varieties Origin
1 Adzelvieši Latvia 33 Ivory Nederland
2 Armanca Romania 34 KC Bonusz Hungary
3 Asso Italy 35 KC Dora Hungary
4 Austa SK Latvia 36 KC Virtus Hungary
5 Balaton Hungary 37 KC Zuzana Hungary
6 Beniko Switzerland 38 KCA Borana Hungary
Czech Republic
7 Bialobrzeskie Czech Republic
39 Kompoliti Hungary
8 Cannakomp Hungary 40 Kompoliti Hibrid TC Hungary
9 Carma Italy 41 Lipko Hungary
10 Carmaleonte Italy 42 Lovrin 110 Romania
11 Chamaeleon Nederland 43 Marcello Nederland
12 Codimono Italy 44 Markant Nederland
13 Dacia Secuieni Romania 45 Monoica Switzerland
14 Delta-405 Spanish 46 Orion 33 France
15 Delta-Ilosa Spanish 47 Rajan Poland
16 Dioica 88 France 48 Ratza Romania
17 Earlina 8 FC France 49 Santhica 23 France
18 Eletta Campana Italy 50 Santhica 27 France
19 Epsilon 68 France 51 Santhica 70 France
20 Fedora 17 Switzerland 52 Secuieni Jubileu Romania
21 Felina 32 France 53 Silvana Romania
22 Fibrante Italy 54 Succesiv Romania
23 Fibrol Hungary 55 Teodora Romania
24 Fibror 79 France 56 Tiborszallasi HungaryItaly
25 Finola Finland 57 Tisza Hungary
26 Futura 75 France 58 Tygra Poland
27 Futura 83 France 59 Uniko B Hungary
28 Fèrimon Deutschland
60 Uso-31 Nederland
29 Glecia Italy 61 Villanova Italy
30 Gilana Italy 62 Wielkopolskie Poland
31 Glyana Poland 63 Wojko Poland
32 Henola Poland 64 Zenit Romania

Nowadays the EU is the world’s largest hemp-producing market second only to Canada, with France, the Netherlands, Lithuania, and Romania as the major production centres [31]. According to the EU guidelines, also in Italy, the cultivation of industrial hemp has been recently restored through the law n. 242/2016, and the subsequent circular of the Ministry of Agricultural, Food and Forestry Policies (MIPAAF) published on 14 January 2017 that has delineated the conditions for hemp production, its commercialization, and its utilization for specific industrial purposes [38].

Finally, in the US, the federal policy regarding hemp was significantly altered with the 2014 Farm Bill (Agricultural Act of 2014) that allowed the USDA and certain research institutions to grow hemp under an agricultural pilot program. Despite this act, industrial hemp continued to be a niche crop. The great novelty was four years later with the 2018 Farm Bill that has established a new federal hemp regulatory system under the USDA with the aim to facilitate the commercial cultivation, processing, and marketing of hemp and to essentially treat hemp like any other agricultural commodity. Indeed, it removed hemp (i.e., C. sativa L. varieties with a THC content C. sativa L.) through the entry into force of the Cannabis Act, Bill C-45 [40]. In Figure 3 , the main highlights about the C. sativa L. legislation in Canada, the US, the EU and Italy among the EU states, are illustrated.

The main points of the legislation about C. sativa L. (industrial hemp) cultivation in the US, Canada, and the EU with a focus on the Italian Republic among the EU states. The red line separates the legislation related to the prohibition of C. sativa L. cultivation (left part of the red line) from that allowed the reintroduction of growing of this crop (right part of the red line). For more details, see Section 2.3. US: United States; UN: United Nations; THC: delta-9-tetrahydrocannabinol; EU: European Union; USDA: United Stated Department of Agricultural.

3. C. sativa L. Seed

As mentioned above, the C. sativa L. crop has a prehistoric use as an important source of industrial interest’s plant fibre. Nevertheless, in the last decades, there has been a growing interest in the seed of the plant which is the fruit of hemp, commonly named seed, even if it is technically an achene, namely an one-seeded dry fruits in which the pericarp is not as tightly joined to the seed, essentially similar to the cereal caryopsis [28]. Normally, the seeds of hemp grown for fibre production were considered as a waste product, and at most, they were mainly used as animal feed [34,41]. However, in recent times, with the growing recognition of their nutritional features and health benefits, the production of hempseeds has been increased and these seeds have become a product with an important and growing potential market [42]. Therefore, the literature about the nutritional and functional features related to this product has been reviewed in the next sections.

3.1. Hempseed Nutritional Features

Hempseed has commonly been claimed as one of the most nutritionally complete food sources due to its high nutritive traits. It can be consumed as such (whole, hulled seed) or dehulled (hempseed kernel), as well as its processing products, including oil, flour, and protein powder. Despite the fact that some studies highlighted high variability in the hempseed composition according to the genotypes and environmental factors [3,32,34,39,43,44,45,46], it typically contains 25–35% lipids with a unique and perfectly balanced fatty acids (FAs) composition; 20–25% proteins easy to digest and rich in essential amino acids; 20–30% carbohydrates, a great part of which are constituted in dietary fibre, mainly insoluble; as well as vitamins, and minerals ( Table 2 ).

Table 2

Hempseed nutritional characteristics (mg/100 g).

Moisture Fat Proteins CHO Total DF Insoluble DF Soluble DF Ash Ref
1.1–7.2 26.9–30.6 23.8–28.0 n.a. n.a. n.a. n.a. 5.1–5.8 [34]
4.1–4.3 32.8–35.9 24.3–28.1 32.5–37.5 n.a. n.a. n.a. 4.9–6.1 [44]
6.7 ± 0.5 34.6 ± 1.2 25.6 ± 0.6 34.4 ± 1.5 33.8 ± 1.9 30.9 ± 1.5 2.9 ± 0.4 5.4 ± 0.3 [45]
4.0–9.2 25.4–33.0 21.3–27.5 n.a. n.a. n.a. n.a. 3.7–5.9 [46]
6.5 35.5 24.8 27.6 27.6 22.2 5.4 5.6 [47]
8.4 ± 0.02 33.3 ± 0.1 22.5 ± 0.2 n.a. n.a. n.a. n.a. 5.9 ± 0.03 [48]
7.3 ± 0.1 24.5 ± 2.0 24.8 ± 1.1 38.1 ± 2.5 n.a. n.a. n.a. 5.3 ± 0.6 [49]

Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. n.a.: not available; CHO: carbohydrates; DF: Dietary Fibre.

In addition to its nutritional value, hempseed is also rich in natural antioxidants and other bioactive components such as bioactive peptides, phenolic compounds, tocopherols, carotenoids, and phytosterols, the content of which appears to be mostly affected by the environmental and agronomic factors and, to a lesser extent, by genetic variability [3]. Moreover, hempseed contains also some antinutritional compounds that could negatively influence its nutritional value. In the following subsections, these nutritional and antinutritional hempseed’s components are discussed in detail.

3.1.1. Hempseed Fat
Fatty Acid Composition

Fat represents the most important component of hempseeds, particularly from an industrial point of view. Indeed, since hempseeds are oilseeds, the oil is the main food product of industrial interest that it is possible to obtain from them. For this reason, hempseed’s fat is commonly called oil. Several studies [34,39,44,45,46,47,48,49] demonstrated that the oil content of hempseeds belonging to different cvs ranges from 25 to 35% of the whole seed ( Table 2 ). Galasso and colleagues [39] and Irakly and co-workers [3], analysing the seeds belonging to different industrial hemp cvs, highlighted that this variation is mainly due to the genotype. In addition, Irakli and colleagues [3] also observed that even environmental conditions such as geography, climatic conditions, and local agronomic factors have an effect on the total oil content, though slighter than genotype. This evidence is in accordance with the findings of Kriese and colleagues [41] and Mihoc and co-workers [43]. In this latter study, the authors, analysing the oil content of five Romanian industrial hemp cvs grown in two consecutive years in the same site, found that environmental conditions such as high monthly average temperature of 25–26 °C and a low rainfall level (223 mm during the flourishing of plants) resulted in an incomplete maturation of hempseeds and in a decrease in oil content.

As regards the chemical composition of the hempseed’s fat, it is needed to consider that most publications on this argument are referred to the oil extracted from hempseed through specific industrial methods, rather than to the whole seed, because of the high industrial relevance attributable to hempseed oil. However, in this review, we have been focused primarily on the whole hempseed, so, except in the case of a lack of literature data about whole hempseed, we have considered only the publications about this matrix, excluding those specifically concerning the oil. The literature data about the FA composition of the fat component of whole hempseed are reported in Table 3 .

Table 3

Hempseed fatty acid profile (% of oil).



n-6/n-3 Ref.
6.7–7.0 2.1–2.8 9.4–13.0 55.6–56.6 2.6–4.5 14.7–17.3 n.a. 9.6–10.3 n.a. n.a. n.a. [34]
6.0–7.3 2.3–3.5 9.2–15.7 55.0–58.2 0.6–4.5 12.6–19.6 0.2–1.5 9.4–11.7 9.7–16.1 72.2–80.7 2.8–4.5 [39]
7.1–9.1 2.1–2.8 10.3–17.9 51.6–54.2 1.9–5.0 10.5–15.3 n.a. n.a. n.a. n.a. 3.9–5.5 [3]
6.1–7.8 2.3–4.0 12.2–18.8 53.9–59.0 3.5–6.2 12.3–18.9 n.a. n.a. n.a. 72.0–78.6 3.2–5.0 [44]
5.0 2.0 9.0 56.0 4.0 22.0 2 n.a. n.a. 84.0 2.5 [47]
7.0 ± 0.3 2.8 ± 0.4 12.7 ± 1.3 56.2 ± 3.5 2.9 ± 0.4 15.0 ± 1.1 n.a. 10.9 ± 0.5 13.1 ± 1.3 75.1 ± 3.7 4.0 [49]
5.6 ± 0.5 3.9 ± 0.4 16.2 ± 6.2 54.7 ± 4.1 n.a. 16.2 ± 4.0 0.5 ± 0.01 10.9 ± 0.7 17.5 ± 6.3 72 ± 4.3 3.2 [50]

Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. PA: Palmitic Acid (16:0); SA: Stearic Acid (18:0); OA: Oleic Acid (18:2, n-9); LA: Linoleic Acid (18:2, n-6); GLA: γ-Linolenic Acid (18:3, n-6); ALA: α-Linolenic Acid (18:3, n-3); SDA: Stearidonic Acid (18:4, n-3); ∑-SFA: Total Saturated Fatty Acid; ∑-MUFA: Total Monounsaturated Fatty Acid; ∑-PUFA: Total Polyunsaturated Fatty Acid; n.a.: not available.

Overall, the literature data showed that hempseed oil is characterized by high polyunsaturated fatty acids (PUFAs) content and low saturated fatty acids (SFAs) amounts. More precisely, based on genotype and environmental factors, hempseed oil contained up to 90% unsaturated fatty acids [34], of which from 70% to over 80% is composed by PUFAs. The major monounsaturated fatty acid (MUFA) was Oleic Acid (18:1, n-9, OA) which has been shown to reach the highest value (18.78%) in the Canadian cv Joey [44], whereas the lowest OA content (8.42%) was found in the Finola cv grown in Italy [39]. Generally, the amount of OA in hempseed oil is shown to be higher than those found in chia seed (7%) [51] and comparable to those present in linseed (15%) [52]. Among PUFAs, Linoleic Acid (18:2, n-6, LA) was the most representative FA in hempseed oil of all analysed genotypes, accounting for more than half of the total FA. The second prominent PUFAs was α-linolenic acid (18:3, n-3, ALA). Hence, hempseed oil represents an especially rich source of these two fatty acids which are known as Essential Fatty Acids (EFAs), since they cannot be synthesized by mammals and, therefore, must be acquired by diet because they are necessary to maintain healthy human life. Indeed, LA and ALA are the precursors of the n-6 and n-3 PUFAs biologically active in animals, including humans, namely the long-chain PUFAs Arachidonic Acid (20:4, n-6, AA) which derived by the conversion of LA; and Docosahexaenoic Acid (22:6, n-3, DHA) and Eicosapentaenoic Acid (20:5, n-3, EPA) obtained from the ALA precursor. These biologically active forms of EFAs are necessary for many physiological processes, including maintenance of cell membrane structure, and cardiovascular health, the regulation of metabolic and inflammatory processes through the synthesis of prostaglandins and leukotrienes, skin integrity, as well as proper regulation of the brain’s development and function. In this context, it is important to note that the conversion of both LA and ALA into their biologically active PUFAs derivatives occurs at a low conversion rate. Several studies [3,34,39,47] highlighted that the Finola cv was the hemp variety with the highest ALA amount compared to other cvs. The highest ALA content in the Finola cv was found by Callaway (22%) [47] and the lowest was found by Irakli and colleagues (15.3%) [3].

In addition to the absolute concentration of PUFAs in the diet, the n-6/n-3 ratio represents an important index to ensure the maintenance of an optimal state of health, and to prevent the onset of chronic-degenerative diseases characterized by a chronic inflammation status, like cardiovascular and neurodegenerative diseases, as well as cancer [53]. Despite the existence of different lines of thought about the healthiest n-6/n-3 ratio, according to the European Food and Safety Authority (EFSA) [54], the ideal n-6/n-3 ratio has been established as 3:1 to 5:1, that is also the ratio found in the traditional Japanese and Mediterranean diets, where the incidence of coronary disease has been historically low [47]. The levels of LA and ALA found in the fat component of hempseeds make them a food matrix with the ideal, low n-6/n-3 ratio ranging precisely from 3:1 to 5:1, which is useful for reducing the n-6/n-3 ratio in diets, especially of industrialized countries, where there is an unhealthy average n-6/n-3 ratio of about 10:1, due to the too high n-6 and too low n-3 amount in the people’s diets [49]. In addition to LA and ALA, among n-6 and n-3 FAs, hempseed oil also contains their respective biologic metabolites γ-Linolenic Acid (18:3, n-6, GLA) and Stearidonic Acid (18:4, n-3, SDA) that allow to bypass the first critical enzymatic step of δ-6-desaturase, facilitating the conversion into the biologically active form of long-chain PUFAs. Even in this case, Finola cv appeared as the hemp variety with the highest content of both GLA and SDA [3,34,39,47]. Furthermore, GLA performs also an anti-inflammatory activity since it is rapidly converted in Dihomo-γ-Linolenic Acid (DGLA; 20:3, n-6) in the human body. DGLA is located in the cell membrane, where it can act as a precursor of anti-inflammatory metabolites and can compete with AA for the synthesis of metabolites involving in the inflammatory response [55]. In this context, it is important to consider that hempseed oil is not the only one source of GLA, neither the plant source with the highest amount of GLA, in fact, one of the most representative sources of this FA is the borage oil (19–23% of GLA) which however lacks n-3 PUFAs differently from hempseed oil [56]. As regard the SFAs, studies reported that the total amount of them is not over than 12% ( Table 3 ), with a consequent recommended high (>10) PUFA/SFA ratio, considered beneficial to reduce the risk of atherosclerosis and coronary heart disease [32]. The principal SFA was the Palmitic Acid (16:0, PA) with an amount ranging from 2 to 9%, followed by Stearic Acid (18:0, SA).

Concerning the variability in the hempseed oil’s FAs content, in literature there are some conflicting data. Particularly, a common evidence is that the FAs composition differs among cvs. Irakli and co-workers [3] demonstrated that, similarly to the oil content, the FAs profile of hempseeds is drastically affected by genotype. The same authors found that the content of FAs of seven industrial hemp cvs approved for cultivation in Greece and grown in the same site for three consecutive years, was most affected by genotype for ALA primarily, followed by OA and PA (genotype contribution on the variance, 99.6%, 91.2%, and 86.2%, respectively), whereas LA was the FA least affected (genotype contribution on the variance, 42%). Similar data were found by Vonapartis and colleagues [34] for ten Canadian industrial hemp cvs, which did not obtain significant differences among the analysed cvs for LA, but they found noticeable differences in the ALA concentration. Contrarily, Galasso et al. [39] detected high and significant variability for both LA and ALA contents of twenty hempseed accessions and cvs.

The Unsaponifiable Matter

Generally, any oil matrix is composed of saponifiable and unsaponifiable matter. The former consists of all the oil substances containing an ester portion that can be removed by treatment with irreversible alkaline hydrolysis, including mono-, di-, and tri-acylglicerols and phospholipids. The latter, according to the International Organization for Standardization (ISO) 18609:2000 definition, consists in all the substances dissolved in the product which cannot be saponified by the caustic alkalis but are soluble in the ordinary fat solvent (e.g., hexane). The unsaponifiable matter includes sterols, aliphatic and terpenic alchols, as well as fat-soluble vitamins. Literature data about the composition of the unsaponifiable matter of the fat component of whole hempseed are very scarce; in fact, almost all of them concern the oil of hempseed. One of the first reports in which the unsaponifiable matter of the oil of hempseed has been investigated in detail was the work of Montserrat-De La Paz and colleagues [57]. They demonstrated that the unsaponifiable matter of hempseed oil represents from 1.8 to 1.92% of the total oil, and the most relevant compounds of this oil fraction are tocopherols and phytosterols. Tocopherols are naturally occurring, fat-soluble compounds with high antioxidant activity. They include the different isomers α-, β-, γ-, and δ-tocopherol and represent the dominant antioxidants in hempseed oil, protecting it from oxidation thanks to their ability to scavenge free radicals. As said, most publications in which the tocopherol content has been assessed concern the oil of hempseed instead of whole hempseed, and in fact, the obtained results are expressed referring to the oil (e.g., mg/100 g of oil) rather than to the seed (e.g., mg/100 g of seeds). Anyway, they provide important information about the content of these functional compounds, and considering the lack of data referred to whole hempseed, these publications have been considered in this specific case. The literature data obtained from the studies that evaluated the tocopherol profile of hempseed and hempseed oil are reported in Table 4 , where the results expressed per 100 g of seeds have been separated from those expressed per 100 g of oil.

Table 4

Hempseed oil unsaponifiable matter: tocopherol profile.

Type of Analyzed Sample Total Tocopherols α-Tocopherol β-Tocopherol γ-Tocopherol δ-Tocopherol Ref.
mg/100 g seed
Whole seed n.a. n.a. n.a. 21.21–294.9 62.0–115.7 [34]
Oil 14.33–34.04 0.70–3.05 0.06–0.30 15.42–29.40 0.51–2.49 [41]
Whole seed n.a. n.a. n.a. 4.6–11.3 0.6–1.3 [3]
Whole seed 90 5 n.a. 85 n.a. [47]
Whole seed n.a. 0.35 ± 0.09 n.a. 0.55 ± 0.13 n.a. [49]
mg/100 g oil
Whole seed 61–135 n.a. n.a. n.a. n.a. [39]
Oil 56.28–58.22 23.4–24.62 31.6–32.20 1 1.28–1.40 [48]
Oil n.a. 2.78 ± 0.01 n.a. 56.41 ± 0.02 n.a. [52]
Oil 80.28 ± 4.50 3.22 ± 0.65 0.81 ± 0.16 73.38 ± 2.86 2.87 ± 0.83 [57]
Oil n.a. 2.56 ± 0.06 0.60 ± 0.005 59.79 ± 1.21 3.97 ± 0.15 [58]
Oil 79.7 3.4 0.6 73.3 2.5 [59]
Oil 97.13 4.32 ± 0.65 n.a. 89.26 ± 1.92 3.55 ± 0.25 [60]
Oil 92.97 4.71 ± 0.54 n.a. 84.11 ± 1.74 4.15 ± 0.44 [61]

1 β-tocopherol + γ-tocopherol. Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. n.a.: not available.

Obviously, when the values are reported per 100 g of oil, the tocopherol amounts are higher in comparison to the values referring to 100 g of seeds, as a consequence of the concentration of these compounds in the extracted oil. In any case, all works reported γ-tocopherol as the most abundant isomer, followed by α-, δ- and β-tocopherols. Among these isomers, γ-tocopherol has been suggested to be the most active antioxidant in lipids [32], and therefore, it contributes together with other antioxidant compounds like polyphenols to provide high oxidative stability to hempseed and, especially, to its oil, whereas, the α-isoform is considered as the only one tocopherol bioactive form, namely the form with vitamin E activity in the human body [62]. Regarding the daily intake of vitamin E as α-tocopherol, EFSA has set an average intake (AI) of 13 mg/day for males and 11 mg/day for females [62]. According to literature data ( Table 4 ), the α-tocopherol content in whole hempseed can reach up to 5 mg/100 g of seeds [47]. A serving portion of hempseed corresponds to 30 g [44]; hence, the daily intake of a serving portion of whole hempseed can contribute to satisfying up to 14% for women and 12% for men for the vitamin E AI, whereas, the γ-tocopherol content found in the oil of hempseed has been shown to be higher than those found in both linseed and canola seed oils [52].

The total tocopherol amount in hempseed oil has been shown to be higher than that found in sunflower, sesame, and amaranth oil [48]. It can reach even values higher than 90 mg/100 g of oil based on the type of extraction process used to obtain oil from the seed. Indeed, on an industrial scale, various oil extraction techniques exist, each of which can differ in performance in terms of economic costs, extraction yield, and composition and physicochemical quality of the extracted oil [63]. One of these techniques is the cold-pressing method which, however, has low extraction efficiency and leads to obtaining an oil with high chlorophyll levels, probably due to intensive mechanical destruction of hempseed cells during the pressing and the consequent release of the pigments from chloroplasts. High amounts of chlorophyll negatively influence the oil quality and shelf-life, since it can lead to oil photooxidation due to the chlorophyll’s role as a sensitizer [64]. To obtain a qualitatively better oil, it is possible to use an alternative extraction process such as supercritical fluid extraction (SFE), ultrasound assisted extraction (UAE), or microwave assisted extraction (MAE). SFE is based on the use of a gaseous medium above or near its critical temperature and pressure to recover extracts from solid matrices. Carbon dioxide (CO2) is the most commonly supercritical fluid used in the food industry for extraction from plant materials. Aladìc and colleagues [64] demonstrated that this method of extraction can extract more efficiently the tocopherols than the traditional cold-pressing, leading to two- or three-fold higher γ-tocopherol content in the extracted oil. Another alternative extraction process that has been shown to improve both the yield and nutritional quality of the hempseed oil was the enzyme-assisted cold-pressing (EACPM) method. Indeed, Latif and co-workers [65] found that, by using this extraction technique, the level of total tocopherols in the hempseed oil increased from 4.8 to 14.1% (based on the enzyme’s type) in comparison to that obtained by the cold-pressing method. Finally, UAE and MAE resulted even more efficient in increasing the extraction not only of tocopherols (+17% and +11%, respectively) but also of other oil-soluble antioxidant compounds present in the hempseeds, such as polyphenols, since the oil obtained through these techniques were shown to have higher oxidation stability and antioxidant capacity than that extracted by SFE. This has been attributed either to the capacity of both UAE and MAE processes to extract oil at a lower extraction temperature and a shorter process time [60,61]. These methods can extract oil and oil-soluble components from seeds using the effect of ultrasounds and microwaves, respectively, on the seeds. The ultrasounds, propagating through the cells, generate the phenomenon of cavitation, which provides a greater solvent penetration into the sample matrix, increasing the contact between the sample and the solvent, and thereby, enhancing the efficiency (yield) and reducing the time of extraction, whereas, the microwaves can easily penetrate into the sample pores causing the solvent trapped in the pores to heat evenly and rapidly; in this way, the kinetics of extraction increases, leading to shorter extraction times, higher extraction rates, lower costs, and less solvent use.

The extraction technique can have an influence on the tocopherol amount of the oil but not on that of the whole hempseed. Factors that mainly affect the tocopherols amount in the seeds and indirectly, also in the derived oil, are both genotype and, above all, environmental factors. About this, Irakli and colleagues [3] observed that the differences found in the tocopherols amount of seven industrial hemp cvs grown in Greece in three consecutive years, were mainly due to the effect of growing year (71% of the total variance) than the genotype (24% of the total variance). This, adding to the use of different extraction techniques used for the tocopherol analysis from hempseed, could explain the much lower tocopherol amount found by the authors in comparison to the very high tocopherols concentration obtained by Vonapartis and co-workers [34].

Phytosterols are fat-soluble compounds found only in plants; they cannot be synthesized in human and are characterized to have a structure similar to that of cholesterol. Thanks to this chemical feature, when phytosterols are ingested, in the intestine, they are able to reduce the cholesterol solubility, excluding it from lipid micelles and to compete with free cholesterol uptake, thereby preventing the cholesterol intestinal absorption. To date, only three reports are investigated the phytosterols content and profile of whole hempseed [49,50] or hempseed oil [57] ( Table 5 ).

Table 5

Hempseed oil unsaponifiable matter: phytosterol profile.

Type of Analysed Sample Total Phytosterols β-Sitosterol Stigmasterol Campesterol Ref.
mg/100 g seed
Whole seed n.a. 53.61 ± 3.15 2.47 ± 0.25 11.54 ± 1.03 [49]
Whole seed 124 ± 12 79.7 ± 0.1 3.4 ± 0.9 7.3 ± 0.6 [50]
mg/100 g oil
Oil 279.37 ± 12.43 190.5 ± 5.93 10.02 ± 0.75 50.57 ± 3.20 [57]

Data are expressed as mean ± standard deviation. n.a.: not available.

As noted for tocopherol content, the total phytosterol content is more concentrated when expressed for hempseed oil rather than for whole seeds. Anyway, the most abundant phytosterol has been shown to be β-sitosterol with a value of 190.5 mg/100 g for hempseed oil [57] and 79.7 [50] and 53.61 mg/100 g [49] for the whole hempseed belonging to two different cvs. β-sitosterol in the seed plays an important role in the fluidity of plant cell and membrane and has a role in cellular differentiation. In humans, it can be effective to reduce hypercholesterolemia; can have favorable effects against colon cancer; and possesses antiviral, antifungal, and anti-inflammatory properties [50]. According to Vecka and colleagues [50], the amount of β-sitosterol in whole hempseed is higher than in linseed (79.7 vs. 55.4 mg/100 g seeds) and it is similar to the richest source of β-sitosterol analysed in the same study, namely pistachio (85.9 mg/100g seeds). The other two main phytosterols found in hempseed are campesterol and stigmasterol. The latter was described as a compound able to inhibit several pro-inflammatory factors and potentially effective in the prevention of osteoarthritis [50].

Finally, the other still little explored components of the unsaponifiable matter of hempseed oil are carotenoid. Analysis of total carotenoids has been performed only bya few papers [48,64,66] on the hempseed oil obtained by CO2 SFE and cold-pressing process, whereas data on the carotenoids profile on whole hempseed are reported only by Irakli and colleagues [3]. According to these papers, the total carotenoids of hemp oil has been found to range from 7.8 to 8.2 mg/100 g for oil obtained by two different cold-pressing methods applied on Hlesiia cv [48] and amount to 3.15 or 12.54 mg/100 g for oil obtained by cold-pressing and CO2 SFE, respectively [64]. In another work [66], the amount of total carotenoids in hemp oil obtained by CO2 SFE was 3.42 mg/100 g. These differences may be due to the adoption of different CO2 SFE parameters as well as genotype and environmental factors as reported in the publication of Irakli and colleagues [3]. As said, this is the only one report that analysed the carotenoid profile of whole hempseeds belonging to seven different cvs, showing that all analysed varieties contained the three main carotenoids lutein, zeaxanthin, and β-carotene, with lutein as the most abundant carotenoid ranging from 1.4 to 3.4 mg/100 g seeds, followed by β-carotene (0.2–0.8 mg/100 g seeds) and zeaxanthin (0.2–0.5 mg/100 g seeds). In this case, the total carotenoid content was found ranging from 1.4 to 4.3 mg/100 g seeds with values significantly affected by both genotype and growing year.

3.1.2. Hempseed Proteins

The protein content of whole hempseed can vary from 20 to 25% ( Table 2 ) according to variety and environmental factors. This amount can further increase in some hempseed-processed products such as dehulled seed and hempseed meal or cake (also called hempseed flour), that is, the remaining fraction of hempseed obtained after expelling its oil fraction [45,46,48,49]. Mattila and colleagues [45] demonstrated that in hempseed the proteins are mostly located in the inner layer of the seed, in fact they found only a low quantity of total proteins in the hull. Therefore, the increase in the protein content of processed products can be explained as a consequence of protein concentration after removing some component of the whole seed that totally or almost lacks in protein, such as the hull, where most of the fibre is located and the removal of which leads to a 1.5 times increase in both protein and oil amount. More proteins are also present when both hull and oil (the major component of whole hempseed) are removed. Indeed, their removal leads to obtaining the hempseed-processed product with the highest protein (up to over 50%) and the lowest fat content (even less than 10%, based on the type of extraction methods used) [46].

Research about the hempseed proteins originated from the early 20th century and highlighted that the two main proteins of hempseed are the storage protein albumin, a globular protein, and edestin, a legumin. This latter is the most abundant component, constituting about 82% of total hemp protein content. It is a hexamer of about 300 KDa composed by six identical subunits, each of which is in turn made up of an acidic (AS) and a basic (BS) subunit with molecular weights of about 33.0 and 20.0 KDa, respectively, that are linked by one disulphide bond [67,68]. In addition to edestin, the other components that have been found were albumin components (13% of total protein) and β-conglycinin (a vicilin-like protein) (up to 5% of total protein), the presence of which has been recently confirmed also by Pavlovic and co-workers [38] and in a recent genome-wide study [69] in which two albumin and one vicilin-like encoding genes in addition to three edestin isoforms where identify, each encoded by a different gene, differing for the amount of sulphurated amino acids that are particularly abundant in the isoform-type 3. Nevertheless, in the report of Pavlovic and co-workers [38], the authors found that edestin amounted to about 65% of total hempseed proteins. This result is in line with what was found from the HPLC and MS/MS analysis performed by Mamone and colleagues [70], but it is less than what was obtained in the previous studies by Tang and colleagues [67] and by Wang and co-workers [68]. Moreover, these latter authors also found that the solubility of hempseed proteins at acidic pH was lower than that of soy proteins, and this may be due to the formation of covalent disulphide bonds among individual molecules of edestin, resulting in insoluble protein aggregates. Another physio-chemical property investigated was the thermal one. It was found that the denaturation temperature of hempseed proteins was 92 °C. This evidence is in agreement with what was observed by Raikos and colleagues [71] about the effect of heat treatment (80 °C or over) on the structural characteristics of hempseed proteins and consequently, on their digestibility. Indeed, high temperatures can lead the proteins to unfold and to expose their hydrophobic groups, favouring protein-protein interactions instead of the protein-water ones, and, hence, the formation of insoluble protein aggregates to which digestive enzymes cannot access. In this context, Wang and co-workers [68], investigating on the in vitro digestibility of hempseed protein isolates, had previously shown that untreated hempseed proteins were much more digestible compared to soy proteins. The high digestibility of hempseed proteins has been confirmed also by Mamone and colleagues [70], who observed that only a handful of peptides survived to an in vitro digestion process. On the contrary, Lin and colleagues [72] observed that heat pre-treatment on hempseed proteins at 100 °C for 15 or 30 min, improved their digestibility. The authors explained this evidence as a consequence of the improvement in the digestive enzymes’ bioaccessibility on target proteins through increased exposure of susceptible peptide bonds after protein unfolding.

Regarding the nutritional value of hempseed proteins, it is important to consider that the nutritional quality of a protein is defined by its amino acid composition and by its digestibility and bioavailability. The protein’s amino acid composition along with the individual’s amino acid requirement, are important to establish the amino acid score, which is the relative contribution that the amino acids contained in the protein meet the individual’s amino acid requirement, whereas, the protein digestibility is closely related to the bioavailability of its amino acids, since it measures the degree to which the protein is digested and their components—the amino acids—are absorbed by the gastrointestinal tract and, hence, introduced into the human body. Several authors investigated the hempseed proteins’ amino acid composition [45,46,47,67,68,73]. Some of them analysed the protein extracted from whole hempseed while others examined commercial hempseed protein isolate, so the obtained results are expressed on either a whole seed basis (g of amino acids per 100 g of seeds), or total protein basis (g of amino acids per 100 g of protein). In Table 6 , the literature data about the amino acid composition for whole hempseed are reported.

Table 6

Hempseed protein amino acid content (g/100 g seed).

Ala Arg Asp Cys Glu Gly His * Ile * Leu * Lys * Met * Phe * Pro Ser Thr * Trp * Tyr Val * Ref.
1.28 3.10 2.78 0.41 4.57 1.14 0.71 0.98 1.72 1.03 0.58 1.17 1.15 1.27 0.88 0.20 0.86 1.28 [47]
1.23 2.76 2.13 0.31 4.58 1.24 0.64 0.62 1.53 1.28 0.50 1.02 1.14 1.27 0.85 n.a. 0.73 0.68 [48]
0.94 2.69 2.33 0.36 3.83 1.02 0.58 0.86 1.47 0.84 0.56 1.01 0.89 1.12 0.79 n.a. 0.78 1.13 [45]
0.96 2.28 2.39 0.41 3.74 1.06 0.55 0.80 1.49 0.86 0.56 1.03 0.90 1.19 1.01 0.23 0.68 1.14 [46]

* Essential amino acids. Ala: alanine; Arg: arginine; Asp: asparagine; Cys: cysteine; Glu: glutamate/glutamine; His: histidine; Iso: isoleucine; Leu: leucine; Lys: lysine; Met: methionine; Phe: phenylalanine; Pro: proline; Ser: serine; Thr: threonine; Trp: tryptophan; Tyr: tyrosine; Val: valine; n.a.: not available.

Amino acid composition obtained for hempseed proteins by various authors, are in good agreement and highlighted (1) that hempseed proteins contain all essential amino acids (EAAs) required by humans, and (2) that the most abundant amino acid is glutamic acid (3.74–4.58% of whole seed) followed by arginine (2.28–3.10% of whole seed). As previously anticipated, several authors [47,67,68] compared the amino acid composition of hempseed proteins to that of soy proteins and casein. The soy proteins have been chosen since they are one of the most important and commonly used plant sources of high-quality proteins [67], whereas casein is a highly digestible animal protein, considered a complete protein source, and therefore, it is commonly used as a reference protein to assess the nutritional quality of other proteins [46]. Moreover, soy proteins and casein are considered good sources of amino acids for infants. From this comparison, it emerged that hempseed proteins have a good amount of sulphur-containing amino acids, higher than both casein and soy proteins. Furthermore, in comparison to soy proteins, the amino acid content of hempseed proteins was higher or similar, except for aspartic acid, glutamic acid, and lysine that resulted in being higher in soy proteins, whereas, if compared to casein, the amino acid content of hempseed proteins was higher or similar, except for tyrosine, leucine, methionine, and lysine that were more abundant in casein. Among EAAs, only three (isoleucine, lysine, and phenylalanine) resulted in being lower in hempseed proteins in comparison to casein, while the others appeared to be higher or similar and the proportion of EAAs to the total amino acids for hempseed proteins resulted in being higher than soy proteins and similar to casein. However, to understand if a protein can satisfy the human nutritional requirement, it is necessary to estimate the amino acid score for each amino acid element. The amino acid score for hempseed proteins has been calculated in different papers [46,67,68] based on the Food and Agriculture Organization/World Health Organization (FAO/WHO) amino acid suggested requirements for children 2–5 years old. The results obtained from all reports agree with the evidence that lysine was one of the limiting amino acids since its score was lower than 1 (0.75 in [67]; 0.72 in [68]; and 0.62 in [46]). Instead, conflicting results were found for other limiting amino acids of hempseed proteins. In both the papers of Tang and Wang and colleagues [67,68], others limiting amino acids were shown to be the sulphur-containing amino acid (methionine + cysteine) with an amino acid score of 0.65 [67] and 0.62 [68]. Hence, comparing the sulphurated amino acid score with the lysine amino acid score, the former resulted in the first limiting amino acid followed by lysine. Contrarily, House and co-workers [46] found that lysine was the first limiting amino acid followed by tryptophan (amino acid score, 0.87) and leucine (amino acid score, 0.94) and the limitation in the lysine content of hempseed proteins, ranks hempseed in the same range of the main cereal grains. These differences in the results may be related to the fact that the analyses were performed on different type of samples (i.e., commercial hempseed protein isolates and proteins extracted from whole hempseed). Tang and colleagues [67] have also calculated the amino acid score based on the FAO/WHO amino acid suggested requirements for children 10–12 years old and for adults, showing that, in these cases, there are no limiting amino acids.

House and colleagues [46] investigated the in vivo digestibility of hempseed proteins using a rat bioassay for protein digestibility, with the aim to evaluate the actual amino acid bioavailability. The authors observed that the in vivo protein digestibility of hempseed proteins collocates hempseed in the same range as the major pulse protein sources, such as lentils, and above cereal grain products. Furthermore, they also found that the presence of hull in the seed negatively affects the digestibility of the hempseed proteins. In fact, removal of the hull fraction from the hempseed led to an average increase in the protein digestibility from 85.2 to 94.9%. The authors supposed that the high fibre content of the hull may exert an influence on the digestibility of the proteins, but it is also possible that this decrease is, almost in part, due to the presence of some antinutritional factors such as phytate and trypsin inhibitors [39,74,75], with a different distribution in the various parts of the whole hempseed (see Section 3.1.5).

Overall, whole hempseed can be considered a rich-protein source containing a protein amount higher or similar than other protein-rich products, such as quinoa (13.0%) [45], chia seeds (18.2–19.7%) [76], buckwheat seeds (27.8%) [45] and linseeds (20.9%) [45]. Nutritionally, the protein fraction of hempseed is highly digestible, has a good profile of EAAs required for infants similar to those of casein except for lysine that is the first limiting amino acid in hempseed proteins, even if this limitation is related only for the amino acid requirement for infants up to 5 years old who require a larger proportion of lysin. Furthermore, in addition to EAA profile, it is important to consider also the benefits provided by the amount of other non-EEAs such as arginine. In fact, arginine is a dietary precursor for the formation of nitric oxide (NO), a potent mediator of vascular tone, and therefore it is very important for the health of the cardiovascular system. Additionally, arginine and NO specifically, have been linked to optimal immune function and to muscle repair [46], so from this point of view, the proteins of hempseed represent an important source of digestible arginine. Hence, whole hempseed or their derived products such as hempseed meal or hempseed protein isolate can be considered a good viable, vegetable-based protein source for human diet.

3.1.3. Hempseed Carbohydrate and Dietary Fibre

Dietary fibre is defined as the part of plant material in the diet, which is resistant to enzymatic digestion and that includes cellulose, non-cellulosic polysaccharides such as hemicellulose, pectin, gums, mucilage and a non-carbohydrate component, namely lignin. Nutritionally, the dietary fibre is considered an integral part of the carbohydrate fraction of a food matrix. As previously said, the total carbohydrate content of hempseed can range between 20 and 30% ( Table 2 ). Actually, only a few literature reports analysed the total carbohydrate and fibre of hempseed. Among these, Callaway [47] found that the total carbohydrate content of the whole hempseed belonging to the Finola cv amounted to 27.6 g/100 g of seeds, whereas Mattila and colleagues [45] by analysing the nutritional value of some commercial protein-rich seeds, among which is hempseed, found that the total carbohydrate content of whole hempseed was similar to those found in the whole flaxseed (34.4 ± 1.5 g/100 g of seeds and 29.2 ± 2.5 g/100 g of seeds, respectively). However, the most interesting result obtained in both studies was that a great part of the total carbohydrate of the analysed hempseed was constituted by dietary fibre, the most of which was the insoluble fraction ( Table 2 ). In particular, Callaway found a Total Dietary Fibre content (TDF) of 27.6 g/100 g of seeds [47], demonstrating that the entire carbohydrate fraction consisted in dietary fibre, whereas in the study of Mattila and co-workers [45], the TDF of hempseed amounted to 33.8 ± 1.9 g/100 g of seeds, representing the 98% of the total carbohydrate. Since the remaining carbohydrate after excluding the amount of TDF is essentially starch, it is possible to assert that hempseed represents a low-starch content food matrix and a good source of dietary fibre, above all, the insoluble fraction. The high content of Insoluble Dietary Fibre (IDF) was found also by Multari and co-workers [77] for hempseed flour, which resulted in an IDF content of 25.49 g/100 g, whereas the Soluble Dietary Fibre (SDF) content was 0.16 g/100 g, thus highlighting that hempseed is one of the richest sources of IDF among several high-protein crops such as green pea, buckwheat, and fava bean (IDS, 8.69 ± 0.07 g/100 g, 6.98 ± 0.01 g/100 g, and 9.39 ± 0.30 g/100 g, respectively). These results were rather consistent with those obtained by Callaway (IDF, 22.2 g/100 g; SDF, 5.4 g/100 g) [47] and by Mattila and colleagues (IDF, 30.9 ± 1.5 g/100g; SDF, 2.9 ± 0.4) [45] for the amount of SDF and IDF in whole hempseed.

An estimate of the IDF could be obtained also through the analysis of Neutral Detergent Fibre (NDF), which measures the amount of the cell wall components, namely, hemicellulose, cellulose and lignin. Vonapartis and colleagues [34] reported that the average concentration of NDF in hempseed of ten industrial hemp cvs grown in Canada, was 35.7 g/100 g and this result was in good agreement to that obtained by House and colleagues (NDF, 32.1 g/100 g) [46]. To note, it has been demonstrated that much of the fibre fraction of whole hempseed is located in the hull, as the fibre content obtained for dehulled hempseed was significantly lower than that found for the whole hempseed [45,46].

As previously said, the high fibre content of whole hempseed can negatively affect the protein digestibility; however, it is also important to take into account that the consumption of dietary fibre provides several health benefits in the human body. Indeed, dietary fibre, including the insoluble fraction, is considered a functional product acting as a probiotic, among others. In particular, it has been shown that it can improve insulin sensitivity; can reduce appetite and food intake, thus decreasing the risk of obesity and diabetes; and can lower the blood total cholesterol and low-density lipoprotein (LDL); moreover, because of the dietary fibre resists to digestion in the small intestine, it reaches the large intestine, where it is fermented by the gut microbiota, to produce short chain fatty acids with anti-carcinogenic and anti-inflammatory properties [78].

Hence, considering the health benefits derived by the ingestion of dietary fibre together with the considerable amount of fibre in hempseed, it would merit consideration as an ingredient to enrich the fibre content of foods, thereby improving their nutritional value. In this context, it should be taken into account that the use of whole hempseed (as it or defatted) would be more appropriate since almost all the fibre is located in the hempseed hull.

3.1.4. Hempseed Minerals

The total mineral content of a food matrix is indicated by the amount of ash that is the inorganic matter of the sample. Minerals are considered as micronutrients because their dietary requirement is relatively low (1–2500 mg/day depending on the mineral’s type); nevertheless, they are needed to maintain optimal health, playing physiological and structural essential roles. Based on their dietary requirements, minerals can be classified as macro-elements (i.e., minerals needed in amount of >50 mg/day), including phosphorous, potassium, magnesium, calcium; and sodium, and as micro-elements or in-trace elements (i.e., minerals needed in amounts of

Although different authors analysed the total ash amount in several varieties of hempseeds ( Table 2 ), highlighting that they are a good source of total minerals also considering other oilseeds like chia seeds [76] and linseeds [79] (4.9–6/100 g for hempseeds, 4.56–5.07 g/100 g for chia seeds and 3.5 g/100 g for linseeds), only a few authors investigated their minerals profile [43,44,45,47,48,49] showing that they can be considered a good source of useful macro- and micro-elements. The results obtained by these authors are reported in Table 7 .

Table 7

Hempseed mineral composition value (mg/100 g) of different industrial hemp cultivars.

P 1 K 1 Mg 1 Ca 1 Na 1 Fe 2 Mn 2 Zn 2 Cu 2 Cd 2 Ref.
1160 859 483 145 12 14 7 7 2 n.a. [47]
890 n.a. 240 90 n.a. 7 6 6 n.a. n.a. [48]
n.a. 252 268 94 6.8 10 4 5 0.5 n.a. [49]
n.a. 463–2821 237–694 144–955 n.a. 113–240 6–11 4–9 n.a. 0.1–0.4 [43]
1014–910 727–866 430–482 94–121 22–27 11–13 12–15 10–11 0.8–0.9 n.a. [44]
1170 921 496 127 n.a. 4 11 7 1.9 0.0015 [45]

1 Macro-element. 2 In-trace element. Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. P: phosphorous; K: potassium; Mg: magnesium; Ca: calcium; Na: sodium; Fe: iron; Mn: manganese; Zn: zinc; Cu: copper; Cd: cadmium. n.a.: not available.

In general, the mineral profile of seeds can widely vary based on environmental condition, mineral soil composition, the use or not of fertilizers, the type of fertilizer if used, as well as the plant variety. However, except to Siano and colleagues [49], other authors who have investigated the mineral profile of hempseeds belonging to different varieties and grown in various countries, obtained consistent and comparable values [43,44,47,48]. The major macro-elements found in hempseeds were phosphorous (P), potassium (K), magnesium (Mg), calcium (Ca), and sodium (Na), whereas among the in-trace elements, iron (Fe), manganese (Mn), zinc (Zn), and copper (Cu) have been reported.

Considering either EFSA’s Dietary Reference Value (DRV) [80] and the Food and Nutrition Board of the Institute of Medicine’s Dietary Reference Intake (DRI) [44], and the mineral content of hempseeds reported for different hemp cvs, it is possible to claim that hempseeds represent an excellent natural source of P, K, Mg, Ca, Fe, Zn, Cu, and Mn. Particularly, the amount of P, the most abundant mineral found in hempseeds, resulted in being higher also than that found in niger seeds (Guizotia abyssinica (L.f.) Cass.) and linseeds (Linum usitatissimum L.), which are oilseeds like hempseeds and are considered optimal phosphorous’ sources (P average content, 784.64 mg/100 g and 461.35 mg/100 g, respectively) [81]. The level of K in hempseeds is in general higher compared to that found in linseeds (568.91 mg/100 g) [81], and is equivalent to that observed in hazelnut (863 mg/100 g), thought to be an optimal source of this macro-element [82]. Interestingly, the high K amount along with a relatively low Na content, leads to a high K/Na ratio, which is believed to be related to cardioprotective effects as it promotes a high K intake considered to be inversely related to blood platelet aggregation and stroke incidence. Mg also contributes to hearth function and health, so that a Mg deficiency can lead to cardiac dysfunction. The amount of this mineral in hempseeds results in being similar to walnut (Mg range: 381–443 mg/100 g) which is one of the most important sources of Mg [83]. Among the in-trace elements, Fe is of particular importance considering its essential role for human health and its widespread dietary deficiency. Interestingly, the hempseed’s Fe content resulted to be exceptionally high in the study of Mihoc and colleagues [43] in comparison to others works ( Table 7 ), but this may be due to the very high Fe level in the experimental growth soil (1900–2043 mg/100 g). Lan and co-workers [44] highlighted that the hempseed’s Fe content is much higher than cereal grains, and for this, hempseeds could be used to enrich cereal food products, ameliorating iron deficiency. In the same study, the authors have also calculated the percent contribution of minerals per serving of hempseeds (30 g of seeds) to Reference Daily Intake (RDI) for adult males from age 19 to 30, finding that the highest % RDI supplied by hempseeds of the analysed industrial hemp cvs, was for Fe and Mn (average % RDI, 46.68 and 169.14, respectively), concluding that all analysed varieties represent an excellent sources especially of Fe, Mn, Cu, Zn, P, and Mg. Additionally, it has been shown an increase in the content of some minerals in hempseed kernel after dehulling. Particularly, in the Hungarian Hlesiia cv, hull removal led to an increase in phosphorous (1.5 times), iron (1.25 times), and zinc (2 times) [48]. Whereas Mattila and co-workers [45] observed that whole hempseed held 30–65% fewer macro-elements and Zn among in-trace elements in comparison to hemp hulls, whilst Cu and Mg were more evenly distributed in both the seed’s kernel and hull.

See also  Bend oregon cannabis seeds

It is known that hemp plant with its wide root system is among the plants appropriate for phyto-depuration, namely decontamination of soil from the high and toxic level of heavy metals such as cadmium (Cd). For the non-smoking population, the major source of exposure to Cd is food and among the most important Cd food sources can be mentioned integral cereals, potatoes, seafood, fungi, and oilseeds. A dietary exposure to Cd in humans leads to a relatively low, but efficient absorption of the metal in the kidney and liver, where it has a very long biological half-life ranging from 10 to 30 years. Cd is primarily toxic to the kidney, especially to the proximal tubular cells, where it accumulates over time and may cause renal dysfunction. Cd can also cause bone demineralization, either through direct bone damage or indirectly, as a result of renal dysfunction. Moreover, the International Agency for Research on Cancer has classified Cd as a human carcinogen (group 1) after that data on human exposure to Cd in the general population have been statistically associated with increased risk of some cancer types such as lung, endometrium, bladder, and breast cancers [84]. Taking into account the high capacity of hemp to absorb minerals from soil, including heavy metals, Mihoc and colleagues [43] evaluated the hemp plant capacity to translocate the absorbed Cd into the seeds in a soil with high Cd content (>0.3 mg/100 g) in the absence or presence of one of two different fertilizers (K and P fertilizers). They analysed the seeds belonging to five industrial hemp cvs approved for growth in Romania and they showed that hemp is able to absorb and translocate to the seeds from 130 to 400 µg/100 g of Cd, with the highest values obtained for plants treated with both K and P fertilizers. Considering the highly cadmium toxicity for human health, the European Food Safety Authority’s Panel on contaminants in the food chain [85] has set the tolerable weekly intake (TWI) for cadmium at 2.5 µg/Kg of body weight, whereas the FAO/WHO recommended 100 µg/Kg in cereals and legumes and up to 300 µg/Kg in medicine as the cadmium upper limit for safe human consumption [43]. Hence, the value of Cd found in hempseeds by Mihoc and colleagues [43] far exceeds the upper limit set by the FAO/WHO, even if according to the EFSA TWI value, for an adult man with an average body weight of 70 Kg, the TWI for Cd is 175 µg, and 30 g (a serving portion) of hempseeds belonging to plants grown in a soil with high Cd content, has a Cd level below the TWI (39–120 µg of Cd). In addition, the medium Cd content in soil is generally of 0.05–0.08 mg/100 g, namely from 6 to 37.5 times lower than that used in the work by Mihoc and colleagues [43]. Indeed, in another work investigating the heavy metal content in twenty-one hempseed samples collected from north western Turkey, the Cd content in the samples was found to be within the range of 0.5–2.3 µg/100 g, much lower than the upper limit recommended from the FAO/WHO [84]. Similarly, Mattila and colleagues [45] observed that the Cd level in whole hempseed was 1.5 µg/100 g. In their study, Mihoc and co-workers [43] also investigated whether and how the minerals’ soil composition, the presence or absence of different fertilizers and the seeding distance could influence the minerals profile of the analysed hempseeds. They observed that both fertilizers at different levels of administration, decreased the absorption of Zn and Mn due to both the soil’s pH increase which limited the availability of minerals from soil, and the mineral-phosphate complexes forming for the P excess owing to the use of fertilizer. Furthermore, the authors showed that the content of Ca, Mg, and K in the seeds was mainly affected by varieties. The uptake of Ca by the plants was disturbed also by fertilizer, whereas K uptake was influenced also by further factors, such as seeding distance and environmental factors such as soil moisture and temperature.

3.1.5. Hempseed Antinutritional Compounds

The antinutritional factors are biological compounds present in human or animal foods that reduce nutrients’ bioavailability or food intake, or the metabolism of which may lead to the release of toxic products, thereby contributing to impaired gastrointestinal and metabolic performance. Generally, compounds such as saponins, phytic acid, alkaloids, certain oligosaccharides, protease inhibitors, cyanogenic glycosides, glucosinolates, and tannins are traditionally incorporated into this group. Referring to hempseed, only a few reports [39,73,74,75] investigated about the antinutritional compounds in this seed, and the antinutritional factors that have been considered were phytic acid, trypsin inhibitors, condensed tannins, cyanogenic glycosides, and saponins. The literature data about these analyses are shown in Table 8 .

Table 8

Hempseed antinutritional compounds.

Phytic Acid 1 Condensed Tannins 2 Trypsin Inhibitors 3 Cyanogenic Glycosides 4 Sapoins 2 Ref.
4.5–7.6 * n.a. 10.8–27.8 * n.a. n.a. [39]
6.2–7.7 * 214.0–456.0 * 10.8–27.7 * 50.0–170.0 * 47.0–70.0 * [73]
5.3 ± 0.4 * 105.0 ± 4.0 ** n.a. n.a. n.a. [74]
6.1–7.4 * 135.0–214.0 * 18.2–28.4 * 60.0–240.0 * 5.9–8.1 * [75]

1 g/100 g. 2 mg/100 g. 3 U/mg. 4 ppm. * On defatted matter. ** On whole seed. Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. n.a.: not available.

Phytic acid is a natural plant compound acting as the major storage form of P as well as the primary P reserve for the plant. Indeed, it constitutes 60 to 70% of the total P in cereal grains, oilseeds, and legumes and generally comprises 1–5% weight in cereals, oilseeds, legumes, and nuts [86]. From a chemical point of view, PA is a myo-inositol hexakisphosphate (IP6) composed by an inositol ring esterified with six phosphate groups that are not internally connected; hence it has up to 12 replaceable protons allowing it to bind with multivalent cations (i.e., Zn 2+ , Fe 2+/3+ , Ca 2+ , Mg 2+ , Mn 2+ , and Cu 2+ ), positively charged proteins, and in some cases, starch through hydrogen bonds [87], forming insoluble complexes known as phytates. Both phytate-mineral and phytate-protein complexes are not readily absorbed by monogastric animals including humans because of their inability to metabolize phytic acid due to the lack of a sufficient level of phytate-degrading enzymes in their digestive tract. Thus, these complexes negatively affect the bioavailability of dietary and endogenous minerals and proteins as well as the digestive enzymes’ activity; therefore, for these reasons, phytic acid is considered an antinutrient. However, phytic acid may also have beneficial effects in the prevention and treatment of several pathological conditions related to oxidation and cancer [74], maybe due to its ability to chelate Fe ions, that lead phytic acid to inhibit iron-driven hydroxyl radical (–OH • ) formation and, hence, to strongly suppress lipid peroxidation and the oxidation of other biomolecules. Hence, for optimum physiological benefit of phytic acid, the phytate content in the upper part of the gut should be low to avoid negative effects on mineral and protein absorption and bioavailability, but at the same time, it should be high enough to use its antioxidant and anticancer activity. However, to date, accurate and clear information on the phytate dosage required to elicit beneficial effects in human is still limited. In accordance with Russo and Reggiani [73], to increase the safety for feed and food formulation, it is preferable to reduce the phytic acid content to at least 0.45 g/100 g of defatted sample. According to literature data, the results obtained by different authors about the phytic acid content in hempseed ( Table 8 ) are in good agreement and show that the level of this antinutritional compound ranges between 4 and 8% of the dry weight of the defatted matter. Galasso and colleagues [39] found a significant variability in the phytate content among different hemp cvs, and Russo [75] showed that French monoecious varieties had lower content than Italian dioecious ones, but this evidence is exactly the opposite of what Galasso and co-workers [39] found analysing twenty hempseed cvs and accessions of different origin, among which, the French varieties have been to be those with the highest phytic acid content. These differences in the results could be explained by the significant influence of genotype, growing year and the interaction between these two factors on the antinutritional compounds’ amount, phytic acid included [73]. Compared to other seeds, the content of phytic acid in hempseed seems to be higher. For example, Russo and Reggiani, and Russo and co-workers [73,75] highlighted that the phytic acid content of hempseed was higher than those found in soy bean (2%), and Mattila and colleagues [74], comparing different type of oilseed, legumes, and pseudo-cereal grains, observed that oilseeds in general, including hempseed, linseed, and rapeseed, form a group with a higher phytic acid content in comparison to other legumes (e.g., fava bean and lupin) and pseudo-cereal grains (e.g., quinoa and buckwheat), and among the analysed oilseeds, whole hempseed was that with the highest phytic acid level.

Condensed tannins (CTs) are phenolic compounds (flavonoid oligomers, specifically), ubiquitous in the plant kingdom, designated as proanthocyanidins. They are considered as antinutritional compounds because of their ability to form insoluble complexes with proteins and minerals, negatively affecting nitrogenous compounds uptake and absorption of minerals [73], and thus reducing the nutritional value of foods. Moreover, based on their concentration, CTs can affect the palatability of the meal. Nevertheless, being phenolic compounds, in the monomeric form, they also have some beneficial effects on health acting not only as antioxidants, but also as anticarcinogenic, cardioprotective, anti-microbial and anti-diabetic compounds [74]. According to Russo [75], the attention threshold for CTs is 1% of dry weight of the product. Although the amount of CTs found in hempseed meal ( Table 8 ) has been shown to be higher than other plant sources, for example soy (10 mg/100 g), the hempseed meal’s CTs content is however below than the attention threshold, so it neither is toxic, nor affects the hempseed meal palatability [75]. Russo and Reggiani [73] found significant variability for the CTs content in monoecious and dioecious cvs, with a double level in the monoecious varieties than dioecious ones. Mattila and co-workers [74] evaluating the amount of CTs in whole hempseed and in the hull of hempseed, observed that the hull had slightly higher CTs content than whole hempseed, even if the difference was rather small (105 ± 4 mg/100 g and 144 ± 5 mg/100 g, respectively). The same authors also found that CTs in hempseed were essentially epi-catechin polymers (i.e., procyanidins).

Trypsin inhibitors (TIs) are a type of endogenous antinutritional factor commonly present in various crops, seeds, and vegetables, among which are pulses and legume seeds, nuts, oilseeds, and cereal grains. They can have a negative impact on the nutritional value of food and feed products as they affect protein utilization and digestion in human and animals. Their role in the plant is to protect the plant against microbial proteinases and to regulate the activity of endogenous proteinases. From a nutritional point of view, the ingestion of TIs reduces the digestibility of food proteins and the bioavailability of amino acids because they can pass unaltered through the stomach as they are stable against pepsin and at low pH [88], and in the small intestine, they are able to inhibit the biological activity of the digestive enzymes trypsin and chymotrypsin—both important for the digestion of protein in living organisms—by competitive binding and in this way, they lead to the formation of an irreversible trypsin/chymotrypsin enzyme-TI complex. TIs have been largely studied mainly in legume seeds, particularly in soybean, as it is one of the richest sources of these antinutrients. Guillamòn and colleagues [89], investigating the TIs content in different types and varieties of legume seeds, identified three groups of legume seeds according to the TIs content:

the highest content group including different soy (Glycine max) cvs with a TIs content ranging from 43 to 84 U/mg of the sample;

the medium content group corresponding to common bean (Phaseolus vulgaris) varieties containing from 17 to 51 U/mg of the sample; and

the lowest content group including lentil (Lens culinaris) and fava bean (Phaseolus vulgaris) cvs containing from 3 to 10 U/mg of the sample.

Although most of the works regarding TIs are performed on soy and legume seeds in general, some literature data about the amount of these antinutritional compounds in oilseeds such as Sacha inchi (Plukenetia volubilis L.) [90] and linseed [91] are also reported. The TIs amount in hempseed meal reported by different authors ( Table 8 ) was found to range between 10.8 and 28.4 U/mg, and the differences in the TIs content is probably due to both genotype and growth conditions [39,74,75]. These values are similar to those found for the TIs content obtained for linseed meal (13.8–24.7 U/mg) by Russo and Reggiani [91] and, considering the grouping made by Guillamòn, they would place both linseed and hempseed in the medium content group of TIs. Interestingly, Pojić and co-workers [92] highlighted that the inner fraction of hempseed, containing predominantly cotyledon particles, is the part of the seed with the highest TI activity compared to the fraction containing the hull particles. By contrast, Mattila and colleagues [74] found that the TI activity between whole hempseed and hempseed hull was similar, indicating that TIs are equally located through the hempseed’s kernel and hull.

Cyanogenic glycosides are nitrogen-containing secondary metabolites that serve to the plant as a protective device against predators such as the herbivores. The level of cyanogenic glycosides produced by the plant is dependent upon the age and variety of the plant, as well as the environmental factors [93]. They are considered toxicants for humans because, structurally, they are glycosides of 2-hydroxynitriles that can be hydrolysed by the enzyme β-glucosidase into cyanohydrin, which is unstable and thus dissociates, leading to the toxic hydrocyanic acid. Although this is a violent poison, oral intake of cyanogenic glycosides (e.g., via food) is not necessarily toxic, particularly in the short-term intake. Indeed, hydrolysis of the cyanogenic glycosides in the digestive tract or by the liver leads to a slow release of hydrocyanic acid that is readily detoxified by the body. According to Russo [75], at levels below 100 ppm, the cyanogenic glycosides are not harmful to health. The amount of these antinutrients in hempseed has been investigated only in two reports [73,75], showing that, in the hempseed meal, their level significantly varies according to genotypes [75] and monoecious or dioecious cvs, with monoecious varieties containing lower cyanogenic glycosides than dioecious ones [73]. Moreover, these studies highlighted that the hempseed meal of some hemp cvs has a cyanogenic glycosides content above the safety limit, but since this value refers to hempseed meal, it is resulted to be more concentrated compared to the whole seed.

Finally, saponins comprise a large family of structurally related compounds containing a steroid or triterpenoid aglycone (sapogenin) linked to one or more water-soluble oligosaccharide moieties. At larger quantities, these compounds are gastric irritants, and they can exert toxic properties causing haemolysis of red blood cells. However, at low doses, they may have a plasma cholesterol lowering effect in humans, as well as strong cytotoxic effects against cancer cell lines, and are important in reducing the risk of many chronic diseases [74]. The FAO/WHO established a safety limit of 12% of saponins for quinoa seeds which are among the main saponins’ plant sources [94]. Russo and Reggiani [73,75] found that the saponins amount in hempseed meal of different cvs was well below than 12%, and lower than other plant sources such as linseed and soy, despite the results they obtained from two separate studies being very different, with the level of saponins showed in one work [73] almost ten-fold higher than that obtained in the other work [75].

Concluding, among the various antinutritional compounds analysed in hempseed, TIs and, above all, phytic acid were the most abundant, based on a comparison with other edible seeds. Overall, it has been highlighted that all the analysed antinutritional compounds are positively correlated, and therefore, it is possible that the biosynthetic pathways of these compounds in hemp are expressed simultaneously during the seed’s development [73].

3.2. Hempseed Functional Features

The functional properties of hempseeds are related not only to their high nutritional value which awards them important beneficial features for human health, but also to the presence of different bioactive compounds, among which are unique phenolic compounds with antioxidant, anti-inflammatory, and neuroprotective actions, as well as bioactive peptides that will be discussed in detail in the next sections.

3.2.1. Hempseed Phenolic Compounds
Composition Studies

Phenolic compounds are plant-derived secondary metabolites that are commonly produced by the plants as defence agents against biotic and abiotic stress, such as the attack of predatory species and UV light, respectively. These compounds, thanks to their chemical structures, have intrinsic antioxidant activity; therefore, they may protect cell constituents against oxidative damage and, hence, limit the risk of various degenerative diseases associated with oxidative stress. Indeed, in the human body they can exert a multitude of physiological activities, among which are cardioprotective and anti-inflammatory effects. Often, literature values about total antioxidant capacity and total phenolic content of a matrix are difficult to absolutely compare, due to the variety of analytical and extraction methods and the wide use of different reference compounds in the quantitation. Hence, in this review, we quantitatively compared the literature data obtained about these parameters by different authors, only if possible.

The first investigations about the antioxidant power and the total phenolic content (TPC) of hempseed were performed on hempseed oil. As previously said, the most abundant antioxidants in this product are tocopherols, especially the γ-isoform which confers to this oil a high oxidative stability despite the high level of unsaturated fatty acids that are highly susceptible to oxidation. However, together with tocopherols, also phenolic compounds contribute to the high oxidative stability of hempseed oil [52,58,95,96]. Indeed, it has been shown that hempseed cold-pressed oil represents a good dietary source of antioxidants which could have potential application in health promotion and disease prevention from oxidative damage, and therefore, it could be used to improve the quality and stability of food products. Smeriglio and colleagues [95] evaluating in detail the polyphenolic profile and the antioxidant properties of cold-pressed hempseed oil of the Finola cv, found that this product contained significant amounts of polyphenols, especially flavonoids such as flavanones, flavonols, flavanols, and isoflavones, the most representative and abundant of which were naringenin, kaepferol-3-O-glucoside, epicatechin, and daidzein, respectively. The presence of flavonoids in hempseed cold-press oil was demonstrated also by Faugno and co-workers [97] who investigated the polyphenol profile of cold-pressed oil of Uso 31 cv. The authors used the LS-ESI-MS/MS technique to assess the polyphenol qualitative and quantitative compositions of the oil and to investigate the influence of some agronomic practices on the quantitative variability of polyphenolic compounds. They found that, among phenols, the most representative compounds were dihydroxybenzoic acid, caffeoyl-tartaric acid isomers, p-coumaric acid, N-caffeoyltyramine, and N-feruoyltyramine, whereas, among the flavonoid subfamily, they found the glycosides of quercetin, kaempferol and isorhamnetin. Moreover, the authors observed that the highest production of polyphenols has been obtained without pre-seeding fertilization and with 60-plant/m 2 crop density, whereas when the plant density was halved, the abundance of phenolic compounds was compromised. In general, as said, the quantitative variability of polyphenols is affected by the influence of multiple biotic and abiotic factors, which take place in the biosynthetic pathway of these compounds, as reported also by Irakli and colleagues [3], who highlighted that the amount of phenolic compounds in the whole hempseed is affected by genotype, growing year, and the interaction between these factors. However, the growing year and so, the environmental and agronomical conditions, were the factor that most affected the variability of the TPC (contribution to total variance, 59%). In Table 9 , the literature data about the TPC extracted by different methods but analysed by the same technique (Folin–Ciocolteau) and expressed using the same reference compound (gallic acid) are reported, and they show the high variability of the parameters.

Table 9

Total phenolic content (mg Gallic Acid Equivalent (GAE)/g) of hempseed cold-pressed oil or whole hempseed.

Type of Sample TPC Ref.
Whole hempseed 13.68–51.60 [34]
Whole hempseed 3.82–7.80 [3]
Whole hempseed 0.77 ± 0.04 [49]
Cold-pressed oil 1.88 ± 0.003 [52]
Whole hempseed 0.96 ± 0.35 [74]
Cold-pressed oil 2.68 ± 0.09 [95]
Cold-pressed oil 0.44 ± 0.001 [96]
Whole hempseed 0.92 ± 0.04 [98]
Whole hempseed 2.33 ± 0.07 [99]

Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. TPC: Total Phenolic Content.

Although tocopherol was reported as the main antioxidant for hempseed oil, it would not be the same for the whole hempseed. Indeed, Irakli and co-workers [3] observed a significant positive correlation between the TPC and antioxidant activity of hempseeds belonging to seven industrial hemp cvs approved for cultivation in Greece and only weak correlation between γ-tocopherol and antioxidant activity, concluding that the antioxidant capacity of hempseed is due, mainly, to phenolic compounds rather than to the tocopherols. The high positive relation between the TPC and the radical scavenging activity of hydroalcoholic hempseed extract was also reported by Chen and colleagues [100]. These results can be explained by the fact that polyphenols are polar, hydro-soluble compounds and, thus, that only a few of them are isolated during oil extraction whereas most remain associated to the hemp cake [98]. Conversely, the tocopherols, that are fat-soluble, are extracted more efficiently, and hence, are more abundant in oil. This is in accordance with the results of Siano and co-workers [49] and Moccia and colleagues [98] who have analysed and compared the TPC and the radical scavenging activity of whole hempseed, hempseed flour, and hempseed oil of Fedora cv, showing that, although the values obtained for whole hempseed and hempseed flour were similar for both evaluated parameters, those for hempseed oil were significantly lower. Regarding the TPC of whole hempseed, Galasso and colleagues [39] highlighted that the value obtained for hempseed were slightly higher than those found for linseed (5.88–10.63 mg Caffeic Acid Equivalent (CAE)/g of dry weight of defatted hempseed vs. 4.64–9.40 mg CAE/g of dry weight of defatted linseed), which is considered a matrix rich in total phenols among the oilseeds [101]. In addition, the TPC and the total antioxidant capacity of whole hempseed could increase consequently the germination of seed, leading to a derived product–the hempseed sprouts—enriched with beneficial bioactive compounds [99,102].

Various authors found that in whole hempseed, polyphenols are mainly located in the hull rather than in the kernel [74,92,100] and that the main phenolic compounds that have been detected in C. sativa L. seeds are lignans, phenols derived from the shikimic acid biosynthetic pathway. Particularly, they originate from cinnamic acid derivatives which are biochemically related to the metabolism of phenylalanine. Lignans detected in hempseed are also called phenylpropionamides due to their chemical components and belong to two main groups known as phenolic amides and lignanamides [3]. The first ones are made by an ammine moiety (tyramine, derived from the tyrosine oxidative decarboxylation) linked to a phenolic moiety (a hydroxycinnamic acid, such as coumaric, caffeic or ferulic acid). The second ones are derived by a random polymerization of phenolic amides. Some of these phenols are found exclusively in the C. sativa L. plant. More than 20 kinds of phenylpropionamides, most of which are lignanamides, have been isolated from hempseed. Chen and co-workers [100] isolated and identified two hempseed lignans with strong in vitro antiradical activity and protective effect against in vitro oxidation of human LDL in an ethanol extract of hempseed hull. These compounds were the phenolic amide N-trans-caffeolyltyramine and the lignanammide cannabisin B, which were identified as the most abundant phenolic compounds in the hull fraction of hempseed also by Pojić and colleagues [92] who in addition, showed that the most abundant polyphenols in the cotyledon inner fraction of hempseed were catechin and p-hydroxybenzoic acid. The other phenylpropionamides identified as the most abundant in hempseed of different varieties were the lignanamides cannabisin A [3], cannabisin F, and grossamide [74]. Also, Yan and co-workers [103] isolated and identified a total of 14 phenolic compounds characteristic of the hempseed, twelve of which were lignanamides. Further phenylpropionamides recently isolated from hempseed were cannabisin I [104], cannabisin Q, and coumaroylaminobutanol glucopyranoside (CLG) [105], corresponding to the glycoside of 4-((E)-p-coumaroylamino)butan-1-ol previously described by Yan and colleagues [103].

Biological Effects

Concerning the functional effect, most of the phenolic compounds isolated from hempseed have been shown to have high radical scavenging activity compared to quercetin, and, in addition, the phenolic amide N-trans-feryoryltyramine and especially, the lignanamides 3,3′-demethyl-grossamide and 3,3′-demethylheliotropamide were also able to in vitro inhibit the acetylcholinesterase (AChE) enzyme at a concentration of 100 µg/mL, thus exhibiting properties similar to the medicines used for the treatment of mild to moderate Alzheimer’s disease (AD) such as galanthamine [103]. Bourjot and co-workers [104] found that, among the phenolic amides they have extracted from hempseed flour, N-trans-caffeoyltyramine had the highest antioxidant and arginase inhibitor activities. In this regard, the inhibition of arginase could raise NO bioavailability that ameliorates endothelial functionality and it can also reduce oxidative stress which plays a central role in the onset and progression of endothelial dysfunction involved in various diseases, including cardiovascular ones. However, the most important biological effects attributable to hempseed phenylpropionamides are the anti-inflammatory and neuroprotective activities. In this context, Zhu and co-workers [106] had recently isolated and characterized the chemical and functional features of two unique hempseed bioactive compounds named sativamides A and B. According to the authors, from a chemical point of view, they are non-lignanamide compounds characterized by a benzo-angular triquinane core (i.e., a core consisting of fused five-membered hydrocarbon rings and arranged in an angular position), derived from N-trans-caffeoyltyramine. Interestingly, it has been shown that pre-treating of the SH-SY5Y human neuroblastoma cell line with 50 µM of sativamides A or B, reduced the cell death caused by endoplasmic reticulum stress that has been shown to play an important role in neurodegenerative diseases, such as Parkinson’s disease and AD. The same cell line was also used by Maiolo and colleagues [107] to create a cellular model of Parkinson’s disease, on which the neuroprotective effect of various natural compounds, among which is N-trans-caffeoyltyramine extracted from hempseed, was tested. The obtained results highlighted that 150 µM of the hempseed’s phenolic amide was able to prevent the cell death induced by up to 150 µM of H2O2 treatment and due to oxidative stress and mitochondrial dysfunction caused by this toxic compound. Oxidative stress and mitochondrial dysfunction are thought to contribute to cell death in Parkinson’s disease; therefore, the resulting effect of 150 µM N-trans-caffeoyltyramine can be considered as potentially neuroprotective.

The neuroprotective effect of different hempseed phytochemicals has been shown to be related particularly to the anti-inflammatory and antioxidant action of some of these compounds on microglia cells which are immune cells of the central nervous system that are involved in regulating the immune responses in the brain, thus playing an important role in brain infection and inflammation. The persistent and/or over-activation of these cells is often related to neuronal damage and onset of neurodegenerative diseases, such as AD and Parkinson’s disease, and multiple sclerosis, that in fact, are characterized by chronic inflammation and oxidative stress. About this, Zhou and colleagues [105] investigated the anti-neuroinflammatory and neuroprotective action of each of the twenty phenolic compounds that they have isolated from hempseed, on the release of the inflammatory cytokine TNF-α from Lipopolysaccharide (LPS)-stimulated BV2 microglia cells, treated with 15 µM of each interest compounds. The authors highlighted that, among the analysed phenylpropionamides, those with a higher inhibitory activity on the Tumor Necrosis Factor α (TNF-α release were lignanamides and compared to resveratrol—the positive control—the much stronger inhibitory action was found for the CLG. To understand the molecular mechanism underlying the neuroprotective action of the most bioactive hempseed phenylpropionamides, various studies were performed by different authors. More specifically, to date, the investigated compounds were CLG [108], grossamide [109], and cannabisin F [110]. In all cases, BV2 microglia cells were pre-treated with 5, 10, or 15 µM of each tested compound 1 h before the addition of 100 ng/mL of LPS for 24 h. After 24 h of LPS exposure, it has been shown that all three lignanamides were able to decrease the release of the inflammatory cytokines IL-1β, IL-6, and TNF-α in a dependent-manner by the inactivation at different level of the NF-κB inflammatory pathway. Moreover, CLG and cannabisin F were also found to have the ability to promote the expression of nuclear factor erythroid 2-related factor 2 (Nfr-2), a protein important in modulating redox homeostasis, in regulating the cellular antioxidant response against reactive oxygen species (ROS) and in attenuating oxidative stress. Normally, this protein is located in the cytoplasm, but in response to oxidative stimuli, Nrf2 transferred to the nucleus and activated downstream genes involved in the antioxidant defence. Although LPS stimulation leads to an increased production of ROS by microglia-stimulated cells, it has been demonstrated that the pre-treatment with CLG or cannabisin F upregulated the Nfr-2 pathway, thus exerting a beneficial antioxidant effect [108,110]. In addition, it has also shown that cannabisin F was able to enhance its inhibitory action on the NF-κB transcription factor even by inhibiting the downregulation of the silent information regulator transcript-1 (SIRT1) induced by LPS. SIRT1 is a histone deacetylase that inhibits NF-κB transcriptional activity through deacetylation of its p65 subunit, thus leading to the reduction of inflammatory cytokines. LPS stimulation induces the downregulation of SIRT1, increasing the inflammatory status, but this can be counteracted by cannabisin F [110]. The anti-neuroinflammatory and neuroprotective effect of hempseed phenols was observed also in vivo on an LPS-induced neuroinflammatory model mice [111]. In particular, the beneficial effects were obtained after three weeks of treatment with 1 g/Kg/day of hempseed extract (concentration of the extract, 233.52 ± 2.50 µg/mg) and consisted of a reduced expression of the inflammatory cytokines IL-1β, IL-6, and TNF-α in the brains and the prevention of LPS-induced damage to the hippocampal nerve cells as well as an improvement in the animal’s learning, memory, and their cognitive function. The phenylpropionamides isolated from hempseed and the literature studies about their biological action are listed in Table 10 .

Table 10

Hempseed phenylpropionamides and their biological effect.

Compound Biological Effect Ref.
N-trans-caffeolyltyramine Strong in vitro scavenging DPPH radical and ORAC antioxidant activity;
LDL protection against in vitro oxidation;
In vitro AChE and arginase inhibitory activity;
In vivo anti-neuroinflammatory action;
In vitro prevention of H2O2-induced cell death.
N-trans-feryoryltyramine In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
N-trans-caffeolyoctopamine In vivo anti-neuroinflammatory action. [111]
N-trans-cumaroyltyramine In vivo anti-neuroinflammatory action. [111]
Cannabisin A In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
Cannabisin B Strong in vitro scavenging DPPH radical and ORAC antioxidant activity;
LDL protection against in vitro oxidation;
In vitro arginase inhibitory activity.
Cannabisin C In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
Cannabisin D In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
Cannabisin E In vivo anti-neuroinflammatory action [111]
Cannabisin F In vitro scavenging DPPH radical and ORAC antioxidant activity;
In vivo anti-neuroinflammatory action;
In vitro inhibition of the NFκB inflammatory pathway, activation of Nfr-2 antioxidant pathway and upregulation of SIRT1.
Cannabisin M In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
Isocannabisin N In vivo anti-neuroinflammatory action [111]
Grossamide In vitro inhibition of the NFκB inflammatory pathway.
In vivo anti-neuroinflammatory action;
3,3′-demethyl-grossamide In vitro scavenging DPPH radical activity;
In vitro AChE inhibitory activity;
In vivo anti-neuroinflammatory action.
3,3′-demethylheliotropamide In vitro AChE and arginase inhibitory activity. [103]
Sativamides A In vitro reduction of ER stress-induced cell death. [106]
Sativamides B In vitro reduction of ER stress-induced cell death. [106]
4-((E)-p-coumaroylamino)butan-1-ol In vitro inhibition of TNF-α release. [105]
Cumaroylaminobutanol glucopyranoside In vitro inhibition of TNF-α release;
In vitro inhibition of the NFκB inflammatory pathway and activation of Nfr-2 antioxidant pathway.
3.2.2. Hempseed Bioactive Peptides

Together with phenolic compounds, other kinds of hempseed’s functional compounds are the bioactive peptides. The evidence of the existence of these peptides has been demonstrated by the findings about the bioactive features observed for the products obtained by the hydrolysis of hempseed proteins. Indeed, it has been shown that, although hempseed proteins have limited bioactive properties, their hydrolysis provides hydrolysates with higher bioactivity [112,113,114], including antioxidant [72,112,113,114,115,116,117,118], antihypertensive [114,119], antiproliferative [72,112], hypocholesterolemic [120,121], anti-inflammatory, and neuroprotective [113,122] effects. This evidence suggests that bioactive peptides are encrypted in the protein native structure and are released during the hydrolysis process. Depending on the hydrolysis conditions (i.e., type of proteases used, period, and time of hydrolysis), hydrolysates with different kinds and efficiency degrees of activity can be obtained. This is due to the fact that hydrolysis conditions can influence the type of obtained peptides, namely the size and the amino acid profile—and hence, the structure—which in turn, influence the activity and the function of peptides. In this context, literature data agree that important factors which affect the bioactivities of the peptides are their molecular weight and amino acid composition. In general, low-molecular weight peptides are more bioactive than the high-molecular weight ones, since they more easily escape enzymatic degradation in the gastrointestinal tract, and therefore, they can be absorbed and introduced as such into the blood stream than larger peptides. Moreover, small peptides are likely more easily able to interact with specific target sites, such as an enzyme’s active site, in comparison to larger peptides. Instead, the peptide’s amino acid composition is fundamental to define its structure and, therefore, to influence the strength and the efficiency of the interaction with the peptide’s target site; in fact, the amino acids composition is the basis of the peptide’s structure-function relationship.

About hempseed protein hydrolysates, different reports [114,115,116,119,122] confirmed that the type and level of proteases used as well as the time of hydrolysis affect the degree of hydrolysis, the amino acids profile, and the molecular weight of the obtained peptides due to the fact that different proteases have different specificities, and therefore, they will produce different types of peptides with different activities. Moreover, these publications demonstrated that, overall, independently to the hydrolysis’ type, hempseed proteins are highly susceptible to proteolysis and most of the liberated bioactive peptides have a molecular weight less than 10 KDa and a high hydrophobicity rate. More specifically, Tang and colleagues [115] and Wang and co-workers [116] observed that hempseed hydrolysates with a higher degree of hydrolysis, a higher amount of hydrophobic amino acids, and a higher surface hydrophobicity possessed higher in vitro antioxidant activity (particularly, the α, α-diphenyl-β-picrylhydrazyl (DPPH) radical scavenging and Fe 2+ chelating abilities). Their results were consistent with those obtained by Logarušić and colleagues [112], who also found that the obtained hydrolysates showed cytotoxic and antiproliferative activity on HeLa cancer cells and a stimulatory effect on the proliferation of normal HaCaT cells. However, the effective concentration at which the hydrolysates exerted these functional activities depended on the hydrolysis condition, thus highlighting that different hydrolysis methods generate peptides with different structure and, hence, different activity. Similar results were obtained also by Rodriguez-Martin and colleagues [113], who in addition to the in vitro antioxidant activity demonstrated that specific hempseed hydrolysates’ fractions possessed neuroprotective action, being able to down-regulate the expression levels of TNF-α and IL-6 inflammatory cytokines and to increase the mRNA levels of the anti-inflammatory IL-10 gene at the concentration of 100 μg/mL in LPS-stimulated BV2 microglia cells. Furthermore, Malomo and colleagues investigated both in vitro and in vivo hypotensive [119] and in vitro neuroprotective [122] activity of hempseed protein hydrolysates obtained by different hydrolysis methods, highlighting that the hydrolysates’ activity was determined mostly by the type and sequence of peptides’ amino acids rather than by the degree of hydrolysis that is related to the level of the proteases used and the time of the hydrolysis process. Particularly, the authors observed that the hypotensive effect of hempseed protein hydrolysates was due to their angiotensin-converting enzyme (ACE) and renin-inhibitory activity, which seemed to be related to high proline and phenylalanine content, respectively, though also other additional peptides’ structural factors were likely to be involved in the overall functional effect. In the other work [122], the authors showed that hempseed hydrolysates exert an in vitro neuroprotective action through inhibition of the activity of the acetylcholinesterase enzyme (AChE) and observed that the most active hydrolysates were those with the highest negatively charged amino acids amount. Also, arginine was the second most abundant amino acid found in the hydrolysates with higher AChE inhibitory action, and according to the authors, this was probably due to the fact that it is responsible for binding the peripheral anionic site (PAS) of AChE that is believed to be an important enzyme binding site for inhibitors, thus highlighting the importance of the structure-function relationship. Nevertheless, none of these reports that have investigated the bioactive features of hempseed protein hydrolysates elucidated the amino acids profile and structural features of peptides responsible for the investigated functional effects, nor the specific relationship between their function and structure.

In this regard, Aiello and co-workers [121] found that hempseed peptides with a hypocholesterolemic effect contained 8−10 amino acid residues and were characterized by a high hydrophobicity rate, a hydrophobic N-terminus, and a negatively charged C-terminus. These were identified as features essential to interact with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCoAR), the enzyme that mediates the rate-limiting step of the intracellular cholesterol production. These peptides seemed to be generated especially through peptic hydrolysis of hempseed proteins because it has been observed that, in comparison to hydrolysates obtained using other peptidases, the peptic hydrolysate exerted a significantly higher hypocholesterolemic activity on HepG2 cells already at a concentration of 0.25 mg/mL [120]. This hypocholesterolemic effect has been attributed to a statin-like mechanism, since like statins, the peptic hempseed hydrolysate was able to decrease the cholesterol level (1) by acting as direct inhibitor of HMGCoAR and (2) by increasing the level of sterol-responsive element binding protein 2 (SREBP2), a transcription factor playing a crucial role in the regulation of genes involved in the cholesterol homeostasis, such as the low-density lipoprotein receptor (LDLR) coding gene. Therefore, the increase in the SREBP2 level leads to an increase in the LDLR expression on the HepG2 surface and to a consequent increase in the circulating cholesterol uptake.

As said, another bioactive property attributed to hempseed protein hydrolysate was the anti-hypertensive activity [119]. Publications investigating the structural features of the hydrolysate’s component peptides found that most bioactive peptides able to inhibit renin and/or ACE contained three or four amino acids and some particular structural characteristics related to its sequence. They had a good hydrophobicity/hydrophilicity balance; contained hydrophobic amino acids at the C-terminal, aromatic, or branched-chain amino acid residues near the C-terminal; and hydrophobic residues at the N-terminal. Moreover, when a branched-chain, hydrophobic amino acid residue and/or an ionizable functional group were present at the N-terminal or near it, the ACE-inhibitory activity may be enhanced [121,123,124,125]. Hempseed peptides with these structural features that has been shown to possess in vitro ACE-inhibitory activity were the Glycine-Valine-Leucine-Tyrosine (GVLY), Leucine-Glycine-Valine (LGV) [124], Tryptophan-Valine-Tyrosine-Tyrosine (WVYY), and Proline-Serine-Leucine-Proline-Alanine (PSLPA) peptides, whereas the peptides Tryptophan-Tyrosine-Threonine (WYT), Serine-Valine-Tyrosine-Threonine (SVYT), and Isoleucine-Proline-Alanine-Glycine-Valine (IPAGV) showed dual inhibition of ACE and renin enzymes [123], with the tripeptide WYT exhibiting the strongest renin inhibition related to the presence in its sequence of the main structural features characteristics of renin-inhibitor peptides, namely one hydrophobic side chain (tryptophan) at the N-terminal, bulky chains (tyrosine) at the C-terminal, one hydrogen bond donor (tryptophan), and two hydrogen bond acceptors (threonine and tyrosine) [125]. Girgih and colleagues [125] found that the hempseed peptides inhibited ACE through a mixed-type model of enzyme inhibition, implying that peptides bound to both active and non-active sites, thus blocking the substrate binding or producing changes in the enzyme’s conformation, which reduced the substrate affinity with the active site. These interactions between peptide and ACE were mainly stabilized by electrostatic and hydrophobic interactions and hydrogen bond formation. Whereas the hempseed peptides inhibited renin enzyme by an uncompetitive model of enzyme inhibition, implying that peptides bound to the renin−substrate complex, causing reduction in the reaction velocity as well as the catalytic efficiency. Also in this case, the main involved interactions were the electrostatic and hydrophobic ones, as well as multiple hydrogen bonds. Of note, these bioactive peptides originated by simulated gastrointestinal digestion of hempseed proteins. In addition, the in vivo hypotensive ability of the WVYY, PSLPA, WYT, SVYT, and IPAGV peptides were assessed after oral administration of 0.5 mg/mL of each peptide to spontaneously hypertensive rats. The results demonstrated that all analysed peptides were able to significantly reduce the systolic blood pressure (SBP) of animals, but PSLPA, SVYT, and IPAGV exerted a long-lasting SBP-lowering effect, indicating a more efficient absorption coupled with strong binding to target enzymes and resistance to structural inactivation by gastrointestinal tract or blood circulatory system proteases [123].

Hydrophobicity represents a particularly important feature for all bioactive peptides in general and for the antioxidant ones in particular. Indeed, along with the short length of the peptides, hydrophobicity is essential to facilitate the crossing of the intestinal barrier and to enhance the peptides permeability through the cell membrane via hydrophobic association with the lipid bilayer, and in antioxidant peptides, it promotes the effective interaction with free radicals and their inhibition, thus achieving potent antioxidant effects [121]. It has been shown that the hydrophobic amino acids such as valine, alanine, and leucine, represent 50% of the total amino acids in antioxidant hempseed peptides and that they are distributed on both sides of the peptide chain [126]. The hydrophobic, aromatic amino acids such as phenylalanine and tryptophan are also abundant since they can enhance the metal chelating ability due to the several binding sites on their aromatic rings [127]. Another amino acid residue recurring in the sequence of antioxidant peptides, is histidine, especially located at the N- or C-terminal where it can enhance the radical scavenging activity due to its imidazole ring that is effective in metal-ion chelation [126,127].

Finally, Ren and co-workers [128] identified two hempseed peptides with α-glucosidase inhibitory activity and therefore, with antidiabetic property. These peptides were the dipeptide Leucine-Arginine (LR) and the pentapeptide Proline-Leucine-Methionine-Leucine-Proline (PLMLP). Even in this case, the hydrophobic amino acids gave a great contribution to the performance in the inhibition of α-glucosidase activity, and the P and L residues seemed to be particularly important; in fact, they were been considered as vital amino acids playing α-glucosidase inhibitory action separately or synergistically.

In conclusion, it is important to highlight that, although the in vitro and, in part, in vivo (animal) studies have demonstrated the functional effects of hempseed protein hydrolysates and of single isolated peptides, human studies investigating the peptides’ stability into the gastrointestinal tract and their bioavailability, namely the capacity to reach the target site in the active and functional form, are still lacking and they should be investigated.

4. Hempseed Dietary Supplementation

Considering the antioxidant and anti-inflammatory properties related to the hempseed’s components, different authors investigated whether hempseed food supplementation could have the ability to counteract chronic-degenerative diseases characterized by chronic inflammatory and oxidative stress conditions, such as cardiovascular and neurodegenerative diseases. Until now, most of the studies have been conducted on animal models and only a few literature reports have been found on humans, underlining the requirement to investigate the effects of the supplementation with hempseeds and their derivatives on human health and to understand their potentiality as ingredient for functional foods. With this in mind, in the following subsections, literature publications about the effects of hempseed- and hempseed products-based supplementation in animals’ and humans’ studies have been reviewed.

4.1. Animal Studies

According to the WHO, cardiovascular diseases (CVDs) are the first cause of worldwide death [129]. Atherosclerosis, hypercholesterolemia, and hypertension represent among the major risk factors of CVDs and both hypercholesterolemia and hypertension, along with chronic inflammation and oxidative stress, are considered as the factors that promote the process of atherosclerosis [130]; hence, their prevention would reduce the risk of atherosclerosis and CVDs onset. Diet represents an important non-pharmacological tool that can reduce cardiovascular risk and, thus, improve health outcomes of people at risk, and in this context, the antioxidant and anti-inflammatory properties of whole hempseed could represent an effective and efficient dietary intervention to promote the treatment and prevention of the CVDs. Therefore, some authors investigated the potential anti-hypercholesterolemic, anti-hypertensive, and anti-atherosclerotic ability of hempseeds or hempseed derived products such as hempseed oil, hempseed flour, or hempseed protein hydrolysate, after dietary administration, mainly on rats’, mice’s, or rabbits’ CVDs models.

Regarding this, Kaushal and colleagues [131] evaluated whether 1 month of supplementation of 10% whole hempseeds in Wistar rats fed high-fat, pro-hypercholesterolemic diet had the ability to ameliorate hypercholesterolemia-associated cardiovascular effects. The obtained results highlighted that when 10% whole hempseeds was added to a normal, balanced diet, it did not caused any changes in the serum lipid parameters, the aorta’s wall histology, and the redox and inflammatory status of the animals in comparison to the control (i.e., rats fed a normal, balanced diet without hempseeds supplementation), however, the supplementation of a high fat diet with 10% hempseeds led to a significantly ameliorated effect of serum parameters (i.e., decreased total cholesterol, LDL, and triglycerides levels), redox and inflammatory status, as well as the prevention in the development of the aortic changes related to atherosclerosis. As said, inflammation and oxidative stress are involved in the atherosclerosis changes. It is known that high-fat diet is responsible for the activation of the inflammation inducible genes such as cyclooxygenase-2 (COX-2), which lead to increase the expression of pro-inflammatory prostaglandins Prostaglandin E (PGE). The COX-2 inflammatory pathway is closely related to the redox status because it can be activated by oxidative stress and vice versa (i.e., the COX-2 inflammatory pathway can generate oxidative stress). Based on the obtained results, the authors asserted that 10% hempseeds supplementation was able to exert the anti-hypercholesterolemic effects through redox-sensitive modulation of the inflammatory pathway of PGs biosynthesis. In particular, it would seem that the antioxidant properties of hempseed, which include the ability to scavenge free radicals, to chelate metal ions, and to inhibit the LDL oxidation, may improve the redox status in the high-fat diet induced hypercholesterolemic rats, and thus, it can induce a redox shift of the COX-2 pathway toward the production of anti-inflammatory PGs of D- and J-series.

The beneficial effect of the short-term (20 days) hempseed feeding in Wistar rats on the prevention of hypercholesterolemia and coronary artery disease was observed also by Karimi and co-workers [132]. Indeed, they found that the hempseed dietary treatment did not significantly affect the mean fasting triglyceride, total cholesterol and albumin levels, but it was able to improve the blood lipid and protein profiles, since it significantly decreased the mean fasting serum LDL level, and significantly increased the mean fasting serum HDL and total protein levels. These actions were attributed to the high and low contents of PUFAs and SFAs, respectively, in hempseeds, as well as to their relatively high amount of phytosterols, especially β-sitosterol. Actually, Seo and colleagues [133] showed that also hydrophilic components of hempseeds could exert an anti-atherosclerotic effect. In their study, the authors treated via intragastric inoculation Apo-E Knock Out (KO) mice atherosclerotic animal models, with a hempseed water extract for 14 weeks. The lack of Apo-E in these genetically modified mice led to increase in total plasma cholesterol and triglycerides and decrease of serum HDL-cholesterol level and, as consequence, generated atherosclerotic lesions similar to those found in humans. The treatment with hempseed water extract reduced the atherosclerotic plaque formation, as well as the serum level of total cholesterol and LDL-cholesterol and increased the serum HDL-cholesterol level. Moreover, a reduction in the serum level of the inflammatory cytokine TNF-α demonstrating a decrease in the inflammatory status related to atherosclerosis was found also. As previously said, all these findings have been generally attributed to the hempseed lipidic fraction, that is missing in the hempseed water extract used in this study, and therefore, the authors concluded that some hydrophilic compounds of hempseed, presumably phenolics, possessed the observed anti-atherosclerotic action, but the specific compounds and the molecular mechanisms by which they exerted this protective action have still to be elucidated.

The ability of the dietary hempseeds supplementation to reduce the dietary cholesterol uptake in the presence of an enriched-cholesterol diet, was observed also by Lee and co-workers [134] in Drosophila melanogaster and was attributed to the ability of some hempseed components, PUFAs LA and ALA in primis, to down-regulate the expression of the Niemann-Pick C1-Like 1 (NPC1L1) gene, coding for a key intestinal cholesterol absorption protein. By contrast, Prociuk and colleagues [135] found that 8 weeks of 10% hempseeds supplementation of a cholesterol-enriched diet in albino New Zealand rabbits did not decrease the cholesterol plasma level but led to an approximately 12-fold increase in the plasma GLA level, resulting in a normalization of the platelet aggregation. Indeed, it was shown that the enriched-cholesterol diet without hempseeds supplementation increased the cholesterol plasma level and the platelet aggregation, raising the risk of acute coronary syndrome. The addition of hempseeds to the diet was however able to inhibit the platelet aggregation despite the presence of high circulating cholesterol, and this effect was exactly attributed to the high GLA plasma level. All these results that showed an overall beneficial effect of hempseeds dietary supplementation on atherosclerosis are still in contrast to those found by Gavel and co-workers [136]. Indeed, they found, by investigating the effect of the addition of 10% hempseeds to the cholesterol-enriched diet of albino New Zealand rabbits on atherogenesis and aortic contractile function, that this dietary supplementation would not be able to protect the aortic vessel from the atherosclerotic plaque formation. In this case, the hempseeds supplementation provided only mildly beneficial effects against contractile disfunction associated with atherosclerotic vessel.

In female subjects, the risk of coronary heart disease and other CVDs related to the rise of the concentration of circulating total cholesterol and LDL-cholesterol, can also increase as a consequence of menopause, which is associated also to other relative complications related to the estrogen deficiency, like depression, anxiety, and possibly impaired cognition. In this context, Saberivand and colleagues [137] demonstrated that whole hempseeds dietary supplementation (until 10%) in a balanced diet of the ovariectomized rat model of menopause, may improve the menopausal complications including the cardiovascular ones. In particular, the authors have shown that 3 weeks of dietary supplementations with 1%, 2%, or 10% of hempseeds were able to conserve the triglycerides and total cholesterol plasma level close to the control group (non-ovariectomized rats), preventing the dyslipidemia and the weight gain that usually occurs after ovariectomy (or menopause) as a consequence of the decline of the estrogen levels. Indeed, it was found that the decline of plasma estrogen levels was prevented by the hempseeds dietary treatment, probably thanks to the presence of phytoestrogens, such as β-sytosterol, in hempseeds. In addition, the authors even observed that the hempseeds dietary supplementation was also capable of exerting an antidepressant activity, as well as of preventing the accrual of blood calcium and thus preventing the bone loss and promoting the bone homeostasis.

As previously underlined, along with hypercholesterolemia, hypertension represent another main CVDs risk factor. It is defined as a systolic blood pressure (SBP) higher than 140 mmHg or a diastolic blood pressure (DBP) higher than 90 mmHg [138]. The in vitro studies which demonstrated the existence of hempseed peptides with anti-hypertensive properties (see Section 3.2.2) led some researchers to evaluate the in vivo hypotensive ability of hempseed products on the spontaneously hypertensive rats (SHRs). This animal model is characterized by high plasma ACE and renin enzyme activities as well as a decrease in the antioxidant defence and higher oxidative stress in comparison to the normotensive rats. It has been shown that a diet supplemented with 1% of hempseed proteins hydrolysate was effective both to prevent the hypertension development in SHRs and to act as treatment to reduce the SBP in SHRs with still established hypertension through the reduction of the plasma ACE activity [138]. Moreover, the same supplemented diet led also to a reduction of the oxidative stress in SHRs normalizing the plasma total antioxidant capacity, which reached a value similar to normotensive rats, and enhancing the cellular antioxidant defences, namely the catalase and superoxide dismutase enzymes’ activity [117]. The anti-hypertensive and antioxidant effects were not so marked in the SHRs fed a diet supplemented with 1% hempseed protein isolate instead of the hempseed protein hydrolysate. This evidence was explained with the fact that the already hydrolysed peptides are more bioactive or more bioavailable than those obtained by the gastrointestinal digestion of hempseed proteins [117,138], suggesting the advantage of the use of hempseed protein hydrolysate rather than whole hempseed or hempseed proteins isolate as an ingredient to formulate functional foods or nutraceuticals for the prevention and treatment of hypertension. Interestingly, the hypotensive effect of these hempseed products was not observed in normotensive rats, suggesting an action directly related to the higher ACE plasma activity than the physiological level [138].

Others animal studies were performed to explore the potential beneficial effect of the dietary intake of hempseeds and their products on neurodegenerative diseases, generally associating with aging, oxidative stress, and neuroinflammation, such as AD, cognitive deficit, memory impairments and multiple sclerosis (MS). Most of these studies were carried out after that epidemiological evidence highlighted that some Chinese population, habitual consumers of hempseeds which make up an integral part of their daily diet, are characterized by significant numbers of long-lived centenarians’ individuals with good cognition and few health problems [139,140]. About this, Lee and co-workers [134] found that a Drosophila melanogaster model of AD reared in a hempseed meal media, significantly suppressed the cytotoxicity of amyloid β42 (Aβ42) peptides accumulation, ameliorating the eye degenerative phenotype, and this neuroprotective effect of hempseed meal was attributed to the PUFAs LA and ALA. Further evidence has demonstrated that the daily inclusion and long-term consumption of hempseeds into the diet may promote the longevity and the lifespan extension; may improve cognitive function; and may prevent age-related diseases, including obesity, diabetes, and cancer in old mice, as a consequence of the adjustment of some nutritional imbalances typical of the western diet (e.g., the n-6/n-3 PUFAs ratio), and the capability to regulate the expression of genes involved in the regulation of 5′AMP-activated protein kinase (AMPK) signalling that can reduce the oxidative stress and can inhibit the inflammatory response induced by the NF-κB pathway [140]. It has been also shown that daily oral administration of hempseed oil on an MS mice model can have positive effects on the treatment of this chronic-inflammatory and neurodegenerative disease characterized by wide demyelination, since it can exert immunomodulatory action, in particular the anti-inflammatory one, and can improve the re-myelination of neuronal myelin sheath in the brain, with a protective effect on the central nervous system (CNS) [141]. This protective effect of hempseed oil in CNS tissues seems to be a consequence of the increase in the intake of n-3 PUFAs and the n-6 anti-inflammatory GLA and of the reduction of the n-6/n-3 PUFAs ratio and of SFAs intake, all of which are factors able to regulate the mTOR signalling pathway in order to shift the immune response from pro- to anti-inflammatory one, thus reducing the chronic inflammation, which is an important factor for MS onset and development [141,142]. However, in many of the reports that demonstrated the neuroprotective effect of hempseeds or derivatives dietary supplementation, the hempseeds’ supplement was not the only one administrated. In fact, hempseeds were often administrated in combination with other products such as bitter vegetable (Sonchus oleraceus) [140] or evening primrose oil [141,142], and therefore, based only on these data, it is not possible to understand whether the beneficial effects can be obtained also with the solely ingestion of the hempseeds supplement or whether they are closely related to a co-operative action of the both administrated supplements.

Hence, although different evidence of an effective beneficial action of hempseeds or hempseed derivatives on CVDs and neurodegenerative disease animal models is present in scientific literature ( Table 11 ), further studies are still needed to clarify the exact molecular mechanisms involved as well the type and the doses of the more efficient hempseed product necessary to exert the in vivo beneficial function, that are all essential factors to develop a potentially functional food.

Table 11

Literature studies on the effect of hempseed or hempseed products’ dietary supplementation on animal models.

Supplement Type Purpose Experimental Design Results Ref.
Hempseed meal hydrolysate (HMH) Evaluation of the antioxidant ability of an HMH-containing diet to attenuate the plasma levels of some oxidative stress markers in growing and adult SHRs rats. 8-week old SHRs (n = 8) fed control or 1% HMH-containing diets ad libitum for 8 weeks (for analysing the preventive effect).
20-week old SHRs (n = 4) fed control or HPH-containing diets ad libitum for 4 weeks (for analysing the treatment effect).
Dietary intervention with a specific HMH on young and adults SHRs exerted an antioxidant action by:
• The increase of the SOD and CAT activities in both growing and adult SHRs;
• The significant decrease of the TPx plasma level in both growing and adult SHRs and NTRs.
Hempseed Investigation of the aspects of dietary hempseed against hyperlipidemia-associated CV risks. 1 month of 10% hempseed supplemented high fat-diet on Wistar rats. The 10% hempseed dietary treatment had an anti-hyperlipidaemic effect by inducing:
• The serum level decreases of the cholesterol, LDL and triglycerides;
• The increase of the HDL serum level;
• A significant reduction in the aorta thickness;
• Less intima damage foam cells formation and smooth muscle cell proliferation;
• The remarkable decrease in the lipid deposition, plaque size, and lesion surface area distribution;
• The decrease of the pro-inflammatory PGEs expression;
• The increase of the anti-inflammatory PGDs expression.
Hempseed Evaluation of the effect of hempseed feeding on lipid and protein profiles. 20-days of hempseed supplementation (free access) on Wistar rats. Short-term hempseed dietary intake can have hepatoprotective properties and beneficial effect on the prevention of CVD by favouring:
• The decrease of the mean fasting serum LDL level;
• The increase of the mean fasting serum HDL and total protein levels.
Hempseed water extract (HWE) Evaluation of the anti-atherosclerotic activity of hempseed water extract in ApoE KO mice. 14-days of intragastric inoculation of 300 µL of hempseed water extract or distilled water (control) to six-week-old, male ApoE KO (n = 7). Dietary HWE ingestion exerted an anti-atherosclerotic effect through:
• The reduction of the atherosclerotic plaque formation in the aortic sinuses;
• The reduction of the serum GOT concentration, demonstrating less liver damage after the treatment;
• The decrease of total serum cholesterol and LDL, and the increase of serum HDL;
• The significant decrease of TNF-α serum level.
Hempseed Meal (HSM) Investigation of the protective effects of the dietary intake of HSM and its LA and ALA components on AD and CVD Drosophila melanogaster models. GMR-Aβ42 Drosophila melanogaster line (AD model) reared in cornmeal-soybean standard media with the LA, ALA, and GLA amounts present in the HSM (for the effect on AD phenotype).
Wild-type Drosophila melanogaster larvae reared in HSM media with 35.1 μg/mL of cholesterol (for the CV effect).
Thanks to their LA and ALA contents, HSM dietary uptake may exert beneficial effects on AD and CVD through:
• The suppression of suppressed Aβ42 cytotoxicity in the GMR-Aβ42 flies’ line reared on HSM mean (beneficial effect on AD);
• The reduction of dietary cholesterol uptake observed in the wild-type flies reared on the cholesterol media (beneficial effect on CVD).
Hempseed Investigation of the ability of dietary hempseed to reduce platelet aggregation under hypercholesterolemia. Male New Zealand rabbits fed 125 g/day of control diet supplemented with 10% of hempseed and 0.5% of cholesterol for 8 weeks. Hempseed supplementation to a hypercholesterolemic diet is able to normalize the platelet aggregation by increasing the GLA plasma level. [135]
Hempseed Investigation of the dietary hempseed ability to inhibit atherosclerosis and the associated vascular contractile dysfunction in a cholesterol-induced rabbit model. Male albino New Zealand rabbits fed 125 g/day of control diet supplemented with 10% of hempseed and 0.5% of cholesterol (to induce atherosclerotic plaque formation) for 8 weeks. Dietary hempseed supplementation did not generate protection against atherosclerotic plaque formation in hypercholesterolemic diet, but it provided mildly beneficial effects against contractile dysfunction associated with atherosclerotic vessels. [136]
Hempseed Investigation of the ability of hempseed dietary intake on the prevention of ovarian hormone deficiency-induced hypercholesterolemia in ovariectomized rats and on the complications of estrogen deficiency such as depression, anxiety, and bone loss problems. Bilateral ovariectomized six-month-old female Wistar rats (n = 5) fed 1%, 2%, or 10% hempseed supplemented diets or a control diet (standard commercial diet) for 3 weeks. Until 10% of hempseed dietary supplementation improved the post-ovariectomized complications in rats since it:
• Prevented the accrual of blood calcium, preventing the bone loss;
• Prevented the body weight gain induced by ovariectomy;
• Conserved the TGs and TC plasma levels as those of the non-ovariectomized rats, preventing dyslipidaemia;
• Resulted in an antidepressant activity.
Hempseed meal hydrolysate (HMH) Evaluation of the effect of HMH-containing diet on the prevention and treatment of hypertension in growing SHRs and in SHRs with established hypertension. 8-week old SHRs (n = 8) fed control or 1% HMH-containing diets ad libitum for 8 weeks (for the preventive effect).
20-week old SHRs (n = 4) fed control (without HPH) or HPH-containing diets, ad libitum for 4 weeks (for analysing the treatment effect).
Dietary intervention with a specific HMH on young and adult SHRs exerted a preventive and therapeutic effects since it led to:
• The attenuation of the normal increases of SBP in young growing SHRs;
• The significant reduction of SBP in adult SHRs;
• The significant reduction of the plasma ACE and renin activities in both young and adult SHRs.
Hempseed and bitter vegetable (HB) Evaluation of the beneficial effect of the HB diet on chronic diseases and on the slowing of the aging process. 15-month-old C57BL/6 female mice (n = 10) fed low CHO, low SFA, and high PUFA content-HB diets containing hempseed and bitter vegetable (Sonchus oleraceus) (2:1) or control (western diet), ad libitum until only 20% of the mice in one group survived. The HB diet is capable of promoting health and longevity since it:
• Significantly increased the mice lifespan;
• Improved the spatial learning and memory, and the locomotory activity;
• Exerted beneficial effects on hepatic steatosis, hepatotoxicity, and plasma lipid profiles including the normalization of the size, weight, and colour of the liver and the reduction of hepatic lipid accumulation and of the ALT, AST, and TG levels.
• Provided protective effects against the aging-related abnormalities in spleen morphology and inflammation;
• Increased the antioxidant defences and decreased the oxidative stress;
• Decreased the systemic inflammation by lowering the plasma level of the inflammatory cytokines (i.e., TNF-α, IL-1β, MCP-1 and IL-6), and by increasing the plasma level of anti-inflammatory IL-10;
• Improved the gut microbiota profile leading to a significant decrease in the gut levels of E. coli and a significant increase in the gut levels of Bifidobacterium and Lactobacillum species after 11 weeks of dietary intervention;
• Increased the sensitivity to insulin;
• Increased the hepatic expression of genes associated with longevity (i.e., AMPK, Sirt1, Nrf-1, and FOXO3).
Hempseed oil and Evening primrose oil (HSO/EPO) Evaluation of the MS’ therapeutic effect of co-supplementation with HSO/EPO. 14 days of HSO/EPO oral administration on adult female C57BL/6 (n = 6) EAE mice (MS model) The HSO/EPO dietary treatment can exert a beneficial effect on MS treatment since it is able to:
• Act as an immunomodulator, down-regulating the mRNA expression of mTORC1 (which promotes Th1 and Th2 cells differentiation) and of the pro-inflammatory cytokines IFN- in lymph node;
• Exert an anti-inflammatory action through increasing the mRNA expression of mTORC2 (which promotes Th2 cells differentiation) and of the anti-inflammatory cytokines IL-10 in lymph nodes;
• Reduce the infiltration of the inflammatory cells in brain;
• Promote the re-myelination of neurons’ myelin sheath.

ACE: angiotensin I-converting enzyme; AD: Alzheimer Disease; ALA: α-Linolenic Acid; ALT: Alanine Transaminase; AMPK: AMP-activated protein kinase; ApoE KO: Apolipoprotein E Knockout; AST: Aspartate Aminotransferase; CAT: Catalase; CHO: Carbohydrate; CVD: Cardiovascular Disease; EAE: Experimental Autoimmune Encephalomyelitis; FOXO3: Forkhead box O3; GLA: γ- linolenic acid; GOT: glutamic oxaloacetic transaminase; HDL: High Density Lipoprotein; IFN-γ: Interferon γ; LA: Linoleic Acid; LDL: Low Density Lipoprotein; MCP-1: Monocyte Chemoattractant Protein 1; MS: Multiple Sclerosis; mTORC1: mTOR Complex 1; mTORC2: mTOR Complex 2; rf-1: Nuclear respiratory factor 1; NTRs: Normotensive Rats; PGD: Prostaglandin D; PGE: Prostaglandin E; PUFA: Polyunsaturated Fatty Acid; SBP: Systolic Blood Pressure; SFA: Saturated Fatty Acid; SHRs: Spontaneously Hypertensive Rats; Sirt1: Sirtuin 1; SOD: Superoxide dismutase; TC: Total Cholesterol; TG: Triglyceride; IL: Interleukin; TGs: Triglycerides; TNF-α: Tumor Necrosis Factor α; TPx: Total Peroxide.

4.2. Human Studies

Although the studies about hempseeds and hempseed products dietary supplementation in animals are relatively abundant in scientific literature, only a few papers ( Table 12 ) have faced the issue of the hempseeds and derivatives dietary supplementation in human nutrition and its effects on human health, and all of the few investigations performed to date, were carried out exclusively with hempseed oil as a supplement.

Table 12

Literature studies on the effect of hempseed oil dietary supplementation on humans.

Supplement Type Purpose Experimental Design Results Ref.
Cold-pressed hempseed oil Evaluation of the effect of dietary hempseed oil and olive oil on plasma lipid profiles, TEWL, skin quality, and dermal medication usage in patients with atopic dermatitis. Controlled, randomized single-blind crossover study, based on two intervention periods of 8-weeks last, separated by a 4-weeks washout period. Patients (n = 20) with a diagnosis of atopic dermatitis were randomly divided into two groups. Every patient of each group orally consumed 30 mL/day of olive or hempseed oils.
• Inclusion criteria: BMI < 30 Kg/m 2 ; 25–60 years old.
• Exclusion criteria: assumption of lipid-lowering, anti-hypertensive or asthma medications, nutrient supplements, steroid-containing skin creams, oral cyclosporine, and use of solarium during the study and in the previous month.
A relatively short period of hempseed oil dietary consumption significantly improved skin quality and the atopic symptomology of the patients without any negative side effects or adverse reactions.
The dietary treatment significantly increased the plasma level of LA, ALA, and GLA; significantly decreased the TEWL values and patients’ skin dryness, itchiness, and dermal medication usage.
Cold-pressed under nitrogen atmosphere hempseed oil Evaluation and comparison of the effects of dietary hempseed oil and flaxseed oil on the profile of serum lipids, fasting serum total and lipoprotein lipid concentrations, plasma glucose and insulin concentrations, and hemostatic factors in healthy volunteers. Controlled, randomized single-blind crossover study, based on two intervention periods of 4-weeks last, separated by a 4-weeks washout period. Male (n = 8) and female (n = 6) healthy volunteers were randomly divided into two groups. Every volunteer of each group orally consumed 30 mL/day of flax or hempseed oils.
• Inclusion criteria: BMI < 30 Kg/m 2 ; 25–60 years old; fasting serum concentration of TG < 3.5 mmol/L; fasting serum concentration of TC 5.0–7.5 mmol/L; fasting plasma glucose < 6.0 mmol/L.
• Exclusion criteria: assumption of lipid-lowering, anti-hypertensive medications and nutrient supplements during the study and in the previous month.
In healthy subjects, 4-weeks daily of orally ingestion of hempseed oil:
• Reduced the total plasma TGs concentration;
• Significantly decreased the TC/HDL-C ratio, lowering the risk of coronary heart diseases;
• Significantly changed the FA composition of serum TG and CE, increasing the LA, ALA, and GLA amounts and decreasing the OA content, whereas the AA and DHA amount did not differ;
• Did not modify the plasma glucose, insulin, and hemostatic factor like fibrinogen, FVIIa, and PAI-1.
Hempseed oil capsule Evaluation and comparison of the effects of the hempseed, flaxseed, and fish dietary oils on cardiovascular parameters (lipid profile, LDL oxidation, inflammatory markers and platelet aggregation) in healthy volunteers. Double-blinded, placebo controlled clinical trial. Male (n = 34) and female (n = 54) healthy volunteers were randomly divided into 4 groups (placebo, fish oil, flaxseed oil, and hempseed oil). The volunteers of each group were orally daily supplemented with 2 capsules each containing 1 g of the relative treatment for 12 weeks.
• Inclusion criteria: fasting TC levels • Exclusion criteria: usage of aspirin; ibuprofen; and/or other non-steroidal, anti-inflammatory medications as well as thyroid, anticoagulant, or lipid-lowering medication and the presence of menopause or chronic illness.
2 × 1g hempseed oil capsule daily supplementation, administrated for 12 weeks did not significantly affect the ALA and LA plasma levels; TC, TG, LDL, and HDL amounts, or inflammatory (CRP, and TNF-α) and platelet aggregation analyzed markers (collagen and thrombin-induced platelet aggregation). [145]
Hempseed oil soft capsule Evaluation of the role of hempseed oil in the modulation of hyperlipidaemia and CVD risk in children and adolescents. Randomized, controlled, two-arm parallel-group study. Children and adolescents (n = 36) with diagnosis of primary hyperlipidemia were randomly divided into two groups. Each subject of the test group was dietary supplemented with one hempseed oil soft capsule containing 3 g of oil for 8 weeks. The other group was used as control (without control).
• Inclusion criteria: assessment of primary hyperlipidaemia; 6–16 years old.
• Exclusion criteria: diagnosis of secondary hyperlipidaemia, and/or renal, endocrine, lipid, neurologic, onco-hematologic disorders requiring drug treatment; BMI > 85th percentile; smokers.
The 8-weeks daily intake of 3 g of hempseed oil:
• Did not affect the levels of TC, LDL-C, HDL-C and TGs;
• Did not change the values of body weight, BMI, and blood pressure;
• Significantly modified the RBC FAs composition increasing the total n-3 PUFAs, n-3 LCPUFAs, and n-6 LCPUFAs, and decreasing the n-6/n-3 PUFAs ratio as well as the SFAs and MUFAs.
Hempseed oil and evening primrose oil (HSO/EPO, 9:1) co-supplementation Evaluation of the therapeutic and protective effect of the Hot-natured diet co-supplemented with HSO/EPO or of the HSO/EPO dietary co-supplementation on MS patients. Double blind, randomized trial. Female (n = 42) and male (n = 23) patients with diagnosis of RMSS were randomly divided into three groups. Each group (A, B, and C) was subjected to a Hot-natured diet co-supplemented with 18–21 g of HSO/EPO (9:1) (group A) or to 18–21 g olive oil supplementation (group B), or to 18–21 g of HSE/EPO (9:1) co-supplementation (group C) for 6 months.
• Inclusion criteria: diagnosis of RRMS (EDSS < 6); 14–55 years old.
• Exclusion criteria: diagnosis of secondary or primary progressive MS; pregnancy; corticosteroid treatment; and diagnosis of other chronic neurological and inflammatory diseases such as cancer, rheumatic diseases, and heart diseases.
6 months of Hot-natured diet co-supplemented with HSO/EPO or of HSO/EPO co-supplementation significantly improved the MS clinical condition and inflammatory status of the patients, without any adverse effects.
• Both treatments significantly improved the degree of Th2/Th1 ratio and the value of EDSS and of relapse rate;
• Both treatments significantly increased the level of anti-inflammatory IL-4 cytokine;
• Only the Hot-natured diet co-supplemented with HSO/EPO significantly decreased the level of pro-inflammatory IFN-γ and IL-17 cytokines;
• The co-supplementation of HSO/EPO led to a decreasing (but not statistically significant) trend in the level of IFN-γ and IL-17 cytokines.
Hempseed oil and evening primrose oil (HSO/EPO, 9:1) co-supplementation Evaluation of the Hot-natured diet co-supplemented with HSO/EPO in patients with RRMS on the type and level of produced cytokines. Females (n = 16) and males (n = 7) patients with diagnosis of RRMS were subjected to a Hot-natured dietary regimen co-supplemented with 18–21 g of HSE/EPO (9:1), for 6 months.
• Inclusion criteria: diagnosis of RRMS (EDSS < 6); 14–55 years old.
• Exclusion criteria: diagnosis of secondary or primary progressive MS; pregnancy; corticosteroid treatment; and diagnosis of other chronic neurological and inflammatory diseases such as cancer, rheumatic diseases, and heart diseases.
6 months of Hot-natured diet co-supplemented with HSO/EPO had a beneficial effect in RRMS patients by decreasing the Th1 cells and by promoting the Th2 cell responses. This dietary treatment led to:
• A significant improvement of EDSS;
• A significant decrease of the production of the pro-inflammatory cytokines (IFN-γ and IL-17);
•A significant increase of the production of anti-inflammatory IL-4.
Hempseed oil and evening primrose oil (HSO/EPO, 9:1) co-supplementation Investigation of the effect of the Hot-natured diet co-supplemented with HSO/EPO or of the solely HSO/EPO dietary co-supplementation on MS patient’s liver dysfunction. Double blind, randomized trial. Female (n = 42) and male (n = 23) patients with diagnosis of RMSS were randomly divided into three groups. Each group (A, B, and C) was subjected to a Hot-natured diet co-supplemented with 18–21 g of HSO/EPO (9:1) (group A) or to 18–21 g olive oil supplementation (group B), or to 18-21 g of HSE/EPO (9:1) co-supplementation (group C) for 6 months.
• Inclusion criteria: diagnosis of RRMS (EDSS < 6); 14–55 years old.
• Exclusion criteria: diagnosis of secondary or primary progressive MS; pregnancy; corticosteroid treatment; and diagnosis of other chronic neurological and inflammatory diseases such as cancer, rheumatic diseases, and heart diseases.
6 months of Hot-natured diet co-supplemented with HSO/EPO or of HSO/EPO co-supplementation significantly improved the MS patients’ liver dysfunction, without any adverse effects.
• Both treatments significantly improved the EDSS value;
• Both treatments significantly decrease the AST enzyme serum level;
• Only the Hot-natured diet co-supplemented with HSO/EPO significantly decreased the ALT and GGT enzyme serum levels.
See also  Bubba's sister seeds

ALA: α-linolenic Acid; ALT: (SGPT) alanine-aminotransferase; AST: (SGOT) aspartate- aminotransferase; BMI: Body Mass Index; CVD: Cardiovascular Disease; EDSS: Extended Disability Status Score; FA: Fatty Acid; Cholesteryl ester; FVIIa: coagulation Factor VIIa; GGT: gamma-glutamyl transferase; GLA: γ-Linolenic Acid; HDL-C: High Density Lipoprotein-Cholesterol; LA: Linoleic Acid; LCPUFAs: Long Chain Polyunsaturated Fatty Acids; LDL-C: Low Density Lipoprotein-Cholesterol; MS: Multiple Sclerosis; MUFAs: Monounsaturated Fatty Acids; OA: Oleic Acid; PAI-1: Plasminogen activator inhibitor-1; PUFAs: Polyunsaturated Fatty Acids; RBC: Red Blood Cell; RRMS: Relapsing-Remitting Multiple Sclerosis; SDA: Stearidonic Acid; SFAs: Saturated Fatty Acids; TC: Total Cholesterol; TEWEL: trans-epidermal water loss; TG: Triglyceride.

One of the first studies which investigated the beneficial effect of hempseed oil dietary supplementation was that of Callaway and co-workers [143] in which a 8-week oral consumption of 30 mL/day of hempseed oil in patients with diagnosis of atopic dermatitis, was adopted to evaluate the potential ability of this oil to ameliorate the patients’ symptomatology and medicinal usage. The results of this research highlighted that, contrarily to the olive oil treatment, used as comparison, the hempseed dietary assumption can effectively improve the skin quality and the pathology’s symptoms leading to decrease of skin dryness, itchiness, and dermal medication usage by patients. The authors attributed these findings to the increase in the GLA, SDA, and LA plasma levels as a result of the hempseed oil supplementation. Indeed, both GLA and SDA have anti-inflammatory action which can be beneficial for atopic dermatitis. Particularly, GLA has been shown able to decrease the production of the pro-inflammatory leukotriene B4 (LTB4) by polymorphonuclear neutrophils (PMN), through increasing the plasma level of its biological metabolite, namely the anti-inflammatory DGLA which can directly suppress the LTB4 PMN’s production in the skin. Furthermore, SDA can increase the level of EPA in both erythrocytes and plasma phospholipids contributing to the anti-inflammatory effect, whereas, the increase of the LA plasma level can raise the ceramide amount in the skin’s stratum corneum, reducing the loss of moisture and improving the skin’s dryness, since LA acts as precursor of ceramide 1, an important component of the skin’s lipid lamellar sheet. Finally, the total plasma PUFAs amount of the patients significantly increased after the oral daily assumption of hempseed oil, and this can have facilitated the formation of new skin cells by dermal stem cells, contributing to the obtained amelioration of atopic dermatitis.

Other works employed the hempseed oil as a dietary treatment/supplementation to explore its potential cardiovascular benefits on humans. In this regard, Schwab and colleagues [144] observed that 4-week daily supplementation of 30 mL of hempseed oil was able to reduce the total TGs plasma level and to induce significant changes in the composition of serum cholesteryl-esters (CEs) and TGs of healthy volunteers. Particularly, the content of LA, ALA, and GLA increased whilst the OA concentration significantly decreased after the hempseed oil treatment. In contrast, the proportion of AA and DHA in both TGs and CEs did not change after hempseed oil intake as well as the plasma glucose, insulin, and haemostatic factors, including fibrinogen, coagulation factor VIIa (FVIIa), and plasminogen activator inhibitor-1 (PAI-1). Interestingly, the hempseed oil treatment led to reduction of the TC/HDL-cholesterol ratio which is considered an important index to predict the risk of coronary heart disease. Contrarily, Kaul and colleagues [145] found that the daily assumption of 2 capsules, each containing 1 g of hempseed oil, in healthy volunteers for 12 weeks neither significantly affected any blood lipid parameters (i.e., the TGs, TC, LDL, and HDL plasma levels), nor induced any changes in the LA and ALA plasma concentrations as well as in the inflammatory and platelet aggregation markers, namely TNF-α and C-Reactive Protein (CRP), and collagen and thrombin-induced platelet aggregation, respectively. The authors hypothesized that these findings could be due to a limited and low gastrointestinal absorption of hempseed oil’s LA and ALA, or to the fact that a larger dosage and a longer experimental period may be necessary to obtain significant changes in the evaluated parameters. It is also important to note that these studies have been performed on healthy subjects, and therefore, they do not exclude potential beneficial actions in a specific pathological status. Furthermore, this evidence also introduces the importance and the necessity of identifying the appropriate dosage and vehicle/matrix that will have benefits in healthy people too as a preventive tool. In the context of the usage of hempseeds or their products for a specific pathological target groups, a recent report of Del Bo’ and colleagues [146] explored the effects of hempseed oil supplementation in the modulation of hyperlipidaemia and CVDs risk in children and adolescents (6–16 years old) with primary hyperlipidaemia. In more detailed, the test group was daily supplemented with one hempseed oil soft capsule containing 3 g of oil, which provided 700 mg of ALA, 1400 mg of LA, 30 mg of SDA, and 100 mg of GLA, with 2.3 g total PUFAs and a PUFAs/SFAs ratio of 7.7:1. As a consequence of this treatment, it has been shown that, although the hempseed oil supplementation after 8 weeks did not significantly change the plasma lipid profile of the volunteers, it was able to improve the red blood cell (RBC) FAs composition, significantly increasing the total n-3 PUFAs, including the LC-n-3 PUFAs EPA, DPA, and DHA and decreasing the n-6/n-3 PUFAs ratio, as well as the total amount of SFAs and MUFAs. Considering that an altered FAs composition in RBCs has been shown to be positively related with coronary heart disease, atherosclerosis-related diseases, arterial hypertension, and dyslipidaemia, and that SFAs have been reported to have hypercholesterolemic activity in adults, the observed effect of hempseed oil supplementation could have a contribution in counteracting the negative consequences of hyperlipidaemia on the cardiovascular system. Interestingly, in this work was also noted that the dietary intake of higher ALA amounts led to an increase in the RBCs’ LC-n-3 PUFAs derived by the ALA conversion (EPA, DPA, and DHA) in comparison to the control group, and this evidence could indicate that hempseed oil supplementation may stimulate the endogenous conversion of ALA into its biologically active derivatives. According to the authors and in agreement with Kaul and colleagues [145], the lack of differences between the control and the test group on the serum lipid markers, may be dependent on the food matrix/vehicle used and/or the length of the intervention. This evidence has highlighted again the importance to understand the molecular mechanisms through which hempseed components can exert their beneficial effect on human health, the level of each functional component needed in order to obtained an effective and clinically detectable action, and the more suitable matrix able to maximize the gastrointestinal bioavailability and structurally preservation of these components in the human body.

Finally, another three literature works about the hempseed oil dietary supplementation in humans have been performed on patients affected by MS [147,148,149]. As described in the previous subsection (Section 4.1), the same authors have used an MS mouse model in order to understand the molecular mechanisms underlying the beneficial effects of the co-supplementation of hempseed oil and evening primrose oil on this neurodegenerative, immune-mediated pathology [141,142]. In previous works performed on humans, these authors observed that the co-supplementation of hempseed oil and evening primrose oil in a 9:1 ratio, used alone, or in association to a Hot-natured diet, was able to ameliorate the inflammatory status of MS patients, thus exerting a beneficial effect on this pathological condition. In particular, the authors explained that MS is a Th1-mediated autoimmune disease, which therefore, is characterized by an unbalance Th1/Th2 immune responses and high levels of pro-inflammatory IL-6, IFN-γ and IL-17 cytokines. This latter cytokine is produced by the Th17 cells which, hence, are involved in the development of the pathology, together with Th1 cells [147,148]. A Hot-natured diet is characterized by the consumption of foods with low cholesterol, hydrogenated, trans, and saturated FAs; a plenty of fruits and vegetables, nuts and seeds without additives, olive and grapes oils as the main oils of the diet, fish and seafood, and unrefined carbohydrates and dairy products with honey; contrarily, it excludes the consumption of sugar and refined carbohydrates, alcohol, and smoke. It has been shown that the consumption of the Hot-natured diet is related to a deviation of the immune system toward the Th2 responses. In addition, both hempseed oil and evening primrose oil possess anti-inflammatory features, related to the high PUFAs content and the perfectly balanced n-6/n-3 PUFAs ratio of the former and to the about 9% of GLA content of the latter. Based on all this evidence, Rezapour-Firouzi and co-workers in their studies [147,148] decided to adopt the hot-natured diet co-supplemented with 18–21 g of hempseed oil and evening primrose oil in a 9:1 ratio, as a potential useful dietary intervention for the treatment and attenuation of MS. The authors found that both types of dietary intervention (i.e., the Hot-natured co-supplemented with hempseed oil and evening primrose oil, and the co-supplementation of hempseed oil and evening primrose oil alone) for 6 months have exerted an effective anti-inflammatory action, leading to a significant increase in the IL-4 cytokine level on MS patients and to an improvements of the degree of the Th2/Th1 ratio, the expanded disability status scale (EDSS), and the relapse rate, which are all indexes of the disease severity, and thus performed a beneficial action in the patients, without exhibiting any side effects [147,148,149]. However, only the Hot-diet associated with the hempseed and evening primrose oils co-supplementation resulted in having also the ability to significantly decreased the level of the pro-inflammatory IFN-γ and IL-17 cytokines. Indeed, contrarily, the hempseed oil and evening primrose oil co-supplementation alone showed a decreased trend in the level of these cytokines, which though, was not statistically significant, at least after 6 months of the treatment [147]. In a later report, the same authors [149] also demonstrated that both Hot-natured diet co-supplemented with hempseed and evening primrose oils and the co-supplementation of hempseed and evening primrose oils alone were able to improve the liver function in the MS patients, which generally showed a serious liver injury also as a consequence of the drug treatment, but the former dietary intervention was more efficient than the latter.

In conclusion, in addition to the fact that there is still a lack of studies about the effects of whole hempseed dietary intake on either healthy human subjects or patients with a specific pathological status, to date, the few works present in the scientific literature refer exclusively to hempseed oil supplementation and they are rather inconclusive and not very comparable due to the employment of different types of experimental designs, as well as different dosages, experimental periods, and administration methods of the supplement. Therefore, it appears necessary to deepen and expand the research and the knowledge in this area.

5. Hempseed Foods

In the field of food technology, due to their unique nutritional quality and composition, hempseeds have been exploited as ingredient or means to ameliorate the nutritional and healthy grade of food, in order to obtain healthy and potentially functional foods. In this context, the first efforts in the employment of these seeds by the food industry concerned their use as a means to increase the quality of animal derived food products, namely the use of hempseed or hempseed’s derivatives (i.e., hempseed oil or flour/cake/meal) as livestock feed supplement to ameliorate the quality composition of animal-based food products (e.g., meat, eggs, and milk). Only later, hempseeds and their derivatives have also been used as ingredient to directly enrich daily-consumed foods (e.g., bakery products).

5.1. Hempseed Products as Livestock Supplement

As a means to increase the quality of animal-derived food products, hempseeds and hempseed derivatives, especially hempseed oil, were used as supplements of the laying hens or broiler chickens’ normal diets to obtain eggs or meat enriched with n-3 PUFAs, including the n-3 long chain PUFAs (LCPUFAs) biologically active in humans, like EPA and DHA, due to the ability of the laying hens or broiler chickens to endogenously convert dietary ALA into these LCPUFAs and to deposit them into egg yolk or muscle tissues. In this context, several experiments were performed to assess either the safety of hempseed or hempseed derivatives as feed ingredients in poultry diets as well as their efficacy as a means to nutritionally ameliorate the FAs profile of egg yolk and meat, as an alternative to other n-3 PUFAs sources such as flaxseed, flaxseed oils, or marine oils, and microalgae products. Overall, these studies demonstrated that the performance of laying hens and broiling chickens, including feed intake, egg weight, egg production, feed conversion ratio, body weight, or weight gain, was not affected [150,151,152,153] or was ameliorated [154] by the dietary supplementation with hempseeds (up to 30%) or hempseed oil (up to 12%), and therefore, these products can be included in the bird’s diet without compromising their safety and efficacy. Interestingly, the hens’ performance was more positive if hempseeds were subjected to a heat treatment (specifically 120 °C for 60 min) performed before to supplement the hens’ diet [155]. The safety of the inclusion of these supplementary products to poultry diet was further confirmed by the absence of the markers of hepatic and muscular damage after the hempseed product supplementation [151,154]. In addition, literature reports agree that the inclusion of hempseed products to the poultry diet effectively improved the nutritional value of the eggs and meat and obtained food products with higher total n-3 PUFAs amount, higher PUFA/SFA ratio, and a better-balanced n-6/n-3 PUFAs ratio in comparison to the poultry food products obtained by animals fed a normal diet. More specifically, it has been demonstrated that the total n-3 PUFAs and the individual n-3 PUFA ALA, as well as the n-3 LCPUFAs biologically active in humans, namely EPA, DPA (Docosapentaenoic Acid), and DHA, were increased in both poultry eggs [150,152,153,156,157,158,159,160] and meat (thigh and breast) [150] as the inclusion of the hemp products rose and the n-6/n-3 PUFAs ratio, normally high in common eggs, was reduced [152,157,158,161]. Neijat and colleagues [157] found that, as a consequence of the dietary hempseed and hempseed oil supplementation to the laying hens’ control diet (wheat-barley-soybean meal-based), the ALA content increased in a dose-dependent manner and this increase was higher in the TGs than in the phospholipids (PLs) that, therefore, seem to be less responsive in ALA enrichment in comparison to TGs. The authors found also an increase in the total amount of n-3 LCPUFAs synthesized from ALA (i.e., EPA, DPA, and DHA) in response to the increase in the ALA dietary intakes, reflecting the endogenous synthesis from ALA in hens’ liver and the subsequent deposition in egg yolk. However, contrarily to ALA, this growth did not occur in a dose-dependent fashion for LCPUFAs, such as DHA, which in fact, was accumulated mainly in PLs, until a saturation level [156,157]. Regarding this, it is important to consider that the conversion of ALA to DHA occurs through the sequential actions of the enzymes ∆-6 desaturase encoded by the fatty acid desaturase 2 (FADS2) gene, elongase encoded by the elongase 5 (ELOVL5) gene, and ∆-5 desaturase encoded by the fatty acid desaturase 1 (FADS1) gene. Gakhar and co-workers [152] by evaluating the effect of the consumption of hempseeds or hempseed oil by hens on the expression of these three main biosynthetic genes involved in the PUFAs metabolism found that the FADS1 and FADS2 expressions were reduced by the increasing inclusion of hempseed products in laying hens’ diets, thus providing a possible explanation to the DHA saturation in the egg yolk of hens supplemented with hempseed products. Interestingly, Jing and colleagues [150] showed that the increase in the n-3 PUFAs ALA, EPA, DPA, and DHA occurred both in the egg yolk and in the meat of laying hens’ and broiler chickens fed a hempseed oil supplemented diet, but this increase took place to a different extent based on the food product. Indeed, in comparison to the respective control, the enrichment efficiency for total n-3 PUFAs, ALA, and EPA appeared to be higher in egg yolk than in chicken meat. Furthermore, the DPA amount was higher than DHA in meat, contrarily to egg yolk, where the DHA level was higher than DPA even without supplementation, and after hempseed oil supplementation, the difference between DPA and DHA content in egg yolk or meat became more evident. This finding was attributed to a differential expression and activity of FADS2 and ELOVL5 enzymes that are involved in the conversion of DPA to DHA rather than an effect of the supplementation. In particular, based on the results, it was hypothesized that these enzymes may be low in the muscle tissues of chicken and thus, inhibiting the metabolism of DPA to DHA. Interestingly, Mierliță and colleagues [153] found that the egg yolk produced by hens fed a diet supplemented with whole hempseeds contained a higher ALA and EPA amount and a more remarkable decrease in n-6/n-3 PUFAs ratio in comparison with the egg yolk produced by hens fed a diet supplemented with hempseed cake. Hence, the authors concluded that whole hempseeds supplementation was more effective in ameliorating the nutritional quality of egg yolk than the hempseed cake one.

With regard to the effect of hempseed products supplementation on the n-6 PUFAs content of the poultry eggs and meat, Shahid and co-workers [160] found an increase in the total n-6 PUFAs amount of egg yolk, whereas, Neijat and others [157] observed that, although the level of n-6 LA was higher especially in the TGs, in comparison to the control, the n-6 AA amount decreased as the hemp dietary inclusion increased, reflecting the metabolic competition of n-3 ALA and n-6 LA for the ∆-6 desaturase enzyme, responsible to their conversion in the corresponding LCPUFAs, with the greater affinity of n-3 ALA than n-6 LA, and a consequent favour of n-3 PUFAs metabolism. Similar data was found also by Mierliță and colleagues [153]. Furthermore, it has been also observed that among, n-6 PUFAs, the hempseed products supplementation led to an enrichment of eggs and meat with the GLA [150,161], conferring to these food products a further unique features related to the biological anti-inflammatory and anti-proliferative properties of GLA that have important implications for human health. Similar GLA-enrichment was also shown in the muscle of ducks fed a 15-20% hempseed cake-supplemented diet [162].

Regarding MUFAs and SFAs, literature publications agree that the MUFAs content, mainly OA, decreased with the increase of the level of the hempseed products to the diet, probably due to the inhibition effect of a PUFAs-rich diet on the activity of ∆-9 desaturase, which is essential for the conversion of PA to OA [150,153,155,157]. Whereas, about the effect on SFAs there are some contrasting results. Some authors found a reduction in the SFAs [155,158], as well as in the cholesterol amount [161] in egg yolk after hempseed supplementation. Other researchers [153,157] showed that the overall levels of SFAs and cholesterol of egg yolk were not influenced by a dietary treatment with hempseeds, hempseed oil, or hempseed cake.

Similar findings about the positive effect of the hempseed or derivative dietary supplementation on the nutritional quality of egg yolk and meat were also shown for quails [163]. In this case, 6-week supplementation with up to 20% whole hempseeds, allowed to obtain n-3 PUFAs enriched quail eggs with a reduction of MUFAs—OA in particular—and SFAs—PA in particular—as an additional advantage. In the same study, the quality of the meat of the 5-week whole hempseed supplemented quails was also analysed, and a decrease in thawing and cooking loss were observed, which are both negative indicators for meat quality, with the increase of the dietary hempseed amount, demonstrating that hempseeds supplementation can ameliorate also the meat quality other than the eggs FA profile. In addition to the safety for animals and the efficacy in obtaining more nutritionally beneficial food products, the inclusion of hempseed products into the poultry diet was tested also for the potential negative impacts on the sensory characteristics of the resultant products. Indeed, it was found that dietary supplement as flaxseed or fish oils can compromise the sensory quality of the poultry meat and eggs due to the presence of fish smell/taste. Instead, Goldberg and colleagues [159] demonstrated that the inclusion of up to 20% hempseed or up to 10% hempseed oil in the poultry’s diet did not have any adverse effects on the eggs’ sensory quality. Similar results were obtained by Konca and co-workers [155] for eggs produced by hens supplemented with 15% raw or heat-treated whole hempseeds for 12 weeks.

Hempseeds supplementation in animals’ feed has been shown to be a useful tool also to improve the yield, the quality, and the nutritional value of some milks, such as the goat and sheep ones, and in particular, to positively modify the milk’s FAs content. This by increasing the total concentration of LCPUFAs, n-3 PUFAs, and conjugated linoleic acids (CLAs), and concomitantly by decreasing the concentration of SFAs and the n-6/n-3 PUFAs ratio, with a putative beneficial effect on human health [164,165,166]. Mierliță and colleagues [167] found also an increase in the tocopherol amount and an improvement of total antioxidant capacity of milk obtained from sheep fed a diet supplemented with hempseed (180 g/day) or hempseed cake (480 g/day), in comparison to that obtained by sheep fed a control diet (hay diet completed with high-energy concentrate and sunflower meal), thus demonstrating that despite the increase of the PUFAs content in milk, the safety of this product was not negatively affected by lipid oxidation. The same authors also showed that, between hempseeds and hempseed cake supplementation, the latter was more effective in ameliorating the quality and the nutritional value of the milk, as it was resulted in a significantly lower atherogenic index and a higher hypocholesterolemic/hypercholesterolemic index. Cozma and colleagues [168] found a reduction in the lactose content of the milk produced by goat fed a diet supplemented with hempseed oil (93 g/day). Contrarily, Iannaccone and co-workers [165] showed an up-regulation in the genes involved in lactose biosynthesis, based on the results of a RNA sequencing analysis of the whole-blood transcriptome of lactating sheep fed either a control diet or a 5% hempseed supplemented diet, and this result was in accordance with the increase in the lactose amount found in the resulting milk.

5.2. Hempseed Products as Ingredient for Enriched/Fortified Foods

As a means to directly enrich or fortify daily foods, hempseeds and their derivatives have been assessed as an ingredient added to daily consumed foods, including bakery products such as bread, cookies, crackers, and energy bars, as well as meat and meat products.

Regarding the enrichment of bread with hempseed or derivatives, some works have evaluated the impact on the nutritional, structural, and textural characteristics of both dough and bread, consequentially to the addition of hempseeds or their derivatives. About this, from a technological/rheological point of view, the main issue of the usage of non-conventional ingredient in the bakery industry, in order to fortify the bakery products is their adverse effect on the dough rheological and baking properties, mainly as a result of the dilution of wheat gluten proteins. Consequently, this can negatively affect the end product quality (volume, texture, crumb and crust properties, and colour) that may ultimately affect lowering the consumers’ acceptability. Studies about the enrichment of the bread dough with hempseed flour agree that the addition of hempseed flour in the wheat flour significantly reduced the dough’s water absorption, stability, strength, and starch gelatinization, in a proportional manner to the level of hemp flour added as a consequence of the dilution of gluten amount in the dough [166,169,170]. Pojić and colleagues [166], and Švec and others [169] found that the decrease in the water absorption of the bread dough had a negative impact also on the time required for dough development, but nevertheless, the dough’s stability and strength were not significantly affected by the addition of up to 10% of hempseed flour. Pojic and others [166] also noted that the increase in the hempseed flour content up to 20%, negatively affected both the dough’s stability and strength.

The changes in the dough’s rheological properties, resulting in the addition of hempseed flour, led to a negative impact on the bread quality. In this regard, Pojic and colleagues [166] showed that the bread volume was significantly impaired as the level of hemp flour increased. This result was found also by Hrušková and co-workers [171] and by Švec and colleagues [169] for bread enriched with 10%, 15%, or 20% of hempseed flour, and was confirmed also by Mikulec and others [172] for bread containing 15%, 30%, or 50% of hempseed flour, as well as by Wang and colleagues [173] for bread enriched with 5%, 10%, or 15% extruded hemp-rice flour (EHR), made by the extrusion of the whole hempseeds (30%) together with the rice flour (70%). According to the authors, the decrease in the bread’s volume could be due to the partial replacement of wheat flour with a non-glutinous one, that may dilute the gluten protein of wheat flour and prevent its extension, or to the increased content of fibre, which reduces the ability to retain fermentation gases. However, Wang and colleagues [173] showed that the addition of 15% of EHR led to a significantly increase of the bread volume in comparison to 10% EHR-containing bread. The researchers attributed this evidence to the higher fat content present in the 15% of EHR. This hypothesis was later confirmed by another work of the same authors [174] in which the properties of the dough and the bread made from extruded and non-extruded hemp-rice flour were compared. The obtained results showed that the presence of whole hempseeds in the bread dough did not impair the specific bread volume in comparison with the control. A similar finding was noted also by Švec and co-workers [169] who found that the volume of the bread enriched with whole hempseeds powder (i.e., ground whole hempseeds) was higher than those obtained for the breads enriched with other defatted hempseed products (i.e., hempseed flour or hempseed protein concentrates). This fact has been attributed to the interactions between lipids and proteins and to the influence of the fat in terms of enhancing dough expansion during proofing [166]. The addition of hempseed flour to the wheat flour also changed the physical and rheological properties of the bread’s crust and crumb. The color of both of them became darker after the hempseed flour addition [166,169,172,173]. Švec and colleagues [169] asserted that the 5% enrichment has conferred a pleasant coffee brown colour, which intensified to dark brown by increasing the amount of hempseed flour, whereas, Wang and co-workers [173] observed a significantly decreased in the lightness of both crust and crumb only for the breads enriched with an EHR amount of at least 10%, since the 5%-EHR bread did not show any significant colour’s differences compared to the control bread. Similar changes in the crust and crumb bread’s colour were observed by Wang and colleagues [174] also after the addition of whole hempseeds powder. Interestingly, in this paper, the authors noted that the hempseed extrusion process and the extrusion temperature can further emphasize the lack of the lightness. Regarding the textural properties of bread crumb, Pojic and co-workers [166] found that the presence of hempseed flour as an ingredient of the bread’s mixture significantly decreased the crumb cohesiveness and increased the crumb chewiness and hardness. Analogously, Mikulec and others [172] found an increase in the hardness of the crumb after the addition of hempseed flour, on the baking day. Contrarily, Wang and colleagues [173] showed that the 15% EHR-bread displayed significantly lower hardness compared to the samples enriched with a lower EHR amount (i.e., 5% and 10%), whereas, in their later publications [172], the same authors observed no significantly differences on the crumb hardness in the whole hempseeds powder-containing breads, and this might be attributed to the influence of hemp oil, which probably enhanced crumb texture and crust tenderness. Interestingly, Pojic and colleagues [166] found that the presence of hempseed flour up to 10% in bread formulation did not significantly affect the elasticity and the resilience of the crumb, unlike the addition of 20% of hempseed flour.

Concerning the nutritional quality of the hempseed flour or whole hempseed powder-enriched bread, it has been demonstrated that the addition of hempseed product significantly ameliorated the bread nutritional quality, since it proportionally increased the total protein [166,169,170,171,172] and fat [166] contents, as well as the total, soluble, and insoluble dietary fibre [169]. About this, it is interesting to note that Švec and colleagues [169] showed that the increase in the dietary fibre was higher if the enrichment was made with whole hempseed powder rather than hempseed flour. Furthermore, Pojic and co-workers [166] found that the hempseed flour enrichment also led to an increase in the content of the macro-elements, especially of Mg and Ca and of the micro-elements such as Mn, Cu, and above all, Fe and Zn. At the same time, the Na amount, the complex carbohydrates, and total metabolizable energy of the bread significantly decreased. This nutritional improvement was more marked for the 20% hempseed flour-enriched bread. Also, an increase in the total phenolic content was observed by Mikulec and others [172] as a consequence of adding the hempseed flour, and the most abundant polyphenols included epicatechin, ferulic acid, and protocatechuic acid. However, according to Švec and co-workers [169], the addition of 20% of hemp product (i.e., hempseed flour or whole hempseeds powder) has conferred a less acceptable, partially bitter taste to the bread; by contrast, the addition of 10% hempseed product did not have any negative impact on the sensorial parameters. Mikulec and co-workers [172] found that also the 15% addition level of hempseed flour had an overall acceptability. Therefore, also considering that the negative impact of the presence of the hempseed flour on the bread quality seems to be attenuated with 10% enrichment, the literature generally agrees that the 10% or 15%-substitution level of hempseed flour should accomplish requirements in terms of providing the balance between bread quality, sensorial, and nutritional properties.

Since hempseed is naturally gluten-free, it could be potentially employed as an ingredient to improve the poor nutritional value of the gluten-free products. To date, only a few papers in the literature investigated this issue by evaluating the impact of replacing to a certain extent, the main ingredient of the gluten-free recipe with hempseed derivatives, mainly hempseed flour or proteins. For example, Korus and colleagues assessed the effects of replacing 10% or 20% of gluten-free starch corn with hempseed proteins or flour in the dough of gluten-free bread [175], and the consequences of the substitution with 20%, 40%, or 60% of hempseed flour in the preparation of gluten-free cookies [176] on the rheological, qualitative, sensorial, and nutritional properties of the relative food products. Nutritionally, both studies highlighted that the addition of hempseed product led to significantly improvement of the nutritional value of the gluten-free food, since it rose, at high extent, the amount of total proteins and total dietary fibre, including soluble and insoluble, with higher increase especially in the insoluble fraction as well as fat and minerals [175,176]. Moreover, for the biscuits, it has shown that the carbohydrate content and the energy value of the products decreased proportionally to the level of substitution. Furthermore, the authors also found an enrichment in the antioxidant profile of the hempseed flour-substituted cookies that had significantly higher values of total phenolic (up to 2-fold higher) and flavonoid (up to 2-fold higher) compounds compared to the control, with a resulting rise in the total antioxidant capacity (up to 3-fold higher) [176]. Hence, from a nutritional point of view, either hempseed flour or proteins may be considered valuable ingredients for the formulation of improved gluten-free products. Regarding the rheological properties of the bread’s and cookies’ dough, the authors showed that for the bread mixture, the substitution of corn starch with hempseed flour resulted in a weakening of dough structure, which became more susceptible to deformation; contrarily, the substitution with hempseed proteins reinforced the dough structure. These differences have been attributed to the differences in the interaction and the binding between the hempseed components and water in the dough. Indeed, the authors explained that proteins absorbed more water, and hence, the addition of hempseed proteins could prevent the fulfil hydration of all dough component, thus resulting in dough strengthening. By contrast, hempseed flour contains other components besides proteins, and these significantly modified water binding, thus differently influencing the rheological properties of final dough [175]. For the cookies’ dough, the authors observed a significant increase in the overall hydration properties of the mixture, demonstrated by the higher values of water absorption, water retention, and oil absorption capacity in comparison to the control. These findings were associated to the increase of both the protein (4-fold higher) and total fibre content (20-fold higher) in the dough, which significantly affected the hydration properties of the biscuits’ blend [176]. In addition, contrary to what was observed for the enrichment with hempseed flour of gluten-containing bread, in this case, the addition of hempseed flour led to a significant increase in the quality of the gluten-free bread, as well as an improvement in the bread sensory acceptability, nutritional quality, and storage. Particularly, the authors found an increase in the bread volume, resulting in the addition of both hempseed products. This increase was more evident with raising amounts of hempseed products in the dough, and it was more pronounced in the case of hempseed proteins addition. This is probably due to the absence of gluten proteins, and so, hempseed proteins can act as surface-active and foaming agents, thus allowing to retain and stabilize the gas bubbles in the dough and bread. Interestingly, the bread volume was shown to be negatively related to the crumb hardness that, therefore, was the lowest in the control bread and the highest in the 20% hempseed protein-enriched bread. The limited hardness in the enriched bread was maintained also during the storage, thus limiting the bread’s aging. Contrarily, in the biscuits, the volume decreased after the hempseed flour substitution, whereas the cookies hardness increased, reaching the highest value in the 60% hempseed flour enriched cookies [176]. In both bread and biscuits, the colour of crumb and cookies became darker after the hempseed product substitution as the substitution level increased; this was found to positively affect the product sensory acceptability [175,176]. Moreover, for the gluten-free bread, either the enrichment with hempseed flour or hempseed protein conferred an aroma and taste considered better than the control, nevertheless the taste acceptability was significantly reduced by 20% hempseed flour [175], whereas, as regard the biscuits, the sensory panel highlighted a significant reduction in the sensorial acceptability of the hempseed flour cookies than the control one, especially at a high level (60%) of substitution [176].

Similar results about the water absorption properties, colour, and nutritional and antioxidant changes after the addition of hempseed flour in the mixture, were obtained by Radocaj and colleagues [177] for gluten-free crackers in which brown rice flour was partially substituted with 10%, 20%, 30%, or 40% of hempseed flour. In this work, the authors underlined the possible employment of hempseed flour as a functional ingredient usable to mix with other functional raw materials such as green tea leaves, as it was done in this study, to enhance the nutritional and healthy values of daily food and to develop potentially functional foods, accessible also to the coeliac people. Indeed, with this report, the researchers demonstrated that the addition of hempseed flour is the direct responsible to some nutritional improvement that was even better than those observed for other fortified or enriched products. For example, the authors demonstrated that the addition of hempseed flour permitted to obtained crackers with a content of proteins, fibre, and minerals higher than that found for crackers enriched with pulse flour. Moreover, the addition of hemp flour led to enforcement of the crackers with essential FAs that lack in other analogous products. This remark was in line with the findings by Norajit and colleagues [178], who investigated the effects of the addition of hempseed flour, or whole hempseeds powder, at three different levels (20%, 30%, or 40%), on the nutritional quality and the antioxidant activity of rice flour bars. Interestingly, comparing the nutritional and functional differences (i.e., antioxidant activity) between the rice bars enriched with hempseed flour and that enriched with whole hempseeds powder, the authors showed that the rice bar with whole hempseeds powder had significantly higher total phenolic and flavonoid contents, as well as better antioxidant properties, than the rice bar blended with hempseed flour.

A few studies investigated the incorporation of whole hempseeds or derivatives products (i.e., de-hulled hempseed, hempseed flour, and hempseed proteins) in meat products in order to ameliorate their nutritional value. In this context, Zając and Świątek [179] used the whole hempseeds as added ingredients of liver pâtés with the aim to improve its FA profile. Actually, although the total fat content of the tested pâtés did not significantly change, its FA profile was significantly better since MUFAs and SFAs decreased compared to the control whilst the PUFAs increased. Moreover, the total n-3 PUFAs was almost 6-fold higher than the control product, and even though its level was too low to label the product as a source of n-3 PUFAs accordingly to the EU regulation 1924/2006, nevertheless, its significantly higher amount conferred it a better nutritional value in comparison with the traditional pâtés. The authors also assessed the texture and sensorial properties of the experimental product and demonstrated that the addition of whole hempseeds significantly raised the hardness, chewiness, and the adhesiveness of the pâtés without significantly changed its cohesiveness. Despite these texture variations, the inclusion of whole hempseed did not modify the sensory parameters compared to the control.

Zając and colleagues [180] also investigated the effects of the incorporation of 5% of either whole hempseeds, de-hulled hempseeds, hempseed flour, or hempseed proteins in pork loaves, on nutritional quality, sensorial acceptability, and physical features of the obtained product. From a nutritional point of view, the obtained data showed that, among all hempseed additives, only the whole hempseeds have led to a significant increase in protein, ash, and total fibre content, without significantly changing the total fat amount, whereas, hempseed flour and proteins were the additives that have led to the highest enrichment in the amounts of K, Mn, and Fe, and of Ca, Mg, and Zn, respectively, even though a significant increase in the macro- and micro-elements in comparison to the control, was observed also for the others hempseed additives, in spite of in a minor extent. Furthermore, predictably, only the inclusion of whole hempseeds and de-hulled hempseeds led to a significant improvement in the FAs profile, through decreasing the total MUFAs and SFAs, increasing the total PUFAs, both n-3 PUFAs (4-times and 3-times higher in whole and de-hulled hempseeds enriched sample, respectively) and n-6 PUFAs (2-times higher) and decreasing the n-6/n-3 PUFAs ratio. The improvement of the FA profile of the pork loaves enriched with whole or de-hulled hempseeds, led these samples to have also the lowest thrombogenicity and atherogenicity index. Hence, overall, these two enriched products appeared to be healthier and nutritionally better in comparison to the other enriched pork loaves. Nevertheless, a Thiobarbituric Acid Reactive Sunstances (TBARS) analysis showed that the de-hulling process made the pork loaves enriched with de-hulled hempseeds more prone to oxidation during the storage in comparison to the other samples, probably due to the removal of the hull, that as previously said, it has shown to be the hempseed fraction where most of polyphenols are located [74,92,100]. However, among all evaluated samples, the de-hulled hempseeds enriched one was the sample which has received the higher consumers’ acceptance, even though, interestingly, the authors found that the consumers’ willingness to buy the meat enriched with hempseed products increased after providing the information about the healthy ingredient and therefore, highlighted the importance to furnish the right awareness to consumers about the hempseed’s health benefits.

Finally, hempseed proteins have been also used as an additive for yogurt by Dabija and colleagues [181] with the aim to fortify it and to obtain a new daily product with high nutritional value. In this study, the authors found that among different tested vegetable source proteins (i.e., hempseed proteins, pea proteins, gluten wheat, soy proteins, and pumpkins flour proteins), hempseed proteins have been shown to be those with the lowest syneresis value, which is an index of the expulsion grade of serum, considered as a negative acceptable parameter. This could be related to the high fibre content of hempseed proteins that improved the viscosity and reduced the serum separation levels, as it was confirmed by the rheological analysis. Moreover, the addition of hempseed proteins also induced a reduction in the pH value and an increase in the acidity of the fortified yogurt. Both features can be related to an improvement of the growth of the bacteria present in the yogurt. In addition to these positive changes, no significant differences were found about the acceptance of the fortified sample with hempseed proteins in comparison to the control sample.

Hence, in view of the above, it is clear that there are efforts by researchers to understand the structural, nutritional, and functional roles of the hempseeds and derivative utilization in the development of new heathier and nutritionally improved foods, also for specific intended groups of people such as coeliac ones. However, further investigations are needed for a better comprehension of the most appropriate hempseed product types, matrices, and dosages in order to develop a food product with a greater improvement of nutritional and functional properties, without negatively affecting the physical and sensorial properties of the food product. In-depth investigations are also necessary to identify the most functional hempseed’s compounds, their molecular mechanisms, and their targets in order to comprehend the most adequate concentration of the functional compounds and the vehicle/matrix most suitable to preserve their structure and functionality into the gastrointestinal tract to maximize their bioavailability in the human body and to allow the compounds to reach the target sites. Only in this way, the regular ingestion of the appropriate quantity of food product could actually exert a preventive and beneficial clinically detectable effect, as required in order to claim a food as a functional food.

6. Conclusions

Due to the optimal nutritional composition and to the functional properties of hempseeds, some researchers investigated on one hand, the effects of hempseed dietary supplementation on health and in specific pathological condition, through animal models and humans studies and, on other hand, the possibility to used hempseeds in the food industry as livestock feed supplement to ameliorate the nutritional quality of animal-derived food products, and as ingredient to enrich or fortify daily foods. Overall, the studies performed on animal models have highlighted that there is some evidence about the protective and beneficial effects of hempseeds dietary supplementation especially on inflammatory and chronic-degenerative diseases such as CVDs and neurodegenerative ones, whereas, from the human studies some benefits for the atopic dermatitis treatment, certain blood parameters, and inflammatory responses modulation were emerged following the hempseed oil dietary intake. Nevertheless, the papers present in the scientific literature concerning this issue, are still few and rather inconclusive, referring only to hempseed oil, and is not very comparable due to the employiment of different types of experimental designs, as well as different dosages, experimental periods, and administration methods of the supplement. Finally, the studies respecting the adoption of hempseeds or derivatives in the food industries showed that these products could effectively ameliorate the FAs profile of some animal foods like eggs, milk, and meat, when they are used as livestock feed supplement, whereas when they are employed as ingredients of enriched or fortified foods, many changes occurred in both the rheological and sensorial acceptability of the enriched/fortified products and, often, they were not positively in spite of the improvement of the nutritional quality. Therefore, further investigations are needed to expand the research and knowledge about the potential use of the hempseed or derivatives for the development of functional foods. Particularly, it is necessary to understand what are the most functional hempseed’s compounds, their molecular mechanisms, and their targets, in order to comprehend the most adequate concentration of the functional compounds and the vehicle/matrix most suitable to preserve their structure and functionality into the gastrointestinal tract, and to maximize their bioavailability in the human body. Furthermore, it is also required to identify the best compromise between the functionality and the rheological and sensorial properties, taking into account that a certain reduction of sensorial acceptability could be tolerable by consumers informed about the beneficial effects of the fortified/enriched products in comparison to the common counterpart.

Author Contributions

Conceptualization, B.F.; writing—original draft preparation, B.F.; writing–review and editing, all of the authors. All authors have read and agreed to the published version of the manuscript.

The Biology of Cannabis sativa L. (Cannabis, hemp, marijuana)

This page is part of the Guidance Document Repository (GDR).

On this page

1 General administrative information

1.1 Background

The Canadian Food Inspection Agency’s Plant and Biotechnology Risk Assessment (PBRA) Unit is responsible for assessing the potential risk to the environment from the release of plants with novel traits (PNTs) into the Canadian environment. The PBRA Unit is also responsible for assessing the pest potential of plants imports and plant species new to Canada.

Risk assessments conducted by the PBRA Unit require biological information about the plant species being assessed. Therefore, these assessments can be done in conjunction with species-specific biology documents that provide the necessary biological information. When a PNT is assessed, these biology documents serve as companion documents to Dir94-08: Assessment Criteria for Determining Environmental Safety of Plants with Novel Traits.

1.2 Scope

This document is intended to provide background information on the biology of Canabis sativa L.

  • its identity
  • geographical distribution
  • reproductive biology
  • related species
  • the potential for gene introgression from C. sativa into relatives
  • details of the life forms with which it interacts

Unless specified otherwise, information provided hereinafter concerns the whole genus Cannabis.

Such information will be used during risk assessments conducted by the PBRA unit. Specifically, it may be used to characterize the potential risk from the release of the plant into the Canadian environment with regard to

  • weediness/invasiveness
  • gene flow
  • plant pest properties
  • impacts on other organisms
  • impact on biodiversity

2 Identity

2.1 Name(s)

Cannabis sativa L. Footnote 23

2.2 Family

2.3 Synonym(s)

Synonyms for C. sativa Footnote 23 include:

  • Cannabis sativa subsp. sativa
  • Cannabis indica Lam.
  • Cannabis sativa subsp. indica (Lam.) E. Small & Cronquist
  • Cannabis ruderalis Janisch.

2.4 Common names

Cannabis sativa is commonly known as cannabis, hemp, Indian hemp, marihuana, and marijuana Footnote 23 Footnote 199 .

2.5 Taxonomy and genetics

C. sativa belongs to the Cannabaceae family Footnote 23 . The Cannabaceae family includes 12 genera and about 102 species Footnote 24 , including other economically important species such

  • Humulus lupulus L. (hop)
  • Pteroceltis tatarinowii (blue sandalwood) Footnote 23

C. sativa is diploid (2n = 20) Footnote 193 .

Taxon Scientific name and common name
Kingdom Plantae (plants)
Subkingdom Tracheobionta (vascular plants)
Superdivision Spermatophyta (seed plants)
Division Magnoliophyta (flowering plants)
Class Equisetopsida
Subclass Magnoliidae
Order Rosales
Family Cannabaceae
Genus Cannabis
Species Cannabis sativa L.

The taxonomic classification of C. sativa has long been a subject of differing opinions and botanical debate Footnote 53 Footnote 136 Footnote 197 Footnote 198 . The majority of botanical treatments describe it as highly diverse but monospecific (that is, one species with intraspecific forms) Footnote 135 Footnote 197 Footnote 199 Footnote 200 Footnote 202 . All forms of C. sativa are naturally diploid and sexually compatible Footnote 202 . The high geographical, morphological, and chemical variation in C. sativa results from extensive selection and domestication towards differing utilitarian needs (fibre, drug, oilseed, etc.). This document considers C. sativa to be monospecific. However, some taxonomists treat Cannabis as polyspecific (that is, multiple species), sometimes with infraspecific forms Footnote 52 Footnote 78 Footnote 111 Footnote 112 Footnote 189 . Recent research demonstrates that marijuana and hemp are significantly differentiated at a genome-wide level, suggesting that the distinction between these two populations is not limited to genes underlying production of the cannabinoid Δ 9 -tetrahydrocannabinol (THC) Footnote 188 Footnote 223 .

Small and Cronquist (1976) Footnote 202 identified a threshold for differentiating between industrial hemp (both fibre-type and oilseed-type) and marijuana (drug-type) forms of C. sativa based on the relative dry weight concentration of THC in the plant’s female inflorescences. Plants accumulating levels above 0.3% Δ 9 -THC are considered marijuana/drug-type C. sativa and plants containing levels below this threshold are considered hemp in North America. In the European Union, the threshold is 0.2% Footnote 12 . Modern assessments of cannabinoid content to delineate the differences between industrial hemp and drug-type varieties combine the total content of THC and Δ9-tetrahydrocannabinolic acid (THCA), given that THCA spontaneously decarboxylates to form THC (see section 4.2.1 Cannabinoids). Small and Cronquist (1976) Footnote 202 have proposed a model for classifying the subspecies and varieties of C. sativa based on the characteristics of the achenes (fruits, commonly called seeds) and tetrahydrocannabinol (THC)/ cannabidiol (CBD) ratios:

1. Cannabis sativa subsp. sativa

Plants of limited intoxicant ability, Δ 9 -THC comprising less than 0.3% (dry weight) of upper third of flowering plants and usually less than half of cannabinoids of resin. Plants cultivated for fibre or oilseed or growing wild in regions where such cultivation has occurred.

Cannabis sativa subsp. sativa var. sativa

Mature fruits relatively large, seldom less than 3.8 millimeters (mm) long, tending to be persistent, without a basal constricted zone, not mottled or marbled, the perianth poorly adherent to the pericarp and frequently more or less sloughed off.

Cannabis sativa subsp. sativa var. spontanea Vavilov

Mature fruits relatively small, commonly less than 3.8 mm long, readily disarticulating from the pedicel, with a more or less definite, short, constricted zone toward the base, tending to be mottled or marbled in appearance because of irregular pigmented areas of the largely persistent and adnate perianth.

2. Cannabis sativa subsp. indica (Lam.) E. Small & Cronquist

Plants of considerable intoxicant ability, Δ 9 -THC comprising more than 0.3% (dry weight) of upper third of flowering plants and frequently more than half of cannabinoids of resin. Plants cultivated for intoxicant properties or growing wild in regions where such cultivation has occurred.

Cannabis sativa subsp. indica var. indica (Lam.) Wehmer

Mature fruits relatively large, seldom less than 3.8 mm long, tending to be persistent, without a basal constricted zone, not mottled or marbled, the perianth poorly adherent to the pericarp and frequently more or less sloughed off.

Cannabis sativa subsp. indica var. kafiristanica (Vavilov) E. Small & Cronquist

Mature fruits relatively small, usually less than 3.8mm long, readily disarticulating from the pedicel, with a more or less definite, short, constricted zone towards the base, tending to be mottled or marbled in appearance because of irregular pigmented areas of the largely persistent and adnate perianth.

The terms “sativa” and “indica” have been applied inconsistently and haphazardly. 2 varieties of drug-type C. sativa were referred to by their common names beginning in the 1980s:

  • C. sativa subsp. indica var. indica (referred to as “sativa”)
  • C. sativa subsp. indica var. afghanica (referred to as “indica”)

Extensive hybridization of these varieties has largely eliminated any distinction between modern strains. However, strains are often labelled as “sativa” or “indica” based on the THC:CBD ratios of the plants; this does not reflect their taxonomic classification or genetic background. Furthermore, “sativa” has been used to refer to either plants with a high THC:CBD ratio or to low-THC hemp forms (“C. sativa“). “Indica” may refer to plants with high THC and CBD or to high-THC, low-CBD forms (“C. indica“) Footnote 139 .

2.6 General description

C. sativa is an herbaceous dioecious annual species displaying considerable variability in phenotypic characteristics; monoecious plants can occur or be developed by breedingefforts Footnote 26 Footnote 81 . Cultivars may show differing shoot architectures dependent on selection towards various utilitarian needs, while plants escaped from cultivation may show degrees of reversion to non-domesticated characteristics. For instance, hemp cultivars selected for fibre production are generally tall, with reduced branching and less woody stem tissue to maximize bast fibre production, whereas drug-type C. sativa varieties are generally highly branched to maximize the production of female flowers Footnote 205 .

In general, plants are erect with simple to well-branched stems and highly variable in height depending on genetic constitution and environmental factors, typically ranging from 0.2 to 5 meters (m) (though heights of over 12 m in cultivation are reported) Footnote 205 . Root morphology is adaptable to soil characteristics and water availability. Generally, the root is a laterally branched taproot that may penetrate up to 2.5 m deep to access sub-surface moisture. The stems are erect, furrowed, and usually branched, with a woody interior, and may be hollow in the internodes Footnote 205 .

The larger leaves (sometimes called “fan leaves”) are compound with an odd number (3 to 13) of leaflets that radiate from a single point at the distal end of each petiole. The leaflets are lanceolate or occasionally ovoid or oblanceolate, with serrate (rarely doubly serrate) margins. The petioles are 2 to 7 centimeters (cm) in length, arranged in opposite pairs on the lower stem and alternately near the stem apex. C. sativa can have anthocyanin-streaked foliage and stems; plants can become increasingly purple following frost Footnote 205 .

During the vegetative growth stage, male and female plants are not reliably distinguishable based on appearance. Sexually mature male and female plants are readily distinguishable; male plants typically appear less robust and taller, with more slender stems, smaller leaves, and less branching of the vegetative shoot than female plants Footnote 199 .

Flowers are imperfect (either staminate or pistillate), small, numerous, and congested in the inflorescences, with male and female flowers occurring almost invariably on different plants in the wild, but with both kinds on some modern hemp cultivars Footnote 169 Footnote 205 . Staminate flowers are produced in monoecious plants before the pistillate flowers, with occasional hermaphroditic flowers Footnote 205 . For more information on floral and seed morphology, see section 4.1.

While selected traits in domesticated varieties become genetically fixed through continued selection, environmental conditions may impact morphology. For instance, planting density can influence branching, with high-density plantings resulting in taller, slender-stemmed plants with reduced branching ideally suited for maximizing fibre production in hemp. Conversely, low-density plantings result in less competition and more branching to maximize foliage and flowers containing cannabinoids for drug-type C. sativa production Footnote 199 . Nutrient deficiency (especially nitrogen), low-light conditions, and drought can contribute to poor growth and stunted plants.

3 Geographical distribution

3.1 Origin and history of introduction

C. sativa is one of the oldest domesticated species, being cultivated since antiquity for end uses including fibre, hempseed, and for its psychotropic phytochemicals. There is uncertainty where C. sativa was domesticated and whether there are multiple centres of origin. The extensive use and spread by humans of C. sativa in the last 6,000 years have made it difficult to distinguish between wild, native populations and escapes from cultivation Footnote 25 Footnote 52 . Many areas have been proposed as the centre of origin for C. sativa, including countries in Asia and Europe Footnote 64 Footnote 138 Footnote 191 Footnote 226 .

It has been postulated that hemp plants and drug-type plants were historically selected in different geographic centres. In Europe and northern Asia, C. sativa was cultivated almost exclusively for its fibres, while in southern Asia, it was used as a drug for recreational, cultural, and spiritual purposes Footnote 199 . Thus, there was a north-south separation of C. sativa forms grown mostly for fibre and those grown mostly for drug uses. Northern fibre-type germplasms are adapted to the relatively short growing seasons of such latitudes. Hemp was sequentially introduced to western Asia, Egypt, and Europe between approximately 1,000 and 2,000 Before the Common Era (BCE) Footnote 200 . Drug-type C. sativa germplasms are conversely adapted to southern latitudes experiencing little seasonal changes in photoperiod. Certain forms of drug-type C. sativa flower comparatively earlier, which has been hypothesized to be an adaptation to a shorter growing season imposed by seasonal drought conditions occurring in southwestern Asia Footnote 199 . The varieties from which present C. sativa strains originated have become rare because of widespread crossbreeding Footnote 139 . For a detailed discussion of these historically selected groups of C. sativa, see Chapter 18 of Ernest Small’s monograph on Cannabis Footnote 199 .

3.2 Native range

C. sativa is widely believed to have originated in temperate, central or western Asia and perhaps eastern Asia Footnote 125 Footnote 138 Footnote 199 .

3.3 Introduced range

C. sativa is a globally cultivated and introduced species occurring in North and South America, Europe, Africa, Asia, and Australasia Footnote 14 Footnote 21 . C. sativa is widely present in North America and as of July 2019 was listed as introduced in all Canadian provinces except Newfoundland and Prince Edward Island Footnote 43 , though other sources have reported it in all provinces Footnote 61 Footnote 205 . Most wild populations occur where hemp was historically cultivated, and in Canada, it is well established along the St. Lawrence River and lower Great Lakes regions of Ontario and Quebec Footnote 61 Footnote 205 . In the United States, the naturalized range includes the Midwest and Northeast where hemp was historically cultivated Footnote 13 Footnote 205 .

Wild-growing hemp populations are frequent in Eurasia, particularly in southeast and central Asia and many European countries. To a lesser extent, wild-growing populations are found in South America and Australia Footnote 199 . C. sativa is generally said to be adapted to a northern-temperate climate and seldom escapes cultivation in tropical areas Footnote 199 .

3.4 Potential range in North America

The current known distribution of outdoor production of C. sativa across the globe suggests that its potential global range comprises zone 4 through zone 13 of the global plant hardiness zone map Footnote 128 . C. sativa growth and development in zones 10 and 11 is conditional on adequate precipitations in those areas. Naturalized C. sativa is rare south of 37° degrees north latitude, uncommon in the western United States, and very rare in Mexico Footnote 205 . Domesticated C. sativa tolerates heat well but not cold, with optimal growing temperature between 14 degrees Celsius (°C) and 27°C Footnote 205 . C. sativa may tolerate light frosts (-6°C) but is killed by heavy frosts or extended periods of near-freezing temperature Footnote 205 . Canada’s short growing season may prevent seed maturation and limit the establishment of C. sativa. However, C. sativa may adapt to the shorter photoperiods and cooler temperatures. With the recent increase of legal cultivation of both hemp and drug-type C. sativa in Canada, at least some expansion of the range of plants growing without human care is inevitable (E. Small, personal communication, 2019).

3.5 Habitat

Cultivated drug-type C. sativa and hemp can be grown in outdoor fields, greenhouses, or indoor environments. Wild C. sativa is a nitrophile and grows vigorously in moist but well-drained, well-manured, open and sunny locations situated close to water. C. sativa requires a moist climate or abundant soil moisture for growth, and is highly sensitive to light (that is, for cannabinoid production) Footnote 72 . Plants grow optimally in fertile, sandy-loam soils but will also grow in very sandy soils. In nutrient-deficient soils, especially those low in nitrogen, plants are stunted. Heavy, water-holding clay soils are unsuitable due to the intolerance of C. sativa to waterlogged conditions Footnote 199 . In Eurasia, wild C. sativa has been observed on the edges of cultivated fields, in ravines, hollows, sunny patches in woodland valleys, and on rubbish heaps near settlements or habitation Footnote 72 Footnote 205 . In North America, wild C. sativa tends to grow in well-manured, moist farmyards, and in open habitats, waste places (roadsides, railways, vacant lots), occasionally in fallow fields, and open woods Footnote 13 . C. sativa is generally poorly adapted for penetrating established stands of perennial vegetation; conversely, it is well adapted to sites with recent soil disturbances Footnote 199 .

4 Biology

4.1 Reproductive biology

C. sativa reproduces exclusively by seed and does not naturally reproduce vegetatively Footnote 205 . The life cycle of C. sativa usually takes 4 to 6 months to complete Footnote 54 ; this may be shortened to about 2 months in northern adapted C. sativa or under specific environmental conditions Footnote 129 . C. sativa is a wind-pollinated species; wind can carry pollen long distances. Pollen production lasts approximately 3 weeks, but this varies greatly based on the genotype and sowing date Footnote 27 Footnote 201 .

Wild plants, traditional hemp cultivars and landraces, and drug biotypes are dioecious. Dioecious plants are mostly or entirely cross-pollinated; male C. sativa plants tend to flower 1 to 3 weeks before female plants, therefore favouring outcrossing Footnote 197 . Many recent fibre and oilseed cultivars are monoecious (containing both male and female reproductive organs). Male flowers on monoecious plants typically appear on the distal part of the plant and are produced before female flowers, which are located on the basal parts of the plant Footnote 197 Monoecious plants can self-pollinate to some degree (20 to 25%) Footnote 199 .

Sex development in C. sativa is modifiable by environmental factors and hormonal applications Footnote 110 . Once flowers have differentiated, they will not change, but subsequent flowers on the same plant may develop into the opposite sex. For example, application of auxins or ethylene feminizes C. sativa plants Footnote 108 Footnote 147 whereas gibberellins have been reported to masculinize them Footnote 29 Footnote 48 . Additionally, when C. sativa plants were subjected to ultraviolet light and modified day-length duration the proportion of female and male plants adjusted; female plants increased after seed exposure to ultraviolet light or carbon monoxide and decreased in response to shorter day-length and higher nitrogen levels in the root zone Footnote 104 Footnote 109 .

The initiation of some floral primordia may occur after the main period of vegetative growth, but the production of most flowers is induced in most strains by consecutive days with short photoperiods. For most drug-type C. sativa plants, flowering is triggered when the minimum uninterrupted period of darkness is increased to 10 to 12 hours for some weeks Footnote 54 Footnote 197 . Some biotypes (a group of organisms with the same genetic constitution), especially those from the northernmost and southernmost extremes, are photoperiod insensitive (“autoflowering”). Many biotypes that normally require short-day photoperiodic induction to flower will eventually flower under continuous light Footnote 37 Footnote 110 .

Female flowers are developed in simple inflorescences known as racemes and are present in dense clusters (compound racemes). Female flowers possess a “perigonal bract” that arises under each flower and grows to envelop the fruit. These bracts have the highest density of glandular trichomes – tiny secretory resin glands that produce and accumulate cannabinoids (that is, tetrahydrocanabolic acid [THCA], cannabidiolic acid [CBDA]), and terpenes (that is, monoterpenes and sesquiterpenes) Footnote 126 . The number of glandular trichomes varies amongst individual plants. On female flowers, 3 types of glandular trichomes have been identified based upon their morphology: bulbous, sessile, and stalked Footnote 100 . Bulbous trichomes are the smallest and produce limited specialized metabolites. The 2 main glandular trichome types, sessile and stalked, are similar architecturally; both have a globose head and sit above the epidermal surface by a multicellular stalk Footnote 101 Footnote 126 . The main differences between the 2 types are that stalked trichomes have higher THC concentrations, are larger, and are more abundant. Other young aerial tissues also contain a relatively high concentration of these epidermal secretory glands (albeit substantially less than the perigonal bracts), suggesting a protective function Footnote 199 .

Individual male flowers are short-stalked, drooping, and arranged in larger, loose, determinate inflorescences Footnote 171 . The flowers appear in pairs, usually on special floral branches but they can also be found at the bases of some vegetative branches. Male flowers are greenish or whitish with five petals and prominent stamens, are small in size, extend on short pedicels Footnote 13 Footnote 199 and bear glandular trichomes on their anthers and filaments Footnote 203 . Male flowers produce small, light, and dry pollen grains in large quantities Footnote 79 Footnote 169 and are highly-attractive to pollen-collecting bees and flies. Male plants shed pollen and die several weeks before seed ripening on female plants of the same population Footnote 54 Footnote 169 , while female plants continue to grow as seeds develop. The single achene (fruit, commonly called a seed) in each female flower ripens in 3 to 8 weeks Footnote 54 .

The seeds of C. sativa are ovoid, small ( generally 2 to 5 mm long), and protected by the perianth. They are generally brown or grey in cultivated forms, whereas wild C. sativa seeds are covered by a darkly coloured and mottled perianth Footnote 199 . The seeds of wild C. sativa plants are smaller and lighter than those of domesticated plants, usually less than 3.8 mm in length. Some cultivated domestic plants have 15 seeds in a gram, whereas some wild plants have over 1000 seeds in a gram Footnote 197 . Wild seeds have an elongated and narrowing base and a well-developed abscission zone, which promotes easy seed shattering upon ripening (seeds readily disarticulate from the pedicel) Footnote 149 Footnote 231 . Wild C. sativa seeds mature sequentially on each plant, so that the seeds are dispersed at different times and do not interfere with each other’s ability to fall off the plant Footnote 149 Footnote 199 . Seeds of wild C. sativa exhibit long-term dormancy and irregular germination, and usually exhibit lower germination than domesticated seeds.

4.2 Cannabis sativa biochemistry

The C. sativa plant synthesizes over 100 terpenophenolic secondary metabolites known as cannabinoids Footnote 65 Footnote 76 Footnote 77 Footnote 97 Footnote 167 . C. sativa synthesizes about 140 terpenoids (hydrocarbon terpenes and their oxygenated derivatives); however, none is unique to Cannabis Footnote 41 Footnote 140 Footnote 182 Footnote 187 . C. sativa is valued for the psychoactive and potential pharmacological properties of cannabinoids, whereas certain terpene (monoterpene and sesquiterpene) components are responsible for much of the aroma and flavour. Cannabinoids and terpenes are found in resin synthesized in secretory cells inside the glandular trichome heads pyrophosphate Footnote 116 Footnote 156 . Cannabinoid and terpenoid biosynthetic pathways partially overlap in their initial step with the synthesis of the common precursor geranyl pyrophosphate Footnote 36 Footnote 185 .

See also  Poochie love seeds
4.2.1 Cannabinoids

In living plants of C. sativa and freshly harvested tissues, the cannabinoids exist predominantly in the form of carboxylic acids; for example, THC occurs as tetrahydrocannabinolic acid (THCA), and CBD occurs as cannabidiolic acid (CBDA). Non-enzymatic decarboxylation of the cannabinoids into their neutral counterparts occurs relatively slowly with aging, and catalyzed by heat, light, or alkaline conditions. cannabinoids are formed through decarboxylation of their respective 2-carboxylic acids (2-COOH), a process that is catalyzed by heat, light, or alkaline conditions Footnote 82 Footnote 216 .

Cannabinoids have been subdivided into 10 subclasses Cannabis Footnote 41 Footnote 75 Footnote 179 Footnote 218 (for molecular structures see Brenneisen, 2007 Footnote 41 , p. 17-41):

  1. Cannabigerol (CBG) type: CBG was the first cannabinoid identified Footnote 85 . Other cannabinoids of this group are the CBG precursor cannabigerolic acid (CBGA), the propyl side-chain analogs and a monomethyl ether derivative. CBG is the first cannabinoid synthesized in the plant’s cannabinoid synthesis pathway. It is the precursor of Δ 9 -tetrahydrocannabinolic, cannabidiolic, and cannabichromenic acids, and normally appears in the plant at relatively low concentration because the majority is further metabolized to end products, except in specifically bred strains Footnote 66Footnote 213 .
  2. Cannabichromene (CBC) type: To date, 5 CBC-type cannabinoids, mainly present as C5-analogs, have been identified. Its production is normally maximal at the earlier growth stages of the plant Footnote 67 .
  3. Cannabidiol (CBD) type: 7 CBD-type cannabinoids with C1 to C5 side chains have been characterized. CBD and its corresponding acid, CBDA, are the predominant cannabinoids in industrial hemp. It should be noted that genes encoding the CBD and THC synthases are co-dominant such that one is expressed at the expense of the other Footnote 223 .
  4. Δ 9 -Tetrahydrocannabinol (THC) type: 9 THC-type cannabinoids with C1 to C5 side chains have been identified. THC acid A (THCA-A) and B (THCA-B) are the 2 biogenic precursors of THC, although THCA-B is present to a much lesser extent. THC is the main psychotropic principle; the acids are not psychoactive. Female C. sativa plants have up to 20 times the concentration of THC in comparison to male plants. When females are grown in the absence of males, higher concentrations of THC are produced in their reproductive parts Footnote 203 .
  5. Δ 8 -THC type: Δ 8 -THC and its acid counterpart, Δ 8 -THCA, are considered as THC and THCA artifacts, respectively. The activity of Δ 8 -THC is estimated 20% lower than THC’s Footnote 41 .
  6. Cannabicyclol (CBL) type: This group comprises CBL, its acid precursor, and the C3 side-chain analog. These three cannabinoids are characterized by a five-atom ring and C1-bridge instead of the typical ring A. CBL is known to be a heat-generated artifact from CBC Footnote 41 .
  7. Cannabielsoin (CBE) type: This group includes CBE and its acid precursors A and B, and they are artifacts formed from CBD Footnote 41 .
  8. Cannabinol (CBN) and Cannabinodiol (CBND) types: This subclass comprises 6 CBN- and 2 CBND-type cannabinoids which are oxidation artifacts of THC and CBD, respectively Footnote 41 .
  9. Cannabitriol (CBT) type: 9 CBT-type cannabinoids have been described and they are characterized by additional hydroxy group substitution Footnote 41 .
  10. Miscellaneous types: 11 cannabinoids with unusual structures such as furano ring (dehydrocannabifuran, cannabifuran), carbonyl function (cannabichromanon, 10-oxo-δ-6a-tetrahydrocannabinol), or tetrahydroxy substitution (cannabiripsol), have been identified Footnote 41 .

Pharmaceutical properties and medicinal uses of cannabinoids are described in the scientific literature, for details see Russo Footnote 184 Footnote 185 , Pertwee Footnote 163 , Whiting et al. Footnote 229 , CCSA Footnote 7 , Grotenhermen and Müller-Vahl Footnote 96 , Russo and Marcu Footnote 187 , Urits et al. Footnote 222 , among others.

4.2.2 Terpenoids

The characteristic odor of Cannabis plants can be attributed to a mixture of volatile compounds, including monoterpenes, sesquiterpenes, and other terpenoid-like compounds Footnote 199 . C. sativa terpenoids include, but are not limited to, α-pinene, limonene, β-myrcene, D-linalool, caryophyllene oxide and β-caryophyllene which is typically the most common of all terpenoids in C. sativa Footnote 140 and predominates quantitatively in C. sativa extracts Footnote 99 . The proportion of monoterpenes (such as limonene, myrcene, pinene) in the plant is typically greater than that of sesquiterpenes Footnote 113 , but monoterpenes volatilize readily during curing, drying, and storage resulting in a higher relative proportion of sesquiterpenes such as caryophyllene Footnote 180 Footnote 218 . The particular mixture of mono- and sesquiterpenoids determines the viscosity of the resinous content of the trichomes Footnote 185 . Trichome exudate can trap insects Footnote 137 and the phenomenon is illustrated by Small (2017, p. 219) Footnote 200 .

Pharmaceutical properties and medicinal uses of terpenoids are described in the scientific literature, for further details see Russo Footnote 185 Footnote 186 and Russo and Marcu Footnote 187 .

4.2.3 Biosynthesis of terpenoids and cannabinoids

Terpene synthesis in plants involves 2 compartmentalized pathways: the plastidial methylerythritol phosphate (MEP) pathway, and the cytosolic mevalonate (MEV) pathway Footnote 36 . Both biosynthetic pathways lead to the production of substrates that ultimately serve as precursors for not only terpene synthesis but also cannabinoid synthesis (for further details, see Russo Footnote 185 ; Andre et al. Footnote 28 ; Booth et al. Footnote 36 ).

The biosynthetic pathway producing the major cannabinoids with pentyl side chains (CBCA, CBDA, CBGA, and THCA) is now fully elucidated, with CBCA and THCA being described lately. For more details on cannabinoid biosynthesis see Taura et al. Footnote 214 Footnote 215 , Sirikantaramas et al. Footnote 192 , Flores-Sanchez and Verpoorte Footnote 83 , Russo Footnote 185 , van Bakel et al. Footnote 223 , Gagne et al. Footnote 84 , Stout et al. Footnote 208 , Andre et al. Footnote 28 , and Laverty et al. Footnote 122 . Most of the minor cannabinoids, including those with propyl side chains, likely are produced by fatty acids with varying chain-lengths being fed into the “core” cannabinoid pathway.

Several factors influence the amount and quality of the cannabinoids produced in any given C. sativa plant including, the genotype and plant organs, the growth stage, environmental factors, stressors, and polyploidization.

    Genotype and plant organs

The concentration of cannabinoids and terpenoids varies between plant tissues Footnote 200 and among cultivars or biotypes Footnote 35 Footnote 168 depending on the genetic background of the plant. In general, in any given C. sativa plant, the cannabinoid concentration increases in the following order: roots, large stems, smaller stems, older and larger leaves, younger and smaller leaves, and perigonal bracts covering the female flowers Footnote 200 . The density of resin-containing glandular trichomes, the size of the trichome heads, and biosynthetic efficacy considerations determine the amount of THC, cannabinoids and terpenes synthesized Footnote 199 .

Cannabinoid content in the plant generally increases from the seedling stage to the flowering stage because the glandular trichomes that synthesize cannabinoids are concentrated in the reproductive-stage leaves on the female inflorescence Footnote 107 Footnote 120 Footnote 121 Footnote 165 Footnote 196 Footnote 219 . Seedless drug-type female inflorescences are obtained by eliminating male plants from the growing area, which results in increased concentrations of THC, other cannabinoids, and terpenoids Footnote 54 , largely because seeds, if allowed to develop, are a diluent and a drain on the plant’s carbon allocation to specialized metabolism. Most drug type C. sativa is produced today from female clones that are reproduced using cuttings and rarely produce seed Footnote 45 .

Soil, atmospheric, climatic, and management factors that contribute to vigorous growth and development of plants can increase the absolute production of resin and THC in drug-type C. sativa. Such factors include soil fertility, light, heat, and carbon dioxide (CO2) Footnote 199 .

C. sativa hemp plants subject to abiotic stressors such as nutrient deficiencies or drought tend to produce more THC per unit of biomass Footnote 103 Footnote 148 Footnote 195 .

Polyploidization has been found to have varying effects in terms of cannabinoid and terpenoid production in hemp and drug-type C. sativa. For more detail on this relationship see De Pasquale et al. Footnote 69 , Clarke Footnote 51 , Bagheri and Mansouri Footnote 31 , Mansouri and Bagheri Footnote 130 , and Parsons et al. Footnote 161 . A polyploid form of drug-type C. sativa has not been commercialized.

4.3 Breeding and seed production

4.3.1 Breeding for cannabinoid content

The genetics and underlying biochemistry that regulates the overall ratio of the 4 major cannabinoids are now well known. The upstream portion of the cannabinoid biosynthetic pathway produces CBGA, a common substrate for the enzymes that produce CBDA, THCA, and CBCA. Thus, the overall cannabinoid ratio is dependent on the individual activities of these enzymes, which in turn is dependent on the genetic makeup of the individual plant. In general, most individual C. sativa plants are either CBDA-dominant or THCA-dominant, with the remainder of the major cannabinoids constituting a smaller percentage of the overall cannabinoid content. There are rare instances of genotypes that are dominant for CBCA or CBGA. The alleles that encode the enzymes THCA synthase and CBDA synthase are co-dominant, and thus crossing a CBDA-dominant plant with a THCA-dominant plant produces progeny with equal proportions of these cannabinoids Footnote 28 .

Throughout the ages, hemp largely has been bred for seed and fibre quality. In general, all industrial hemp produced today is CBDA-dominant with low total cannabinoid content compared to drug-type C. sativa Footnote 188 . Regulatory bodies use the proportion of cannabinoids to differentiate drug-type C. sativa and industrial hemp. The upper concentration limit for THCA+THC content in industrial hemp was proposed as 0.3% (dry weight) by Small and Cronquist (1976) Footnote 202 . This threshold is used in Canada and the United States, while the European Union uses a threshold of 0.2% Footnote 200 . In some industrial hemp varieties, there can be individual plants found that are THCA-dominant or THCA/CBDA equal, which may account for why some hemp varieties more commonly fail the THC content criterion when randomly sampled (J. Stout, personal communication, 2020). Breeders could lower THC levels by targeting cannabinoid biosynthetic pathways or by disrupting the morphogenesis of cannabhen randomly sampled (J. Stout, personal communication Footnote 68 .

One of the main breeding objectives for drug-type C. sativa is to increase total cannabinoid content while maintaining THCA-dominance. Some commercial strains of drug-type C. sativa reportedly contain up to 21% THCA in dried female flowers Footnote 35 . Biotechnology companies have developed strains that predominantly produce 1 of the 4 major cannabinoid compounds (THCA, CBDA, CBCA, and CBGA), as well as strains with mixed cannabinoid or terpenoid profiles Footnote 52 . Several commercial drug-type C. sativa strains have been described by Rosenthal Footnote 175 – Footnote 178 , Snoeijer Footnote 206 , Danko Footnote 60 , Grisswell and Young Footnote 95 , Oner Footnote 150 Footnote 151 Footnote 152 Footnote 153 Footnote 154 Footnote 155 , and Backes Footnote 30 . However, while numerous strains have been named, not all reflect unique biotypes largely due to the undocumented nature of drug-type C. sativa breeding programs Footnote 188 . Strain names are not accepted as cultivars under the International Code of Nomenclature for Cultivated Plants Footnote 42 .

4.3.2 Seed production

Varietal purity standards for pedigreed seed production of both registered and certified industrial hemp seed have been developed by the Canadian Seed Growers’ Association Footnote 11 .

4.4 Cultivation and use as crop

C. sativa is used for its fibre, oil (for vegetable oil and oilseed products), and recreational or medicinal drug purposes Footnote 204 . Claimed pharmacological properties attributed to Cannabis are discussed by Russo Footnote 185 Footnote 186 , Whiting et al. Footnote 229 , CCSA Footnote 7 , and Russo and Marcu Footnote 187 , among others. Hemp is universally cultivated as a field crop for its uses as oil, biomass, or both, while legal drug-type C. sativa is cultivated mostly indoors or in greenhouses, with low acreage in outdoor fields Footnote 28 . In Canada, the majority of hemp is grown for seed production Footnote 105 .

Commercial cultivation of industrial hemp in Canada falls under the Industrial Hemp Regulation and the associated requirements from obtaining and maintaining a licence from Health Canada. Only varieties named in the “List of Approved Cultivars”, published by Health Canada, are approved for planting in Canada.

The Cannabis Act and its regulations came into force on October 17, 2018 . The Cannabis Act and its regulations provide the framework for the legal production of drug-type C. sativa. Commercial cultivators of drug-type C. sativa (not for personal use) are required to obtain a licence from Health Canada Footnote 16 Footnote 17 . Applicants may apply under the subclasses of micro-cultivation, standard cultivation, or nursery cultivation.

Crop guides for the cultivation of industrial hemp have been published by several provincial agriculture departments – Alberta Footnote 1 , Manitoba Footnote 18 , Ontario Footnote 19 , Saskatchewan Footnote 22 and the Canadian Hemp Trade Alliance Footnote 10 . Many guides pertaining primarily to the non-commercial cultivation of drug-type C. sativa have been published, including Clarke Footnote 50 , Rosenthal Footnote 174 Footnote 175 Footnote 176 Footnote 177 Footnote 178 , Green Footnote 93 , and Cervantes Footnote 47 .

Vegetative propagation by cuttings and tissue culture techniques are widely practiced in drug-type C. sativa production systems to preserve a known genetic or biochemical profile Footnote 199 Footnote 221 .

4.5 Gene flow during commercial production

C. sativa is a naturally outcrossing species, with rare instances of self-fertilization. In dioecious varieties, a single male flower can produce 350,000 pollen grains and a single plant contains many male flowers Footnote 201 . C. sativa is wind-pollinated. Small and Antle Footnote 201 (2003) measured hemp pollen dispersal and found pollen density fell to less than 1% of the density within the field at 100 m, but the decrease measured at 400 m was proportionally less. Pollen dispersal of over 300 kilometers (km) Footnote 205 and even between North Africa and southwestern Europe has been reported Cabezudo et al. Footnote 44 . C. sativa pollen can remain viable for days, if not over a week under optimal conditions Footnote 33 Footnote 201 . Intraspecific gene flow between industrial hemp and drug type lines cultivated in the field is a growing concern.

In Canada, isolation distances of up to 4.8 km are required for pedigreed industrial hemp seed production Footnote 11 .

4.6 Cannabis sativa as a potential weed of agriculture

C. sativa plants tolerate a wide range of conditions, have high genetic variability, and are adaptable to environmental conditions; these characteristics could increase weediness and the colonization of new locations Footnote 72 . Hemp has been documented to grow as a weed in Footnote 102 Footnote 103 Footnote 197 .

  • field margins
  • farmyards
  • waste places
  • on rubbish heaps near habitations
  • open lots
  • in pasturelands
  • fallow fields
  • along or beside roadsides
  • railways
  • ditches
  • creeks
  • fence rows
  • bridge embankments
  • lowland drainage tributaries
  • open woodlands

Hemp, as a weed, has been documented in southeast and central Asia, Europe, South America, Australia, and Africa Footnote 63 . In North America, hemp has naturalized where its cultivation was concentrated historically in the U.S. midwest and southeast, southern Ontario, and southern Quebec. C. sativa has been reported growing outside of agricultural systems in Canadian provinces from British Columbia to New Brunswick Footnote 194 Footnote 205 . Small et al. Footnote 205 observed hemp volunteers 4 years after the completion of a hemp trial in Ottawa, Canada.

Despite the historical prohibition of drug-type C. sativa production in Canada, insight on its weediness can be gained from the behaviour of hemp in areas where production has been authorized. Hemp has weedy tendencies, as indicated by Small Footnote 195 ; hemp biotypes have been capable of escaping cultivation and adapting very well to growing without human intervention in about 50 generations. However, it is unlikely that drug-type C. sativa would display increased weediness compared to hemp. Throughout centuries of selection, the phenotypes of drug-type C. sativa and hemp have diverged, notably the plant architecture. The short stature of most drug-type C. sativa plants grown in Canada (in contrast to fibre-type C. sativa) minimizes the production of stem tissues while maximizing the production of floral tissues Footnote 205 . Minimizing harvest losses will reduce C. sativa volunteers in subsequent crops. Cold temperatures and short photoperiods would negatively impact the ability of C. sativa, especially types adapted to indoor cultivation and semi-tropical climates, to produce seeds before fall and thus, establish as a weed Footnote 205 .

Many broadleaf herbicides will control volunteer C. sativa. Pre-plant or pre-emergent burndown using 2,4-D or glyphosate will generally control hemp in the spring Footnote 205 . Mechanical control, followed by chemical control the following year, is recommended for mature plants Footnote 205 .

4.7 Means of movement and dispersal

Humans, birds, and water are the primary dispersal agents of C. sativa seeds. C. sativa seeds are highly attractive to birds, hence the opinion of Haney and Bazzaz Footnote 102 that birds were the most important wild animals for disseminating seeds in North America. Some C. sativa seeds can survive the digestive tract of birds Footnote 62 , while others may adhere to claws or bills Footnote 141 . Flood and runoff waters may also disperse seeds Footnote 102 .

5 Related species of Cannabis sativa L.

5.1 Inter-species/genus hybridization

The Cannabaceae family, as currently described, comprises about 102 accepted species and 12 genera including Footnote 24 :

  • Aphananthe (4 spp.)
  • Cannabis (1 sp.)
  • Celtis L. (72 spp.)
  • Gironniera (6 spp.)
  • Humulus (3 spp.)
  • Lozanella (2 spp.)
  • Pteroceltis (1 sp.)
  • Trema (13-spp.)

Cannabis and Humulus (hop) are phylogenetically close Footnote 230 . However, there is no reliable evidence reported in the literature of sexual hybridization between C. sativa and the 3 species of the genus Humulus (H. lupulus (common hop), H. japonicus, and H. yunnanensis).

5.2 Potential for introgression of genetic information from Cannabis sativa into relatives

In Canada, there are no relatives known to interbreed with C. sativa. Thus, the risk of interspecific gene flow is low Footnote 45 . Introgression of genetic information from C. sativa will be restricted to other C. sativa plants. All taxa within the species C. sativa readily crossbreed, often by way of long-distance pollination (see Section 4.5 Gene flow during commercial production).

6 Potential interaction of Cannabis sativa with other life forms

C. sativa plants display mechanical and chemical defense mechanisms including the occurrence of cystolith trichomes, resinous exudate from glandular trichomes, and emission of volatile terpenoids Footnote 162 . Upper surfaces of C. sativa leaves are covered by abrasive cystolith trichomes (that is, unicellular hairs that have particles of calcium carbonate in their base). Cystolith trichomes impart a roughness to the surface of leaves that can cause skin irritation or dermatitis in people handling C. sativa and may discourage herbivory by larger animals Footnote 199 ; they also may impale small insects and damage the mouthparts of larger ones Footnote 124 . C. sativa leaves and floral parts are also covered by glandular trichomes which secrete many organic compounds including terpenoids and cannabinoids. Glandular trichomes may rupture and release a viscous mixture that can trap insects, as illustrated by Small (2017, p. 219) Footnote 200 and described by McPartland and colleagues Footnote 137 , or be unpalatable to herbivores.

Several volatile terpenes produced by C. sativa including limonene, pinene, humulene, and caryophyllene have insecticidal properties Footnote 137 Footnote 142 and are synthesized and accumulated in trichomes Footnote 98 . Although the biosynthesis of terpenoids with insecticidal properties occurs across all forms of C. sativa, drug-type C. sativa produces 3 to 6 times more resinous components, including limonene and pinene, than most hemp varieties Footnote 140 . Cannabinoids such as THC and THCA also possess insecticidal properties Footnote 134 Footnote 137 Footnote 181 Footnote 183 Footnote 215 . The levels of exposure of insects to insecticidal compounds synthesized by C. sativa, such as limonene, pinene, and THC, are unknown.

Pollen-producing male C. sativa flowers are attractive to bees and pollen-collecting flies, particularly when nectar-producing species are absent Footnote 199 . The pollen of C. sativa plants was reported to contain cannabinoids and volatile terpenes Footnote 157 Footnote 182 ; however, this is likely the result of contamination from staminal trichomes as the pollen itself has no trichomes Footnote 199 . The potential impact of C. sativa pollen on bee health at the individual and colony level is unknown.

Herbivores have been known to ingest escaped C. sativa and the plant material (not the seeds) appears to have toxic potential if eaten in very large amounts. In general, C. sativa is not considered to be significantly poisonous Footnote 205 .

According to McPartland Footnote 133 , nearly 300 insect pests have been associated with C. sativa, but very few cause economic losses. Some of the most common and serious pests are mites (e.g., two-spotted mite, Tetranychus urticae, and the hemp russet mite, Aculops cannabicola), borers (such as the European corn borer, Ostrinia nubilalis, and the hemp borer, Grapholita delineana), aphids (such as Phorodon cannabis), budworms (such as Helicoverpa armigera), and beetle larvae (such as Psylliodes attenuata, Ceutorhynchus rapae, Rhinocus pericarpius, Thyestes gebleri, and several Mordellistena spp.). For more detailed information on pests of C. sativa, see McPartland Footnote 133 .

For a list of species associated with C. sativa, please refer to Table 1.

Table 1. Examples of potential interactions of Cannabis sativa with other life forms present in Canada during its life cycle.


Other life forms Interaction with Cannabis sativa (pathogen; symbiont or beneficial organism; consumer; gene transfer) Reference(s)
Agrobacterium spp.
(crown gall, gall)
Synonym: Rhizobium spp.
Pathogen (Bradbury, 1986 Footnote 40 )
Erwinia tracheiphila (Smith)
Bergey et al., Hauben et al.
(bacterial wilt)
Pathogen (Bradbury, 1986 Footnote 40 )
Pseudomonas syringae pvs
(mulberry blight, Wisconsin tobacco disease)
Pathogen (CABI/EPPO, 2009 Footnote 5 ; Bradbury, 1986 Footnote 40 )

Other life forms Interaction with Cannabis sativa (pathogen; symbiont or beneficial organism; consumer; gene transfer) Reference(s)
Alternaria spp.
Pathogen (Farr et al., 2018 Footnote 80 )
Aspergillus spp.
(stalk end rot of fruit).
Pathogen (Clear and Patrick, 1995 Footnote 56 ; Conners, 1967 Footnote 57 ; Elmhirst and Joshi, 1995 Footnote 74 ; Ginns, 1986 Footnote 91 ; Miller et al., 1985 Footnote 143 ; Mills and Abramson, 1981 Footnote 144 )
Botrytis cinerea Pers.
(gray mold)
Synonym: Botryotinia fuckeliana (deBary) Whetzel
Pathogen (Conners, 1967 Footnote 57 ; Gossen et al., 1994 Footnote 92 ; Legault et al., 1989 Footnote 123 ; Parmelee, 1983 Footnote 159 ; Rodriguez et al., 2015 Footnote 172 )
Cladosporium herbarum
(Persoon) Link
(cladosporium stem canker)
Pathogen (McPartland et al., 2000 Footnote 137 )
Colletotrichum dematium (Pers.) Grove
(leaf spot)
Synonym: Vermicularia dematium (Persoon) Fries
Pathogen (Cerkauskas et al., 1991 Footnote 46 ; Ginns, 1986 Footnote 91 )
Fusarium spp.
Pathogen (Clear and Patrick, 1990 Footnote 55 ; Duthie et al., 1986 Footnote 71 ; Farr et al., 2018 Footnote 80 ; Martin and Johnston, 1982 Footnote 131 ; Sturz and Bernier, 1991 Footnote 209 ; Sturz and Johnston, 1983 Footnote 210 ; Wall and Shamoun, 1990 Footnote 225 )
Glomus mosseae (T.H. Nicolson & Gerd.) Gerd. & Trappe Symbiont (Dalpe et al., 1986 Footnote 59 ; Kucey and Paul, 1983 Footnote 119 ; Traquair and Berch, 1988 Footnote 217 )
Macrophomina phaseoli
(Maubl.) S.F. Ashby
(charcoal rot, damping-off)
Synonym: Macrophomina phaseolina (Tassi) Goid
Pathogen (Conners, 1967 Footnote 57 ; Desjardins et al., 2007 Footnote 70 ; Joshi and Hudgins, 2002 Footnote 114 )
Nectria haematococca Berk. & Broome
(dry rot of potato)
Synonym: Fusarium solani (Martius) Sacc.
Pathogen (Conners, 1967 Footnote 57 ; Duthie et al., 1986 Footnote 71 ; Joshi and Elmhirst, 1998 Footnote 115 ; Sturz and Bernier, 1991 Footnote 209 ; Sumar et al., 1982 Footnote 211 )
Ophiobolus anguillides (Cooke in Cooke & Ellis) Sacc.
(stem canker)
Pathogen (Conners, 1967 Footnote 57 ; Ginns, 1986 Footnote 91 )
Pythium aphanidermatum (Edson) Fitzp.
Pathogen (Farr et al., 2018 Footnote 80 ; Gilbert et al., 2008 Footnote 88 )
Sclerotinia sclerotiorum (Lib.) de Bary
(hemp canker, soft rot or stem rot)
Pathogen (CABI, 2018a Footnote 2 ; Farr et al., 2018 Footnote 80 )
Sclerotium rolfsii Sacc.
(southern blight)
Synonym: Athelia rolfsii (Curzi) C. C. Tu & Kimbr.
Pathogen (Chang and Mirza, 2007 Footnote 49 )
Septoria spp.
(blight of hemp, yellow leaf spot)
Pathogen (CABI, 2018a Footnote 2 ; Conners, 1967 Footnote 57 )
Sphaerotheca macularis (Wallr.) Magnus
(powdery mildew)
Synonym: Podosphaera macularis (Wallr.) U. Braun & S. Takam.
Pathogen (Ginns, 1986 Footnote 91 ; Parmelee, 1982 Footnote 158 ; Parmelee, 1984 Footnote 160 ; Wall and Shamoun, 1990 Footnote 225 )
Trichothecium roseum
(false powdery mildew)
Pathogen (Ginns, 1986 Footnote 91 ; Mittal and Wang, 1987 Footnote 145 )
Trichothecium roseum
(false powdery mildew)
Pathogen (CABI, 2018b Footnote 3 )

Other life forms Interaction with Cannabis sativa (pathogen; symbiont or beneficial organism; consumer; gene transfer) Reference(s)
Alfalfa mosaic virus (AMV) Pathogen (CABI/EPPO, 2002 Footnote 4 ; Conners, 1967 Footnote 57 )
Arabis mosaic virus (ArMV) Pathogen (CABI/EPPO, 2015 Footnote 6 )
Cucumber mosaic virus (CMV) Pathogen (Conners, 1967 Footnote 57 )

Other life forms Interaction with Cannabis sativa (pathogen; symbiont or beneficial organism; consumer; gene transfer) Reference(s)
Candidatus Phytoplasma asteris
(yellow disease phytoplasmas)
Pathogen (Wang et al., 1998 Footnote 227 )

Other life forms Interaction with Cannabis sativa (pathogen; symbiont or beneficial organism; consumer; gene transfer) Reference(s)
Heterodera spp.
(cyst nematode)
Pathogen (Ebsary, 1986 Footnote 73 )
Meloidogyne spp.
(root-knot nematode)
Pathogen (Conners, 1967 Footnote 57 ; Ebsary, 1986 Footnote 73 ; Sewell, 1977 Footnote 190 ; Tyler, 1964 Footnote 220 )
Ditylenchus dipsaci (Kühn) Filipjev
(stem nematode)
Pathogen (Creelman, 1962 Footnote 58 ; Kimpinski, 1985 Footnote 117 )
Insects and mites

Other life forms Interaction with Cannabis sativa (pathogen; symbiont or beneficial organism; consumer; gene transfer) Reference(s)
Acalymma vittatum (Fabricius) Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Acheta domesticus (Linnaeus)
(house cricket)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Vickery and Kevan, 1986 Footnote 224 )
Adalia bipunctata (Linnaeus)
(two spotted ladybeetle)
Beneficial organism (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Agriotes spp.
(lined click beetle, wireworm click beetle)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Agromyza reptans Fallén Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Spencer and Steyskal, 1986 Footnote 207 )
Agrotis gladiaria Morrison
(claybacked cutworm)
Consumer (McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Aleochara bilineata Gyllenhal Beneficial organism (CABI, 2018a Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; Gavloski et al., 2011 Footnote 87 ; McPartland et al., 2000 Footnote 137 )
Anagrus atomus (Linnaeus)
(leafhopper egg parasitoid)
Beneficial organism (CABI, 2018d Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; Bostanian et al., 2012 Footnote 38 ; McPartland et al., 2000 Footnote 137 )
Anoplophora glabripennis (Motschulsky)
(Asian long-horned beetle)
Consumer (CFIA, 2016 Footnote 8 ; McPartland et al., 2000 Footnote 137 )
Aphis spp.
(black bean aphid, cotton aphid)
Consumer (Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Apion spp. Herbst Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Arctia caja (Linnaeus)
(garden tiger moth)
Consumer (McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Bemisia spp.
(silverleaf whitefly, tobacco whitefly)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Blattella germanica (Linnaeus)
(German cockroach)
Consumer (CABI, 2018a Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Vickery and Kevan, 1986 Footnote 224 )
Bradysia germanica spp. Winnertz
(fungus gnats)
Consumer (Gillespie and Quiring, 2012 Footnote 90 ; McPartland et al., 2000 Footnote 137 )
Camnula pellucida (Scudder)
(clearwinged grasshopper)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Vickery and Kevan, 1986 Footnote 224 )
Ceutorhynchus spp.
(cabbage curculio, cauliflower weevil)
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Chaetocnema spp.
(corn flea beetle, flea beetle)
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Chelonus insularis Cresson Beneficial organism (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Krombein et al., 1979 Footnote 118 ; McPartland et al., 2000 Footnote 137 )
Chloealtis conspersa (Harris & T.W.)
(sprinkled locust)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Vickery and Kevan, 1986 Footnote 224 )
Chrysopa spp.
(goldeneye lacewing)
Beneficial organism (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Garland and Kevan, 2007 Footnote 86 ; McPartland et al., 2000 Footnote 137 )
Chrysoperla spp.
(green lacewing, pearly green lacewing)
Beneficial organism (CFIA, undated Footnote 9 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; Garland and Kevan, 2007 Footnote 86 ; McPartland et al., 2000 Footnote 137 )
Closterotomus norvegicus (Gmelin)
(strawberry bug, potato bug)
Synonym: Calocoris norvegicus (Gmelin)
Consumer (Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Cnephasia asseclana (Denis & Schiffermüller)
(chrysanthemum web worm)
Consumer (McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Coccinella undecimpunctata Linnaeus
(eleven-spotted ladybeetle)
Beneficial organism (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Cotesia marginiventris (Cresson) Beneficial organism (CABI, 2018a Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Philip, 2015 Footnote 164 )
Cyrtepistomus castaneus (Roelofs)
(asiatic oak weevil)
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Delia spp.
(bean seed fly, cabbage maggot, seedcorn maggot)
Consumer (CABI, 2018 Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 )
Delphastus pusillus (LeConte)
(whitefly predatory beetle)
Beneficial organism (CABI, 2018 Footnote 2 ; Bousquet et al., 2013 Footnote 39 ; CFIA, undated Footnote 9 ; McPartland et al., 2000 Footnote 137 )
Deraeocoris brevis (Uhler)
(Mirid plant bug)
Beneficial organism (CFIA, undated Footnote 9 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Empoasca spp.
(potato leafhopper)
Consumer (Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Encarsia formosa Gahan
(greenhouse whitefly parasitoid)
Beneficial organism (CFIA, undated Footnote 9 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; PMC, 2014 Footnote 20 ; McPartland et al., 2000 Footnote 137 )
Feltiella acarisuga (Vallot)
(red spider mite predatory gall midge)
Synonym: Therodiplosis persicae
Beneficial organism (CFIA, undated Footnote 9 ; Footnote 20 ; McPartland et al., 2000 Footnote 137 ; Mo and Liu, 2007 Footnote 146 )
Forficula auricularia Linnaeus
(European earwig)
Consumer (CABI, 2018a Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Vickery and Kevan, 1986 Footnote 224 )
Frankliniella occidentalis (Pergande)
(western flower thrips)
Consumer (CABI, 2018a Footnote 2 ; Hemming, 2000 Footnote 106 ; McPartland et al., 2000 Footnote 137 )
Graphocephala coccinea (Forster)
(redbanded leafhopper)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Grapholita delineana (Walker) Consumer (McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Harmonia axyridis Pallas
(multicolored Asian ladybeetle)
Beneficial organism (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Helicoverpa zea (Boddie)
Consumer (CABI, 2018a Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Heliothrips haemorrhoidalis ( Bouché )
(greenhouse thrips)
Consumer (Hemming, 2000 Footnote 106 ; McPartland et al., 2000 Footnote 137 )
Hippodamia convergens Guérin-Meneville
Beneficial organism (CFIA, undated Footnote 9 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Liriomyza eupatorii (Kaltenbach) Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Lonsdale, 2017 Footnote 127 ; McPartland et al., 2000 Footnote 137 )
Lixophaga variablis (Coquillett) Beneficial organism (GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Tachinidae resources, 2017 Footnote 212 )
Loxostege sticticalis (Linnaeus)
(beet webworm)
Consumer (McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Lygus lineolaris ( Palisot de Beauvois )
(tarnished plant bug)
Consumer (Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Macrocentrus spp. Beneficial organism (CABI, 2018a Footnote 2 ; Krombein et al., 1979 Footnote 118 ; McPartland et al., 2000 Footnote 137 )
Mamestra configurata Walker
(bertha armyworm)
Consumer (McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Melanoplus bivittatus (Say)
(two-striped grasshopper)
Consumer (CABI, 2018a Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Vickery and Kevan, 1986 Footnote 224 )
Myzus persicae (Sulzer)
(green peach aphid)
Consumer (Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Nabis spp. Latreille Beneficial organism (Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Neocrepidodera ferruginea (Scopoli)
(European rusted flea beetle)
Synonym: Crepidodera ferruginea
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Oecanthus celerinictus Walker & T.J. Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 )
Orius spp. Beneficial organism (CFIA, undated Footnote 9 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Ostrinia nubilalis (Hübner)
(European corn borer)
Consumer (McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Oulema melanopus (Linnaeus)
(oat leaf beetle)
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Papaipema spp.
(burdock borer, common stalk borer)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Pohl et al., 2018 Footnote 166 )
Parthenolecanium corni ( Bouché )
(European fruit lecanium)
Consumer (CABI, 2018a Footnote 2 ; Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Peristenus digoneutis Loan Beneficial organism (CABI, 2018a Footnote 2 ; McPartland et al., 2000 Footnote 137 ; Whistlecraft et al., 2010 Footnote 228 )
Philaenus spumarius (Linnaeus)
(meadow froghopper, spittlebug)
Consumer (CABI, 2018a Footnote 2 ; Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Phorodon humuli (Schrank)
(hops aphid)
Consumer (Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Podisus maculiventris (Say)
(spined soldier bug)
Beneficial organism (CFIA, undated Footnote 9 ; Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Popillia japonica Newman
(Japaneese beetle)
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Psylliodes punctulatus Melsheimer
(hops flea beetle)
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Rhinoncus pericarpius (Linnaeus)
(hemp weevil)
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Scambus pterophori (Ashmead) Beneficial organism (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Krombein et al., 1979 Footnote 118 ; McPartland et al., 2000 Footnote 137 )
Schizocerella pilicornis (Holmgren)
(purslane sawfly)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Krombein et al., 1979 Footnote 118 ; McPartland et al., 2000 Footnote 137 )
Sitona lineatus (Linnaeus)
(pea leaf weevil)
Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Stethorus lineatus spp. Beneficial organism (CFIA, undated Footnote 9 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Supella longipalpa (Fabricius) Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; McPartland et al., 2000 Footnote 137 ; Vickery and Kevan, 1986 Footnote 224 )
Systena spp. Chevrolat Consumer (Bousquet et al., 2013 Footnote 39 ; McPartland et al., 2000 Footnote 137 )
Thrips tabaci Lindeman
(onion (tobacco) thrips)
Consumer (CABI, 2018a Footnote 2 ; GBIF Backbone Taxonomy, 2017 Footnote 15 ; Hemming, 2000 Footnote 106 ; McPartland et al., 2000 Footnote 137 )
Tipula paludosa Meigen
(European crane fly)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Gillespie, 2001 Footnote 89 ; McPartland et al., 2000 Footnote 137 )
Trialeurodes vaporariorum (Westwood)
(greenhouse whitefly)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Maw et al., 2000 Footnote 132 ; McPartland et al., 2000 Footnote 137 )
Trichogramma spp.
(minute egg parasitoid, moth egg parasitoid)
Beneficial organism (CABI, 2018a Footnote 2 ; CFIA, undated Footnote 9 ; Krombein et al., 1979 Footnote 118 ; McPartland et al., 2000 Footnote 137 )
Tetranychus urticae Koch
(two-spotted spider mite)
Consumer (Beaulieu and Knee, 2014 Footnote 34 ; McPartland et al., 2000 Footnote 137 )

Other life forms Interaction with Cannabis sativa (pathogen; symbiont or beneficial organism; consumer; gene transfer) Reference(s)
Arion spp.
(black slug, brown-banded slug, chocolate slug, dark-face slug, dusky slug, forest slug, garden slug, hedgehog slug, orange-banded slug)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Barker, 2002 Footnote 32 ; Grimm et al., 2009 Footnote 94 ; Ranalli, 1999 Footnote 170 ; Rollo, 1974 Footnote 173 )
Deroceras reticulatum (Müller)
(meadow slug)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Grimm et al., 2009 Footnote 94 ; Ranalli, 1999 Footnote 170 )
Limax maximus Linnaeus
(giant garden slug)
Consumer (GBIF Backbone Taxonomy, 2017 Footnote 15 ; Grimm et al., 2009 Footnote 94 ; Ranalli, 1999 Footnote 170 )

Other life forms Interaction with Cannabis sativa (pathogen; symbiont or beneficial organism; consumer; gene transfer) Reference(s)
Birds Consumer (McPartland et al., 2000 Footnote 137 )
Animal browsers (for example, deer, rabbits, rodents) Consumer (McPartland, 1996 Footnote 133 ; McPartland et al., 2000 Footnote 137 )

7 References

[AAF] Alberta Agriculture and Forestry. 2017. Industrial hemp enterprise. [ 2020 February 28 ].

[CABI] Centre for Biosciences and Agriculture International. 2018a. Crop Protection Compendium. CAB International, Wallingford, UK. [2018].

[CABI] Centre for Biosciences and Agriculture International. 2018b. Invasive Species Compendium. CAB International, Wallingford, UK. [2018].

4. [CABI/EPPO] Centre for Biosciences and Agriculture International/European and Mediterranean Plant Protection Organization. 2002. Alfalfa mosaic virus. Distribution maps of plant diseases. CAB International, Wallingford, UK.

[CABI/EPPO] Centre for Biosciences and Agriculture International/European and Mediterranean Plant Protection Organization. 2009. Pseudomonas syringae pv. mori. Distribution maps of plant diseases. CAB International, Wallingford, UK.

[CABI/EPPO] Centre for Biosciences and Agriculture International/European and Mediterranean Plant Protection Organization. 2015. Arabis mosaic virus. Distribution maps of plant diseases. CAB International, Wallingford, UK.

[CFIA] Canadian Food Inspection Agency. 2016. Asian longhorned beetle – Anoplophora glabripennis. [ 2018 September 27 ].

[CFIA] Canadian Food Inspection Agency. Undated. Section 5: Biological Control Agents From Commercial Sources. [ 2018 September 14 ].

[CHTA] Canadian Hemp Trade Alliance. 2020. Hemp production eguide. [ 2020 February 28 ].

[CSGA] Canadian Seed Growers’ Association. 2020. Crop Specific Standards for Industrial Hemp. Pages 10-1 to 11-2 in Circular 6: Canadian Regulations and Procedures for Pedigreed Seed Crop Production. [ 6 August 2020 ].

[EMCDDA] European Monitoring Centre for Drugs and Drug Addiction. 2018. Cannabis legislation in Europe: an overview. Publications Office of the European Union, Luxembourg. doi:10.2810/566650.

[FNA] Flora of North America North of Mexico. 1993+. 19+ vols. New York and Oxford. [2020 February].

[GOC] Government of Canada. 2019a. What industry needs to know about cannabis. [ 2020 March 2 ].

[GOC] Government of Canada. 2019b. What you need to know about cannabis. [ 2020 March 2 ]

[MAFRD] Manitoba Agriculture, Food and Rural Development. n.d. Industrial hemp production. [ 2020 February 28 ].

[OMAFRA] Ontario Ministry of Agriculture, Food and Rural Affairs. 2000. Growing industrial hemp in Ontario. Factsheet, Ontario Ministry of Agriculture, Food and Rural Affairs. [ 2019 May 17 ].

[PMC] Pest Management Center. 2014. Crop profile for greenhouse tomato in Canada. Agriculture and Agri-Food Canada, Ottawa, Canada.

[POWO] Plants of the World Online. 2018. Facilitated by the Royal Botanic Gardens, Kew. [2018].

[SMA] Saskatchewan Ministry of Agriculture. 2017. Hemp production in Saskatchewan [ 2020 February 28 ]

[USDA-ARS] United States Department of Agriculture Agricultural Research Service. 2020. Germplasm Resources Information Network – (GRIN) Online Database. [2020].

[USDA-NRCS] United States Department of Agriculture National Agricultural Statistics Service. 2013. The PLANTS Database. [ 2020 August 21 ].

Abel, E. L. 1980. Marihuana – The first twelve thousand years. Plenum Press, New York, USA. 289 pp.

Ainsworth, C. 2000. Boys and girls come out to play: The molecular biology of dioecious plants. Annals of Botany 86(2):211-221.

Amaducci, S., Colauzzi, M., Zatta, A. and Venturi, G. 2008. Flowering dynamics in monoecious and dioecious hemp genotypes. Journal of Industrial hemp 13(1):5-19.

Andre, C. M., Hausman, J.-F., and Guerriero G. 2016. Cannabis sativa: The plant of the thousand and one molecules. Frontiers in Plant Science 7:19.

Atal, C. K. 1959. Sex reversal in hemp by application of gibberellin. Current Science 28:408-409.

Backes, M. 2014. Cannabis pharmacy: The practical guide to medical marijuana. Black Dog & Leventhal, New York, USA. 272 pp.

Bagheri, M., and Mansouri, H. 2015. Effect of induced polyploidy on some biochemical parameters in Cannabis sativa L. Applied Biochemistry and Biotechnology. 175(5):2366-2375.

Barker, G. M. 2002. Molluscs as crop pests. CABI Publishing, Wallingford, UK.

Bassani, M., Pacini, E. and Franchi, G.G. 1994. Humidity stress responses in pollen of anemophilous and entomophilous species. Grana 33(3):146-150.

Beaulieu, F., and Knee, W. 2014. Plant-feeding mites of the Canadian prairies. Pages 29-72 in H. A. Cárcamo, and D. J. Giberson, eds. Arthropods of Canadian grasslands, Vol 3 biodiversity and systematics part 1. Biological Survey of Canada.

Bergman, R. 2018. Top 8 high yielding strains. [2018 October 11].

Booth, J.K., Page, J.E., and Bohlmann, J. 2017. Terpene synthases from Cannabis sativa. PLoS ONE 12(3): e0173911.

Borthwick, H. A., and Scully, N. J. 1954. Photoperiodic responses in hemp. Botanical Gazette 116:14-29.

Bostanian, N. J., Vincent, C., and Isaacs, R. (eds.) 2012. Arthropod management in vineyards: Pests, approaches, and future directions. Springer Verlag, Dordrecht, The Netherlands.

Bousquet, Y., Bouchard, P., Davies, A. E., and Sikes, D. S. 2013. Checklist of beetles (Coleoptera) of Canada and Alaska, 2nd edition. Pensoft Publishers, Sofia, Bulgaria.

Bradbury, J. F. 1986. Guide to plant pathogenic bacteria. CAB International, Farnham Royal, Slough. xviii +. 332pp.

Brenneisen, R. 2007. Chemistry and analysis of phytocannabinoids and other Cannabis constituents. Pages 17-49 in M. A. Elsohly, M.A., ed. Marijuana and the cannabinoids. Humana Press, Totowa, NJ.

Brickell, C. D., Alexander, C., Cubey, J. J., David, J. C., Hoffmann, M. H. A., Leslie, A. C., Malécot, V., Jin, X. (eds.) 2016. International Code of Nomenclature for Cultivated Plants. Ninth edition. International Society for Horticultural Science, Leuven, Belgium.

Brouillet, L., Coursol, F., Meades, S. J., Favreau, M., Anions, M., Bélisle, P., and Desmet, P. 2010+. Cannabis sativa Linnaeus in VASCAN, the database of vascular plants of Canada. [2020 January].

Cabezudo, B., Recio, M., Sánchez-Laulhé, J. M., Del Mar Trigo, M., Toro, F. J., and Polvorinos, F. 1997. Atmospheric transportation of marihuana pollen from North Africa to the southwest of Europe. Atmospheric Environment 31:3323-3328.

Campbell, L.G., Blanchette, C.M., and Small, E. 2019. Risk analysis of gene flow from cultivated, addictive, social-drug plants to wild relatives. Botanical Review 85: 149-184.

Cerkauskas, R., Nauta, R., and McDonald, M. 1991. First report of spinach anthracnose in Ontario. Plant Disease 75(1):101C.

Cervantes, J. 2015. The cannabis encyclopedia: The definitive guide to cultivation and consumption of medical marijuana. Van Patten Publishing, Vancouver, WA. 596 pp.

Cervantes, J. 2015. Genetic and hormonal regulation of growth, flowering and sex expression in plants. American Journal of Botany 66:717-736.

Chang, K.-F., and Mirza, M. 2007. Sclerotium rolfsii on Alstroemeria in Alberta, Canada. Plant Pathology 43(2):406-409.

Clarke, R. C. 1981a. Marijuana botany: An advanced study: The propagation and breeding of distinctive Cannabis. And/Or Press, Berkeley, CA. 197 pp.

Clarke, R. C. 1981b. The genetics and breeding of Cannabis. Pages 27-59 in N. Hamel, and D. Cross, eds. Marijuana Botany: An Advanced Study: The Propagation and Breeding of Distinctive Cannabis. Ronin Publishing, Berkeley, CA.

Clarke, R. C., and Merlin, M. D. 2013. Cannabis: Evolution and Ethnobotany. University of California Press, Berkely, CA. 434 pp.

Clarke, R. C., and Merlin, M. D. 2015. Letter to the editor: Small, Ernest. 2015. Evolution and Classification of Cannabis sativa (Marijuana, Hemp) in relation to human utilization. Botanical Review 81(3):189-294. The Botanical Review 81(4):295-305.

Clarke, R. C., and Watson, D. P. 2007. Cannabis and natural Cannabis medicines. Pages 1-16 in M. A. Elsohly, ed. Marijuana and the cannabinoids. Humana Press, Totowa, NJ.

Clear, R., and Patrick, S. 1990. Cannabis Fusarium species isolated from wheat samples containing tombstone (scab) kernels from Ontario, Manitoba, and Saskatchewan. Canadian Journal of Plant Science 70(4):1057-1069.

Clear, R., and Patrick, S. 1995. Frequency and distribution of seed-borne fungi infected canola seed from Ontario and Western Canada – 1989 to 1993. Canadian Plant Disease Survey 75(1):9-17.

Conners, I. L. 1967. An annotated index of plant diseases in Canada. Canada Department of Agriculture, Research Branch Publication. 381 pp.

Creelman, D. W. 1962. Summary of the prevalence of plant diseases in Canada in 1961. Canadian Plant Disease Survey 42(2):23-102.

Dalpé, Y., Granger, R. L., and Furlan, V. 1986. Abondance relative et diversité des Endogonacées dans un sol de verger du Québec . Canadian Journal of Botany 64(5):912-917.

Danko, D. 2010. The official High Times field guide to marijuana strains. High Times Corporation, New York. 180 pp.

Darbyshire, S. J. 2003. Inventory of Canadian Agricultural Weeds. Agriculture and Agri-Food Canada, Research Branch, Ottawa, ON, Canada.

Darwin, C. 1859. On the origin of species by means of natural selection, or the preservation of favoured races in the struggle for life. John Murray, London, UK. 502 pp.

Davidyan, G.G. 1972. Hemp: biology and initial material for breeding. Bulletin of Applied Botany, of Genetics and Plant Breeding 48:1-160.

De Candolle, A. 1885. Origin of cultivated plants. D. Appleton & Co, New York, US. 468 pp.

de Meijer, E. P. M. 2014. The chemical phenotypes (chemotypes) of Cannabis. Pages 89-110 in R. G. Pertwee, ed. Handbook of Cannabis. Oxford University Press, Oxford, UK.

de Meijer, E. P. M., and Hammond K. M. 2005. The inheritance of chemical phenotype in Cannabis sativa L. (II): cannabigerol predominant plants. Euphytica 145:189-198.

de Meijer, E. P. M., Hammond, K. M., and Micheler, M. 2009a. The inheritance of chemical phenotype in Cannabis sativa L. (III): variation in cannabichromene proportion. Euphytica 165:293-311.

de Meijer, E. P. M., Hammond, K. M., and Sutton, A. 2009b. The inheritance of chemical phenotype in Cannabis sativa L. (IV): cannabinoid-free plants. Euphytica 168:95-112.

De Pasquale, A., Tumino, G., Ragusa, S., and Moschonas, D. 1979. Influence of treatment with colchicine on the production of cannabinoids in the female inflorescence of Cannabis sativa L. Farmaco 34:841-853.

Desjardins, M., Heard, J., Kaminski, D., and Northover, P. 2007. 2006 Manitoba Crop Diagnostic Centre laboratory submissions. Canadian Plant Disease Survey. 87: 20-26.

Duthie, J., Hall, R., and Asselin, A. 1986. Fusarium species from seed of winter wheat in eastern Canada. Canadian Journal of Plant Pathology 8(3):282-288.

Duvall, C. S. 2019. The African Roots of Marijuana. Durham: Duke University Press.

Ebsary, B. 1986. Species and distribution of Heteroderidae and Meloidogynidae (Nematoda: Tylenchida) in Canada. Canadian Journal of Plant Pathology 8(2):170-184.

Elmhirst, J., and Joshi, V. 1995. Diseases diagnosed on commercial crops submitted to the British Columbia Plant Diagnostic Laboratory in 1994. Canadian Plant Disease Survey 75(1):59-67.

ElSohly, M. 2002. Chemical constituents of Cannabis. Pages 27-36 in F. Grotenhermen, and E. Russo, eds. Cannabis and cannabinoids – Pharmacology, toxicology and therapeutic potential. Haworth Press, New York, USA.

ElSohly, M. A. (ed) 2007. Marijuana and the cannabinoids. Humana Press, Totowa, NJ.

ElSohly, M. A., and Slade. D. 2005. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sciences 78:539-548.

Emboden, W. A. 1974. Cannabis – a polytipic genus. Economic Botany 28:304-310.

Faegri, K., Iverson, J., Kaland, P. E., and Krzywinski, K. 1989. Textbook of pollen analysis. 4th edition. John Wiley & Sons, New York, USA. 340 pp.

Farr, D. F., Rossman, A. Y., Palm, M. E., and McCray, E. B. 2018. Fungal Databases, Systematic Botany and Mycology Laboratory. ARS, USDA.

Faux, A. M., Draye, X., Lambert, R., Andrimont, R., Raulier, P., Bertin, P. 2013. The relationship of stem and seed yields to flowering phenology and sex expression in monoecious hemp (Cannabis sativa L.). European Journal of Agronomy 47:11-22.

Fischedick, J. T., Hazekamp, A., Erkelens, T., Choi, Y. H., Verpoorte, R. 2010. Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry 71(17–18):2058-2073.

Flores-Sanchez, I. J., and Verpoorte, R. 2008. Secondary metabolism in Cannabis. Phytochemistry Reviews 7:615-639.

Gagne, S. J., Stout, J. M., Liu, E., Boubakir, Z., Clark, S. M., and Page, J. E. 2012. Identification of olivetolic acid cyclase from Cannabis sativa reveals a unique catalytic route to plant polyketides. Proceedings of the National Academy of Sciences of the United States of America 109:12811-12816.

Gaoni, Y., and Mechoulam, R. 1964. The structure and synthesis of cannabigerol, a new hashish constituent. Proceedings of the Chemical Society, London, UK.

Garland, J. A., and Kevan, D. K. M. 2007. Chrysopidae of Canada and Alaska (Insecta: Neuroptera): revised checklist, new and noteworthy records and geo-referenced localities. Zootaxa 1486:1-84.

Gavloski, J., Cárcamo, H., and Dosdall, L. 2011. Insects of canola, mustard, and flax in Canadian grasslands. Pages 181-216 in K. D. Floate, ed. Arthropods of Canadian grasslands, Vol 2 Inhabitants of a changing landscape. Biological Survey of Canada.

Gilbert, G., Dallaire, C., and Hamel, D. 2008. Maladies diagnostiquées sur des échantillons de cultures commerciales soumis au Laboratoire de Diagnostic en Phytoprotection du MAPAQ en 2007. Canadian Plant Disease Survey 88:19-37.

Gillespie, D. R. 2001. Arthropod introductions into British Columbia – the past 50 years. Journal of the Entomological Society of British Columbia 98:91-97.

Gillespie, D. R., and Quiring, D. M. J. 2012. Biological control of fungus gnats, Bradysia spp. (Diptera: Sciaridae), and western flower thrips, Frankliniella occidentals (Pergande) (Thysanoptera: Thripidae), in greenhouses using a soil-dwelling predatory mite, Geolaelaps sp. NR. aculeifer (Canestrini) (Acari: Laelapidae). The Canadian Entomologist 122(5):975-983.

Ginns, J. H. 1986. Compendium of plant disease and decay fungi in Canada, 1960-1980. Canadian Government Publishing Centre.

Ginns, J. H. 1986. Botrytis cinerea blossom blight of alfalfa on the Canadian prairies. Plant Disease 78(12):1218.

Green, G. 2003. The cannabis grow bible. The definitive guide to growing marijuana for recreational and medical use. Green Candy Press, San Francisco, CA. 305 pp.

Grimm, F. W., Forsyth, R. G., Schueler, F. W., and Karstad, A. 2009. Identifying land snails and slugs in Canada. Canadian Food Inspection Agency, Ottawa, Canada.

Grisswell, J., and Young, V. 2011. Professor Grow’s book of strains. The 50 Cannabis strains most commonly found at dispensaries. Professor Grow, LLC, Firestone, CO. 160 pp.

Grotenhermen, F., and Müller-Vahl, K. 2016. Medicinal uses of marijuana and cannabinoids. Critical Reviews in Plant Sciences 35(5-6):378-405.

Grotenhermen, F., and Russo, E. 2002. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Haworth Integrative Healing Press (of Haworth Press), New York, USA.

Guennewich, N., Page, J. E., Köllner, T. G., Degenhardt, J., and Kutchan, T. M. 2007. Functional expression and characterization of trichome-specific (-)-limonene synthase and (+)-α-pinene synthase from Cannabis sativa. Natural Product Communications 2(3):223-232.

Guy, G.W., and Stott, C.G. 2005. The development of Sativex- a natural cannabis-based medicine. Pages 231-263 in R. Mechoulam, ed. Cannabinoids as therapeutics. Birkhäuser Verlag, Basel, Switzerland.

Hammond, C.T. and Mahlberg, P.G. 1973. Morphology of glandular hairs of Cannabis sativa from scanning electron microscopy. Am. J. Bot. 60, 524– 528.

Hammond, C.T. and Mahlberg, P.G. 1977. Morphogenesis of capitate glan- dular hairs of Cannabis sativa (Cannabaceae). Am. J. Bot. 64, 1023.

Haney, A., and Bazzaz, F. A. 1970. Some ecological implications of the distribution of hemp (Cannabis sativa L.) in the United States of America. Pages 39-48 in C. R. B Joyce, and S. H. Curry, eds. The botany and chemistry of Cannabis. J. & A. Churchill, London, UK.

Haney, A., and Kutscheid, B. B. 1973. Quantitative variation in the chemical constituents of marijuana from stands of naturalized Cannabis sativa L. in east-central Illinois. Economic Botany 27:193-203.

Haney, A., and Kutscheid, B. B. 1975. An ecological study of naturalized hemp (Cannabis sativa L.) in east-central Illinois. American Midland Naturalist 93:1-24.

Health Canada. 2018. Industrial hemp licensing statistics for 2018. [ 2020 February 24 ].

Hemming, B. S. 2000. Checklist of Alberta THYSANOPTERA (Thrips). [ 2018 September 14 ].

Hemphill, J. K., Turner, J. C., and Mahlberg, P. G. 1980. Cannabinoid content of individual plant organs from different geographical strains of Cannabis sativa L. Journal of Natural Products 43: 112–122.

Heslop-Harrison, J. 1956. Auxin and sexuality in Cannabis sativa. Physiologia Plantarum 4:588-597.

Heslop-Harrison, J., and Heslop-Harrison, Y. 1957. Studies on flowering-plant growth and organogenesis. II. The modification of sex expression in Cannabis sativa by carbon monoxide. Proceedings of the Royal Society of Edinburgh. Section B. Biology 66:424-434.

Heslop-Harrison, J., and Heslop-Harrison, Y. 1969. Cannabis sativa L. Pages 205-225 in L. T. Evans, ed. The induction of flowering. Some case histories. Cornell University Press, Ithaca, USA.

Hillig, K. W. 2005. Genetic evidence for speciation in Cannabis (Cannabaceae). Genetic Resources and Crop Evolution 52:161-180.

Hillig, K. W., and Mahlberg, P. G. 2004. A chemotaxanomic analysis of cannabinoid variation in Cannabis (Cannabaceae). American Journal of Botany 91(6):966-975.

Hood, L. V., Dames, M. E., and Barry, G. T. 1973. Headspace volatiles of marijuana. Nature 242:402-403.

Joshi, V. and Hudgins, E. 2002. New or uncommon diseases diagnosed in British Columbia in 2000-2001. Canadian Journal of Plant Pathology 24(1):86-91.

Joshi, V., and Elmhirst, J. 1998. Diseases diagnosed on commercial crops in British Columbia. Canadian Plant Disease Survey 78:4-16.

Kim, E. S., and Mahlberg, P. G. 1997. Immunochemical localization of tetrahydrocannabinol (THC) in cryofixed glandular trichomes Cannabis (Cannabaceae). American Journal of Botany 84:336-342.

Kimpinski, J. 1985. Nematodes in strawberries on Prince Edward Island, Canada. Plant disease (USA).

Krombein, K. V., Hurd, P. D., Smith, D. R., and Burks, B. D. 1979. Catalog of Hymenoptera in America north of Mexico. Smithsonian Institution Press, Washington, D.C.

Kucey, R. M. N., and Paul, E. A. 1983. Vesicular arbuscular mycorrhizal spore populations in various Saskatchewan soils and the effect of inoculation with Glomus mosseae on faba bean growth in greenhouse and field trials. Canadian Journal of Soil Science 63(1):87-95.

Kushima, H., Shoyama, Y., and Nishioka, I. 1980. Cannabis. XII. Variations of cannabinoid contents in several strains of Cannabis sativa L. with leaf-age, season and sex. Chemical and Pharmaceutical Bulletin 28:594-598.

Latta, R., and Eaton, B. 1975. Seasonal fluctuations in cannabinoid content of Kansas marijuana. Economic Botany 29:153-163

Laverty, K.U , Jake M. Stout, Mitchell J. Sullivan, Hardik Shah, Navdeep Gill, Larry Holbrook, Gintaras Deikus, Robert Sebra, Timothy R. Hughes, Jonathan E. Page, and Harm van Bakel. 2019. A physical and genetic map of Cannabis sativa identifies extensive rearrangements at the THC/CBD acid synthase loci. Genome Res. January 29: 146-156.

Legault, D., Dessureault, M., and Laflamme, G. 1989. Mycoflora of Pinus banksiana and Pinus resinosa needles. II. Epiphytic fungi. Canadian Journal of Botany 67(7):2061-2065.

Levin, D. A. 1973. The role of trichomes in plant defense. Quarterly Review Biology 48:3-15.

Li, H.-L. 1974. The origin and use of cannabis in eastern Asia: Linguistic-cultural implications. Economic Botany 28:293-301.

Livingston, S.J., Quilichini, T.D., Booth, J.K., Wong, D.C.J., Rensing, K.H., Laflamme-Yonkman, J., Castellarin, S.D., Bohlmann, J., Page, J.E., Samuels, A.L. 2020. Cannabis glandular trichomes alter morphology and metabolite content during flower maturation. The Plant Journal, 101:37-56.

Lonsdale, O. 2017 The Liriomyza (Diptera: Schizophora: Agromyzidae) of Canada & Alaska. Magnolia Press, Auckland New Zealand.

Magarey, R. D., Borchert, D. M., and Schlegel, J. W. 2008. Global plant hardiness zones for phytosanitary risk analysis. Scientia Agricola 65:54-59.

Mankowska, G. and Silska, G., 2015. Genetic resources of Cannabis sativa L. in the Collection of the Gene Bank at INF&MP in Poznan. Journal of Natural Fibers, 12(4) :332-340.

Mansouri H., and Bagheri M. 2017. Induction of polyploidy and its effect on Cannabis sativa L. Pages 365-383 in S. Chandra, H. Latta, M. A. ElSohly, eds. Cannabis sativa L – Botany and Biotechnology. Springer International Publishing, Cham, Switzerland.

Martin, R., and Johnston, H. 1982. Effects and control of Fusarium diseases of cereal grains in the Atlantic Provinces. Canadian Journal of Plant Pathology 4(2):210-216.

Maw, H. E. L., Foottit, R. G., Hamilton, K. G. A., and Scudder, G. G. E. 2000. Checklist of the Hemiptera of Canada and Alaska. NRC Research Press, Ottawa, ON.

McPartland, J. M. 1996. Cannabis pests. Journal of the International Hemp Association 3(2): 49, 52-55.

McPartland, J. M. 1997. Cannabis as a repellent crop and botanical pesticide. Journal of the International Hemp Association 4(2):89-94.

McPartland, J. M. 2018. Cannabis systematics at the levels of family, genus and species. Cannabis and Cannabinoid Research 3(1):203-212.

McPartland, J. M., and Guy, G. W. 2017. Models of Cannabis taxonomy, cultural bias, and conflicts between scientific and vernacular names. The Botanical Review 83(4):327-381.

McPartland, J. M., Clarke, R. C., and Watson, D. P. 2000. Hemp diseases and pests: management and biological control. CABI, Wallingford, UK. 272 pp.

McPartland, J. M., Guy, G. W., and Hegman, W. 2018. Cannabis is indigenous to Europe and cultivation began during the Copper and Bronze age: a probabilistic synthesis of fossil pollen studies. Vegetation History and Archaeobotany 27(4):635-648.

McPartland, J.M., and Small E., 2020. A classification of endangered high-THC cannabis (Cannabis sativa subsp. indica) domesticates and their wild relatives. PhytoKeys 144: 81-112.

Mediavilla, V., and Steinemann, S. 1997. Essential oil of Cannabis sativa L. strains. Journal of the International Hemp Association 4:82-84.

Merlin, M. D. 1972. Man and marijuana: Some aspects of their ancient relationship. Associated University Presses, Cranbury, USA. 120 pp.

Messer, A., McCormick K., Sunjaya-Hagedorn, H. H., Tumbel, F., and Meinwald, J. 1990. Defensive role of tropical tree resins: antitermitic sesquiterpenes from Southeast Asian Dipterocarpaceae. Journal of Chemical Ecology 16:3333-3352.

Miller, J. D., Strongman, D., and Whitney, N. 1985. Observations on fungi associated with spruce budworm infested balsam fir needles. Canadian Journal of Forest Research 15(5):896-901.

Mills, J., and Abramson, D. 1981. Microflora and condition of flood-damaged grains in Manitoba, Canada. Mycopathologia 73(3):143-152.

Mittal, R., and Wang, B. 1987. Fungi associated with seeds of eastern white pine and white spruce during cone processing and seed extraction. Canadian Journal of Forest Research 17(9):1026-1034.

Mo, T.-L., and Liu, T.-X. 2007. Predation and life table of Feltiella acarisuga (Diptera: Cecidomyiidae) preying on eggs of Tetranychus urticae (Acari: Tetranychidae). Environmental Entomology 36(2):369-375.

Mohan Ram, H.Y., and Jaiswal, V.S. 1970. Induction of female flowers on male plants of Cannabis sativa by 2-chlorotane phosphonic acid. Experimentia 26:214-216.

Murari, G., Puccini, A. M., Sanctis, R. de, and Lombardi, S. 1983. Influence of environmental conditions on tetrahydrocannabinol (delta-9-THC) in different cultivars on Cannabis sativa L. Fitoterapia 54:195-202.

Naraine, S.G., Small, E., Laursen, A.E. and Campbell, L.G., 2020. A multivariate analysis of morphological divergence of “seeds” (achenes) among ruderal, fibre, oilseed, dioecious/monoecious and marijuana variants of Cannabis sativa L. Genetic Resources and Crop Evolution, 67(3): 703-714.

Oner, S. T. 2011. Cannabis indica: The essential guide to the world’s finest marijuana strains. Volume 1. Green Candy Press, San Francisco, USA. 280 pp.

Oner, S. T. 2012a. Cannabis indica: The essential guide to the world’s finest marijuana strains. Volume 2. Green Candy Press, San Francisco, USA. 208 pp.

Oner, S. T. 2012b. Cannabis indica: The essential guide to the world’s finest marijuana strains. Green Candy Press, San Francisco, USA. 228 pp.

Oner, S. T. 2013a. Cannabis indica: The essential guide to the world’s finest marijuana strains. Volume 3. Green Candy Press, San Francisco, USA. 208 pp.

Oner, S. T. 2013b. Cannabis sativa: The essential guide to the world’s finest marijuana strains. Volume 3. Green Candy Press, San Francisco, USA. 228 pp.

Oner, S. T. 2014. Cannabis sativa: The essential guide to the world’s finest marijuana strains. Volume 3. Green Candy Press, San Francisco, USA. 208 pp.

Page, J. E., and Nagel, J. 2006. Biosynthesis of terpenophenolic metabolites in hop and cannabis. Pages 179-210 in J. T. Romeo, ed. Recent advances in phytochemistry. Elsevier Ltd, Oxford, UK.

Paris, M., Boucher, F., and Cosson, L. 1975. The constituents of Cannabis sativa pollen. Economic Botany (29):245-253.

Parmelee, J. A. 1982. Records of parasitic fungi in Manitoba based on collections from Riding Mountain National Park, 1979. Canadian Field Naturalist.

Parmelee, J. A. 1983. The fungi of Ontario: III parasitic microfungi on vascular plants in Northern Ontario. Research Branch, Agriculture Canada.

Parmelee, J. A. 1984. Microfungi parasitic on vascular plants in Waterton Lakes National Park, Alberta, and environs. Research Branch, Agriculture Canada.

Parsons. J. L., Martin, S. L., James T., Golenia, G., Boudko, E. A., and Hepworth, S. R. 2019. Polyploidization for the genetic improvement of Cannabis sativa. Frontiers in Plant Science 10:476.

Pate, D. W. 1999. The phytochemistry of Cannabis: its ecological and evolutionary implications. Pages 21-42 in P. Ranalli, ed. Advances in hemp research. Food Products Press, New York, USA.

Pertwee, R. G. (ed.) 2014. Handbook of Cannabis. Oxford University Press, Oxford, UK. 747 pp.

Philip, H. 2015. Field crop and forage pests and their natural enemies in western Canada: Identification and management field guide. Agriculture and Agri-Food Canada, Ottawa, Canada.

Phillips, R., Turk, R., Manno, J., Crim, D., and Forney, R. 1970. Seasonal variation in cannabinolic content of Indiana marihuana. Journal of Forensic Sciences 15:191-200.

Pohl, G. R., Landry, J.-F., Schmidt, B. C., Lafontaine, J. D., Troubridge, J. T., Macaulay, A. D., van Nieukerken, E. J., deWaard, J. R., Dombroskie, J. J., Klymko, J., Nazari, V., and Stead, K. 2018. Annotated checklist of the moths and butterflies (Lepidoptera) of Canada and Alaska. Pensoft, Sofia, Bulgaria.

Radwan, M. M., ElSohly M. A., Slade D., Ahmed S. A., Khan I. A., and Ross S. A. 2009. Biologically active cannabinoids from high-potency Cannabis sativa. Journal of Natural Products 72:906-911.

Rahn, B., Pearson, B. J., Trigiano, R. N., and Gray, D. J. 2016. The derivation of modern Cannabis varieties. Critical Reviews in Plant Sciences 35(5-6):328-348.

Rana, A., and Choudhary, N. 2010. Floral biology and pollination biology of Cannabis sativa L. The International Journal of Plant Reproductive Biology 2(2):191-195

Ranalli, P. (ed.) 1999. Advances in hemp research. Haworth Press Binghamton, Binghamton, USA. 272 pp.

Reed, J. 1914. Morphology of Cannabis sativa L. Master of Science thesis, Iowa State University, Iowa, USA.

Rodriguez, G., Kibler, A., Campbell, P., and Punja, Z. 2015. Fungal diseases of Cannabis sativa in British Columbia, Canada. Proc. Poster presented at The American Phytopathological Society Annual Meeting.

Rollo, C. D. 1974. Ecology of the slugs Deroceras reticulatum, D. laeve, and Arion fasciatus in Ontario corn fields. Master of Science thesis, University of Guelph, Ontario, Canada.

Rosenthal, E. 1998. Marijuana grower’s handbook. The indoor high yield guide. 3rd edition. Quick American Archives, Oakland, USA. 261 pp.

Rosenthal, E. 2001. The big book of buds. Marijuana varieties from the world’s great seed breeders. Quick American Archives, Oakland, USA. 214 pp.

Rosenthal, E. 2004. The big book of buds: 2. More marijuana varieties from the world’s great seed breeders. Quick American Archives, Oakland, USA. 192 pp.

Rosenthal, E. 2007. The big book of buds: 3. More marijuana varieties from the world’s great seed breeders. Quick American Archives, Oakland, USA. 256 pp.

Rosenthal, E. 2010. The big book of buds: 4. Marijuana varieties from the world’s great seed breeders. Quick American Archives, Oakland, USA. 240 pp.

Ross, S. A., and ElSohly, M. A. 1995. Constituents of Cannabis sativa L. XXVIII—A review of the natural constituents: 1980–1994. Zagazig Journal of Pharmaceutical Sciences 4:1-10.

Ross, S. A., and ElSohly, M. A. 1996. The volatile oil composition of fresh and air-dried buds of Cannabis sativa. Journal of Natural Products 59:49-51.

Rothschild, M., and Fairbairn, J. W. 1980. Ovipositing butterfly (Pieris brassicae L.) distinguishes between aqueous extracts of two strains of Cannabis sativa L. and THC and CBD. Nature 286:56-59.

Rothschild, M., Bergstrom, G., and Wangberg, S. A. 2005. Cannabis sativa: volatile compounds from pollen and entire male and female plants of two variants, Northern Lights and Hawaian Indica. Botanical Journal of the Linnean Society 147:387-397.

Rothschild, M., Rowan, M. R., and Fairbairn, J. W. 1977. Storage of cannabinoids by Arctia caja and Zonocerus elegans fed on chemically distinct strains of Cannabis sativa. Nature 266:650-651.

Russo, E. B. 2008. Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management 4(1):245-259.

Russo, E. B. 2011. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163:1344-1364.

Russo, E. B. 2018. The case for the entourage effect and conventional breeding of clinical Cannabis: No “strain,” no gain. Frontiers in Plant Science 9:1969

Russo, E. B., and Marcu, J. 2017. Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Advances in Pharmacology 80:67-134

Sawler, J., Stout, J.M., Gardner, K.M., Hudson, D., Vidmar, J., Butler, L., Page, J.E., Myles, S. 2015. The Genetic Structure of Marijuana and Hemp. PLoS One. 10(8):e0133292.

Schultes, R. E., Klein, W. M., Plowman, T., and Lockwood, T. E. 1974. Cannabis: An example of taxonomic neglect. Botanical Museum Leaflets, Harvard University 23(9):337-367.

Sewell, R. 1977. Plant parasitic nematodes from Canada and abroad, 1973-74. Canadian Plant Disease Survey. 57:52-53.

Sharma, G. K. 1979. Significance of eco-chemical studies of cannabis. Science and Culture 45:303-307.

Sirikantaramas, S., Taura, F., Morimoto, S., and Shoyama, Y. 2007. Recent advances in Cannabis sativa research: biosynthetic studies and its potential in biotechnology. Current Pharmaceutical Biotechnology 8:237-243.

Small, E. 1972a. Interfertility and chromosomal uniformity in Cannabis. Canadian Journal of Botany 50:1947–1949.

Small, E. 1972b. The hemp problem in Canada. Greenhouse Garden Grass 11(3): 46-52.

Small, E. 1975. Morphological variation of achenes of Cannabis. Canadian Journal of Botany 53:978-987.

Small, E. 1979. The species problem in Cannabis: Science and semantics, Vol. 2, Semantics. Corpus, Toronto, Canada. 156 pp.

Small, E. 2015a. Evolution and classification of Cannabis sativa (Marijuana, Hemp) in relation to human utilization. The Botanical Review 81:189-294.

Small, E. 2015b. Response to the erroneous critique of my Cannabis monograph by R.C. Clarke and M.D. Merlin. The Botanical Review 81(4):306-316.

Small, E. 2016. Cannabis: a complete guide. CRC Press, Taylor & Francis Group, Boca Raton, USA.

Small, E. 2017. Classification of Cannabis sativa L. in relation to agricultural, biotechnological, medicinal and recreational utilization. Pages 1-62 in S. Chandra, H. Latta, M. A. ElSohly, eds. Cannabis sativa L. – Botany and biotechnology. Springer International Publishing, Cham, Switzerland.

Small, E., and Antle, T. 2003. A preliminary study of pollen dispersal in Cannabis sativa. Journal of Industrial Hemp 8(2):37-50.

Small, E., and Cronquist, A. 1976. A practical and natural taxonomy for Cannabis. Taxon 25(4):405-435.

Small, E., and Naraine, S. G. U. 2016. Expansion of female sex organs in response to prolonged virginity in Cannabis sativa (marijuana). Genetic Resources and Crop Evolution 63:339-348.

Small, E., Beckstead, H. D., and Chan, A. 1975. The evolution of cannabinoid phenotypes in Cannabis. Economic Botany 29:219-232.

Small, E., Pocock, T., and Cavers, P. B. 2003. The biology of Canadian weeds. 119. Cannabis sativa L. Canadian Journal of Plant Science 83(1):217-237

Snoeijer, W. 2002. A checklist of some Cannabaceae cultivars. Part A: Cannabis. Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden, the Netherlands. 60 pp.

Spencer, K. A., and Steyskal, G. C. 1986. Manual of the Agromyzidae (Díptera) of the United States. U.S. Department of Agriculture, Washington, D.C. Agriculture Handbook No 638. 478 pp.

Stout, J.M., Boubakir, Z., Ambrose, S.J., Purves, R.W. and Page, J.E. 2012. The hexanoyl‐CoA precursor for cannabinoid biosynthesis is formed by an acyl‐activating enzyme in Cannabis sativa trichomes. The Plant Journal, 71: 353-365.

Sturz, A., and Bernier, C. 1991. Fungal communities in winter wheat roots following crop rotations suppressive and nonsuppressive to take-all. Canadian Journal of Botany 69(1):39-43.

Sturz, A., and Johnston, H. 1983. Early colonization of the ears of wheat and barley by Fusarium poae. Canadian Journal of Plant Pathology 5(2):107-110.

Sumar, S., Mohyuddin, M., and Howard, R. 1982. Diseases of pulse crops in Alberta, 1978-79. Canadian Plant Disease Survey.

Taura, F., Morimoto, S., and Shoyama, Y. 1996. Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L. Biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acid. Journal of Biological Chemistry 271:17411-17416.

Taura, F., Morimoto, S., Shoyama, Y., and Mechoulam, R. 1995. First direct evidence for the mechanism of delta-1-tetrahydrocannabinol acid biosynthesis. Journal of the American Chemical Society 117:9766-9767.

Taura, F., Sirikantaramas, S., Shoyama, Y., Shoyama, Y, and Morimoto, S. 2009. Phytocannabinoids in Cannabis sativa: Recent studies on biosynthetic enzymes. Pages 51-65 in D. M. Lambert, ed. Cannabinoids in nature and medicine. Wiley-VCH, New York, USA.

Taura, F., Sirikantaramas, S., Shoyama, Y., Shoyama, Y., Morimoto, S. 2007. Phytocannabinoids in Cannabis sativa: Recent studies on biosynthetic enzymes. Chem. Biodiversity 4:1649-1663.

Traquair, J., and Berch, S. 1988. Colonization of peach rootstocks by indigenous vesicular-arbuscular mycorrhizal (VAM) fungi. Canadian Journal of Plant Science 68(3):893-898.

Turner, C. E., Elsohly, M. A., and Boeren, E. G. 1980. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. Journal of Natural Products 43:169-234.

Turner, C., Fetterman, P., Hadley, K., and Urbanek, J. 1975. Constituents of Cannabis sativa L. X. Cannabinoid profile of a Mexican variant and its possible correlation to pharmacological activity. Acta Pharmaceutica Jugoslavica 25:7-15.

Tyler, M. 1964. Some records of known and suspected plant-parasitic, nematodes encountered in Canada in 1964. Canadian Plant Disease Survey 44(4):227-231.

Upton, R., Craker, L., ElSohly, M., Romm, A., Russo, E., and Sexton, M. (eds.) 2013. American herbal pharmacopoeia: Cannabis inflorescence: Cannabis spp.; Standards of identity, analysis, and quality control. American Herbal Pharmacopoeia, Scott’s Valley, USA. 63 pp.

Upton, R., Craker, L., ElSohly, M., Romm, A., Russo, E., and Sexton, M. (eds.) 2013. American herbal pharmacopoeia: Cannabis inflorescence: Cannabis spp.; Standards of identity, analysis, and quality control. American Herbal Pharmacopoeia, Scott’s Valley, USA. 63 pp.

van Bakel, H., Stout J. M., Cote, A. G., Tallon, C. M., Sharpe, A. G., Hughes, T. R., and Page, J. E. 2011. The draft genome and transcriptome of Cannabis sativa. Genome Biology 12:R102.

Vickery, V. R., and Kevan, D. K. M. 1986. The insects and arachnids of Canada. Part 14: The grasshoppers, crickets, and related insects of Canada and adjacent regions. Ulonata: Dermaptera, Cheleutoptera, Notoptera, Dictuoptera, Grylloptera and Orthoptera. Agriculture Canada, Ottawa.

Wall, R., and Shamoun, S. 1990. Diseases of Rubus parviflorus in British Columbia. Canadian Plant Disease Survey 70(2):133-135.

Walter, H. 1938. Cannabis. Pages 875-909 in O. V. Kirchner, E. Loew, C. Schröter, and W. Wangerin, eds. Lebensgeschichte der Blütenpflanzen Mitteleuropas, Vol. 2. Stuttgart, Germany: Eugen Ulmer.

Wang, K., Hiruki, C., and Chen, M. H. 1998. Identification of a phytoplasma causing yellows of Monarda. Plant Pathology 47:103-106.

Whistlecraft, J. W., Haye, T., Kuhlmann, U., Muth, R., Murillo, H., and Mason, P. 2010. A large-scale rearing method for Peristenus digoneutis (Hymenoptera: Braconidae), a biological control agent of Lygus lineolaris (Hemiptera: Miridae). Biocontrol Science and Technology 20(9):923-937.

Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood M., and Kleijnen J. 2015. Cannabinoids for medical use: A systematic review and meta-analysis. The Journal of the American Medical Association. 313(24):2456-2473.

Yang, M.-Q., van Velzen, R., Bakker, F. T., Sattarian, A., Li, D.-Z., and Yi, T.-S. 2013. Molecular phylogenetics and character evolution of Cannabaceae. Taxon 62 (3):473-485.

Zhang, Q., Chen, X., Guo, H., Trindade, L.M., Salentijn, E.M.J., Guo, R., Guo, M., Xu, Y., Yang, M. 2018. Latitudinal adaptation and genetic insights into the origins of Cannabis sativa L. Frontiers in Plant Science 9:1876.